WorldWideScience

Sample records for anti-infective drugs advisory

  1. LC-MS/MS for Therapeutic Drug Monitoring of anti-infective drugs

    NARCIS (Netherlands)

    Veringa, Anette; Sturkenboom, Marieke G.G.; Dekkers, Bart G.J.; Koster, Remco A.; Roberts, Jason A.; Peloquin, Charles A.; Touw, Daan J.; Alffenaar, Jan-Willem C.

    2016-01-01

    Therapeutic drug monitoring (TDM) is a tool used to integrate pharmacokinetic and pharmacodynamic knowledge to optimise and personalize drug therapy. TDM is of specific interest for anti-infectives: to assure adequate drug exposure and reduce adverse events, to increase patient compliance and to pre

  2. Causes and consequences of anti-infective drug stock-outs.

    Science.gov (United States)

    Luans, C; Cardiet, I; Rogé, P; Baslé, B; Le Corre, P; Revest, M; Michelet, C; Tattevin, P

    2014-10-01

    Anti-infective drugs stock-outs are increasingly frequent, and this is unlikely to change. There are numerous causes for this, mostly related to parameters difficult to control: i) 60 to 80% of raw material or components are produced outside of Europe (compared to 20% 30 years ago), with subsequent loss of independence for their procurement; ii) the economic crisis drives the pharmaceutical companies to stop producing drugs of limited profitability (even among important drugs); iii) the enforcement of regulatory requirements and quality control procedures result in an increasing number of drugs being blocked during production. The therapeutic class most affected by drug stock-outs is that of anti-infective drugs, especially injectable ones, and many therapeutic dead ends have recently occurred. We provide an update on this issue, and suggest 2 major actions for improvement: i) to implement a group dedicated to anticipating drug stock-outs within the anti-infective committee in each health care center, with the objectives of organizing and coordinating the response whenever a drug stock-out is deemed at risk (i.e., contingency plans, substitution, communication to prescribers); ii) a national reflection lead by scientific societies, in collaboration with government agencies, upstream of the most problematic drug stock-outs, to elaborate and disseminate consensus guidelines for the management of these stock-outs.

  3. Anti-infective Activity of 2-Cyano-3-Acrylamide Inhibitors with Improved Drug-Like Properties against Two Intracellular Pathogens.

    Science.gov (United States)

    Passalacqua, Karla D; Charbonneau, Marie-Eve; Donato, Nicholas J; Showalter, Hollis D; Sun, Duxin; Wen, Bo; He, Miao; Sun, Hanshi; O'Riordan, Mary X D; Wobus, Christiane E

    2016-07-01

    Due to the rise of antibiotic resistance and the small number of effective antiviral drugs, new approaches for treating infectious diseases are urgently needed. Identifying targets for host-based therapies represents an emerging strategy for drug discovery. The ubiquitin-proteasome system is a central mode of signaling in the eukaryotic cell and may be a promising target for therapies that bolster the host's ability to control infection. Deubiquitinase (DUB) enzymes are key regulators of the host inflammatory response, and we previously demonstrated that a selective DUB inhibitor and its derivative promote anti-infective activities in host cells. To find compounds with anti-infective efficacy but improved toxicity profiles, we tested a library of predominantly 2-cyano-3-acrylamide small-molecule DUB inhibitors for anti-infective activity in macrophages against two intracellular pathogens: murine norovirus (MNV) and Listeria monocytogenes We identified compound C6, which inhibited DUB activity in human and murine cells and reduced intracellular replication of both pathogens with minimal toxicity in cell culture. Treatment with C6 did not significantly affect the ability of macrophages to internalize virus, suggesting that the anti-infective activity interferes with postentry stages of the MNV life cycle. Metabolic stability and pharmacokinetic assays showed that C6 has a half-life in mouse liver microsomes of ∼20 min and has a half-life of approximately 4 h in mice when administered intravenously. Our results provide a framework for targeting the host ubiquitin system in the development of host-based therapies for infectious disease. Compound C6 represents a promising tool with which to elucidate the role of DUBs in the macrophage response to infection. PMID:27139470

  4. Multifunctional Electrospun Nanofibers Incorporated with an Anti-infection Drug and Immobilized with Proteins

    Science.gov (United States)

    Zhou, Shufei

    Electrospinning has been used to fabricate ultrafine fibers with sizes ranging from nano to micrometers. Nanofibers electrospun from biocompatible and biodegradable polymers have been extensively investigated for their potential applications in wound healing and tissue regeneration. These nanofiber materials can be modified to incorporate bioactive molecules, such as antibacterial agents that provide infection control, or functional proteins which promote cell proliferation and tissue reconstruction. Despite the numerous studies on the development and design of nanofibers for biomedical applications, there has been little research on multifunctional nanofibers that are incorporated with both antibacterial drug(s) and bioactive proteins. The objective of the current study is, therefore, to develop nanofibers that are functionalized by several bioactive molecules. In this study, electrospinning was utilized to fabricate nanofibers from biodegradable polymers PLLA (Poly-L-lactide) and the copolymer PLLA-PEG (Polyethylene glycol)-NH2.A water soluble antibiotic drug, Tetracycline Hydrochloride (TCH), was incorporated into the electrospun nanofibers via emulsion electrospinning. The TCH-loaded nanofibers were surface modified to produce functional groups that can be further conjugated with a model protein, Bovine Serum Albumin (BSA).Drug releasing profiles of the medicated nanofibers were monitored and their antimicrobial properties were evaluated. Proteins (BSAs) immobilized on the fiber surface were verified by ATR-FTIR. The number of immobilized BSAs was determined using a UV-Vis spectrophotometer. The results of the study suggested that this multifunctional nanofibrous material could be a promising material for wound dressing or scaffolds for tissue engineering.

  5. 75 FR 10490 - Joint Meeting of the Arthritis Drugs Advisory Committee and the Drug Safety and Risk Management...

    Science.gov (United States)

    2010-03-08

    ... the Drug Safety and Risk Management Advisory Committee; Notice of Meeting AGENCY: Food and Drug...: Arthritis Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee....

  6. 77 FR 13612 - Anti-Infective Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-03-07

    .... to 3:30 p.m. Location: DoubleTree by Hilton Hotel Washington DC/Silver Spring, The Ballrooms, 8727 Colesville Rd., Silver Spring, MD. The hotel telephone number is: 301 589-5200. Contact Person: Minh Doan... of pneumonic plague (plague infection with extensive lung involvement) in African Green Monkeys...

  7. 78 FR 48690 - Anti-Infective Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-08-09

    ... 20993-0002. Information regarding special accommodations due to a disability, visitor parking, and... by Paladin Therapeutics, Inc., for the proposed indication of treatment of patients with visceral... with physical disabilities or special needs. If you require special accommodations due to a...

  8. Improving Pharmacokinetic-Pharmacodynamic Modeling to Investigate Anti-Infective Chemotherapy with Application to the Current Generation of Antimalarial Drugs

    OpenAIRE

    Katherine Kay; Hastings, Ian M.

    2013-01-01

    Mechanism-based pharmacokinetic-pharmacodynamic (PK/PD) modelling is the standard computational technique for simulating drug treatment of infectious diseases with the potential to enhance our understanding of drug treatment outcomes, drug deployment strategies, and dosing regimens. Standard methodologies assume only a single drug is used, it acts only in its unconverted form, and that oral drugs are instantaneously absorbed across the gut wall to their site of action. For drugs with short ha...

  9. Improving pharmacokinetic-pharmacodynamic modeling to investigate anti-infective chemotherapy with application to the current generation of antimalarial drugs.

    Directory of Open Access Journals (Sweden)

    Katherine Kay

    Full Text Available Mechanism-based pharmacokinetic-pharmacodynamic (PK/PD modelling is the standard computational technique for simulating drug treatment of infectious diseases with the potential to enhance our understanding of drug treatment outcomes, drug deployment strategies, and dosing regimens. Standard methodologies assume only a single drug is used, it acts only in its unconverted form, and that oral drugs are instantaneously absorbed across the gut wall to their site of action. For drugs with short half-lives, this absorption period accounts for a significant period of their time in the body. Treatment of infectious diseases often uses combination therapies, so we refined and substantially extended the PK/PD methodologies to incorporate (i time lags and drug concentration profiles resulting from absorption across the gut wall and, if required, conversion to another active form; (ii multiple drugs within a treatment combination; (iii differing modes of action of drugs in the combination: additive, synergistic, antagonistic; (iv drugs converted to an active metabolite with a similar mode of action. This methodology was applied to a case study of two first-line malaria treatments based on artemisinin combination therapies (ACTs, artemether-lumefantrine and artesunate-mefloquine where the likelihood of increased artemisinin tolerance/resistance has led to speculation on their continued long-term effectiveness. We note previous estimates of artemisinin kill rate were underestimated by a factor of seven, both the unconverted and converted form of the artemisinins kill parasites and the extended PK/PD methodology produced results consistent with field observations. The simulations predict that a potentially rapid decline in ACT effectiveness is likely to occur as artemisinin resistance spreads, emphasising the importance of containing the spread of artemisinin resistance before it results in widespread drug failure. We found that PK/PD data is generally very

  10. 2009~2010年我院抗感染药物使用分析%Application analysis of anti-infective drugs in our hospital from 2009 to 2010

    Institute of Scientific and Technical Information of China (English)

    王诗鸿; 王秀中; 郑丽莹

    2012-01-01

    目的 了解我院抗感染药物的应用情况,为临床合理用药提供参考.方法 依托我院药品管理系统的原始数据,对我院2009~2010年抗感染药物的销售金额和用药频度(DDDs)等进行回顾性分析.结果 2009~2010年我院抗感染药物销售金额占药品销售总金额的比例呈下降趋势,在销售金额构成上,注射用药占90%以上,头孢菌素类、喹诺酮类位居前列,注射用头孢地嗪的销售金额和DDDs排序两年均居首位.结论我院抗感染药物使用基本合理,但仍存在少数品种过量使用,选择起点过高等问题,应进一步加强监管力度,促进抗感染药物的合理使用.%Objective To investigate and analyze the application of anti-infective drugs in our hospital, in order to provide references for rational clinical medication. Methods Depending on the original data from the management system of the drug stock, the data of anti-infective drugs application in our hospital from 2009 to 2010 were analyzed in respect of consumption sum, DDDs and so on. Results The consumption sum of anti-infective drugs in our hospital from 2009 to 2010 showed a downward trend. In the constitution of sales amount, intravenous drugs occupied more than 90% among all the anti-infective drugs. Cephalosporins and quinolones ranked the top places in respect of the consumption sum. Cefodizime for injection ranked the first place in respect of the consumption sum and DDDs from 2009 to 2010. Conclusion The use of antiinfective drugs is basically rational in our hospital. However, there are also some inappropriate problems such as drug overdose, selection of senior antibiotics and so on. It's necessary to strengthen supervision dynamicsc for promoting ration use of anti-infective drugs.

  11. 76 FR 36930 - National Advisory Council on Alcohol Abuse and Alcoholism and National Advisory Council on Drug...

    Science.gov (United States)

    2011-06-23

    ... HUMAN SERVICES National Institutes of Health National Advisory Council on Alcohol Abuse and Alcoholism... the National Advisory Council on Alcohol Abuse and Alcoholism and the National Institute on Drug Abuse... Committee: National Advisory Council on Alcohol Abuse and Alcoholism and National Advisory Council on...

  12. 75 FR 70932 - Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and...

    Science.gov (United States)

    2010-11-19

    ... Advisory Committee and the Drug Safety and Risk Management Advisory Committee; Cancellation AGENCY: Food... Support Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee scheduled for... FR 67093). This meeting has been cancelled because the Agency believes the information received...

  13. HT-SPOTi: A Rapid Drug Susceptibility Test (DST) to Evaluate Antibiotic Resistance Profiles and Novel Chemicals for Anti-Infective Drug Discovery.

    Science.gov (United States)

    Danquah, Cynthia A; Maitra, Arundhati; Gibbons, Simon; Faull, Jane; Bhakta, Sanjib

    2016-01-01

    Antibiotic resistance is one of the major threats to global health and well-being. The past decade has seen an alarming rise in the evolution and spread of drug-resistant strains of pathogenic microbes. The emergence of extensively drug resistant (XDR) strains of Mycobacterium tuberculosis and antimicrobial resistance among the ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, and Enterobacter species) as well as fungal pathogens (such as certain species of Candida, Aspergillus, Cryptococcus, and Trichophyton) poses a significant 21st century scientific challenge. With an extremely limited arsenal of efficacious antibiotics, techniques that can (a) identify novel antimicrobials and (b) detect antimicrobial resistance are becoming increasingly important. In this article, we illustrate the HT-SPOTi, an assay that is principally based on the growth of an organism on agar medium containing a range of different concentrations of drugs or inhibitors. The simple methodology makes this assay ideal for evaluating novel antimicrobial compounds as well as profiling an organism's antibiotic resistance profile. PMID:26855282

  14. 临床药师在1例ICU重症患者抗感染药物治疗中的作用%Role of Clinical Pharmacists in Anti-infective Drug Therapy for a Severe Patient in ICU

    Institute of Scientific and Technical Information of China (English)

    陈燕; 王婧; 陆瑶华; 李颖川; 周明; 郭澄

    2012-01-01

    OBJECTIVE: To investigate the role of clinical pharmacists in the determining of drug therapy for ICU severe patients. METHODS: One case of intestinal obstruction patient with septic shock was analyzed descriptively in terms of disease course, drug therapy and outcome. The empirical anti-infective therapeutic strategies for the sepsis induced by the abdominal infection with unsatisfactory anti-infection and undetected pathogen were analyzed. Pharmaceutical care mainly concerned about the change of the routine blood test, biochemical function and other laboratory index, especially the specific inflammatory markers. RESULTS: In the course of therapy, clinical pharmacists identified the intraperitoneal drug-resistant E. coli infection was the main problem and selected a broad-spectrum carbapenem antibiotic for the treatment. De-escalation therapy was performed after controlling severe infection, and then the individual anti-infective program was formulated in the course of antibiotic therapy to promote disease condition. CONCLUSION: Clinical pharmacists should participate in the health care team, and help clinicians to adjust drug treatment programs. This attempt may enhance the effect of drug therapy.%目的:探讨临床药师在ICU重症患者药物治疗方案确定中的作用.方法:描述性分析1例肠梗阻术后休克患者的病程发展、药物治疗情况及转归,分析腹腔感染引起脓毒症、感染控制不佳、病原体不明确时的经验治疗策略.药学监护重点关注血常规、生化功能等实验室指标趋势,特别是特异性炎性指标.结果:临床药师针对多部位的耐药菌感染,明确腹腔大肠埃希菌感染为需解决的主要矛盾,选用耐酶广谱的碳青霉烯类及时控制感染后降阶梯治疗,制订个体化抗感染方案,使得病情好转.结论:临床药师参与医疗团队,协助医师调整药物治疗方案,有利于提升患者的药物治疗效果.

  15. 75 FR 1395 - Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-01-11

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee; Notice of... to the public. ] Name of Committee: Cardiovascular and Renal Drugs Advisory Committee....

  16. 75 FR 59730 - Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and...

    Science.gov (United States)

    2010-09-28

    ... Advisory Committee and the Drug Safety and Risk Management Advisory Committee; Notice of Meeting AGENCY... Risk Management Advisory Committee. General Function of the Committees: To provide advice and... public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to...

  17. 75 FR 32189 - Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety...

    Science.gov (United States)

    2010-06-07

    ... Advisory Committee and the Drug Safety and Risk Management Advisory Committee; Notice of Meeting AGENCY... Risk Management Advisory Committee. General Function of the Committees: To provide advice and... public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to...

  18. 75 FR 12767 - Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and...

    Science.gov (United States)

    2010-03-17

    ... Advisory Committee and the Drug Safety and Risk Management Advisory Committee; Notice of Meeting AGENCY... Risk Management Advisory Committee. General Function of the Committees: To provide advice and... public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to...

  19. 76 FR 40735 - Joint Meeting of the Advisory Committee for Reproductive Health Drugs and the Drug Safety and...

    Science.gov (United States)

    2011-07-11

    ... Health Drugs and the Drug Safety and Risk Management Advisory Committee; Notice of Meeting AGENCY: Food... of Committees: Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committee. General Function of the Committees: To provide advice and recommendations...

  20. 78 FR 20327 - Joint Meeting of the Advisory Committee for Reproductive Health Drugs and the Drug Safety and...

    Science.gov (United States)

    2013-04-04

    ... Health Drugs and the Drug Safety and Risk Management Advisory Committee; Amendment of Notice AGENCY: Food... Drug Safety and Risk Management Advisory Committee. This meeting was announced in the Federal Register... the Drug Safety and Risk Management Advisory Committee would be held on April 18, 2013. On page...

  1. 77 FR 75176 - Drug Safety and Risk Management Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-12-19

    ... HUMAN SERVICES Food and Drug Administration Drug Safety and Risk Management Advisory Committee; Notice..., 2012, Drug Safety and Risk Management Advisory Committee meeting due to unanticipated weather conditions caused by Hurricane Sandy. Name of Committee: Drug Safety and Risk Management Advisory...

  2. 75 FR 23782 - Drug Safety and Risk Management Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-05-04

    ... HUMAN SERVICES Food and Drug Administration Drug Safety and Risk Management Advisory Committee; Notice... forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public. Name of Committee: Drug Safety and Risk Management Advisory Committee....

  3. 78 FR 64957 - Joint Meeting of the Gastrointestinal Drugs Advisory Committee and the Drug Safety and Risk...

    Science.gov (United States)

    2013-10-30

    ... Committee and the Drug Safety and Risk Management Advisory Committee; Notice of Joint Meeting AGENCY: Food... public. Name of Committees: Gastrointestinal Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee. General Function of the Committees: To provide advice and recommendations...

  4. 76 FR 19374 - Joint Meeting of the Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety and...

    Science.gov (United States)

    2011-04-07

    ... Committee and the Drug Safety and Risk Management Advisory Committee; Notice of Meeting AGENCY: Food and.... Name of Committees: Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee. General Function of the Committees: To provide advice and recommendations...

  5. 78 FR 30929 - Drug Safety and Risk Management Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-05-23

    ... HUMAN SERVICES Food and Drug Administration Drug Safety and Risk Management Advisory Committee; Notice... be open to the public. Name of Committee: Drug Safety and Risk Management Advisory Committee. General... and Risk Management Advisory Committee (DSaRM). On July 10, 2013, the Agency plans to discuss the...

  6. Analysis of 572 Cases of Drug-induced Liver Injury Induced by Anti-infective Agents%抗感染药致药源性肝损伤572例分析

    Institute of Scientific and Technical Information of China (English)

    朱曼; 徐元杰; 郭代红; 史录文; 韩晟; 任昭; 蔡乐; 凡超; 陈超; 马亮

    2015-01-01

    目的:了解抗感染药相关的药源性肝损伤(DILI)发生的情况及特点,为防治抗感染药相关的DILI提供参考。方法:采用回顾性分析方法,调取2009-2013年解放军药品不良反应(ADR)监测中心数据库中抗感染药致DILI报告572例,对涉及患者的年龄、性别、主要诊断等基本信息,引发DILI的药物类别与品种、剂型、给药途径、发生时间、实验室指标、DILI分型及临床表现,保肝药物的应用以及转归等情况进行描述性统计、分析。结果:572例DILI中,男性患者412例(72.03%),女性患者160例(27.97%),平均年龄(44.54±23.75)岁;涉及抗感染药六大类57个品种,引发ADR频次较高的药物为利福平、异烟肼、莫西沙星、氟康唑、阿奇霉素、头孢呋辛、头孢哌酮/舒巴坦、左氧氟沙星、头孢西丁和伏立康唑等;静脉滴注是引发ADR的主要给药途径,占74.48%。ADR的发生时间相对集中,多在用药后2周以内(86.19%)。对可进行肝损伤分型的360例ADR评价,以肝细胞损伤型为主,占93.33%。大部分病例在停药和对症治疗后治愈和好转(82.17%)。结论:头孢菌素类、氟喹诺酮类、抗结核药以及抗真菌药物可能是引发抗感染药致DILI的主要药物,临床分型以肝细胞损伤型最为常见,患者大多预后良好。临床医务人员应该提高对抗感染药致DILI的认识,并加强防范。%OBJECTIVE:To investigate the condition and characteristics of drug-induced liver injury (DILI) of anti-infective agents and provide reference for the prevention and treatment of anti-infective agents related DILI. METHODS:Based on retrospective analysis,a total of 572 DILI reports of anti-infective agents were collected from PLA ADR monitoring center during 2009 to 2013, and then analyzed statistically in terms of patient’s age and gender,main diagonosis,categories of DILI

  7. 76 FR 37131 - Joint Meeting of the Gastrointestinal Drugs Advisory Committee and the Drug Safety and Risk...

    Science.gov (United States)

    2011-06-24

    ... Committee and the Drug Safety and Risk Management Advisory Committee; Notice of Meeting AGENCY: Food and... and Risk Management Advisory Committee. General Function of the Committees: To provide advice and... advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will...

  8. 75 FR 17417 - Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management...

    Science.gov (United States)

    2010-04-06

    ... Drug Safety and Risk Management Advisory Committee; Amendment of Notice AGENCY: Food and Drug... Management Advisory Committee. This meeting was announced in the Federal Register of March 8, 2010 (75 FR... meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory...

  9. Anti-infective Natural Products from Cyanobacteria.

    Science.gov (United States)

    Niedermeyer, Timo Horst Johannes

    2015-10-01

    Cyanobacteria are a promising yet underexplored source for novel natural products with potent biological activities. While predominantly cytotoxic compounds have been isolated from cyanobacteria in the past, there are also a significant number of compounds known that possess anti-infective activities. As the need for novel anti-infective lead compounds is high, this manuscript aims at giving a concise overview on the current knowledge about anti-infective secondary metabolites isolated from cyanobacteria. Antibacterial, antifungal, antiviral, antiprotozoal, and molluscicidal activities are discussed. Covering up to February 2015.

  10. 77 FR 14404 - Guidance for the Public, Food and Drug Administration (FDA) Advisory Committee Members, and FDA...

    Science.gov (United States)

    2012-03-09

    ... HUMAN SERVICES Food and Drug Administration Guidance for the Public, Food and Drug Administration (FDA) Advisory Committee Members, and FDA Staff: Public Availability of Advisory Committee Members' Financial Interest Information and Waivers; Availability AGENCY: Food and Drug Administration, HHS. ACTION:...

  11. Anti-infective immunoadhesins from plants.

    Science.gov (United States)

    Wycoff, Keith; Maclean, James; Belle, Archana; Yu, Lloyd; Tran, Y; Roy, Chad; Hayden, Frederick

    2015-10-01

    Immunoadhesins are recombinant proteins that combine the ligand-binding region of a receptor or adhesion molecule with immunoglobulin constant domains. All FDA-approved immunoadhesins are designed to modulate the interaction of a human receptor with its normal ligand, such as Etanercept (Enbrel(®) ), which interferes with the binding of tumour necrosis factor (TNF) to the TNF-alpha receptor and is used to treat inflammatory diseases such as rheumatoid arthritis. Like antibodies, immunoadhesins have long circulating half-lives, are readily purified by affinity-based methods and have the avidity advantages conferred by bivalency. Immunoadhesins that incorporate normal cellular receptors for viruses or bacterial toxins hold great, but as yet unrealized, potential for treating infectious disease. As decoy receptors, immunoadhesins have potential advantages over pathogen-targeted monoclonal antibodies. Planet Biotechnology has specialized in developing anti-infective immunoadhesins using plant expression systems. An immunoadhesin incorporating the cellular receptor for anthrax toxin, CMG2, potently blocks toxin activity in vitro and protects animals against inhalational anthrax. An immunoadhesin based on the receptor for human rhinovirus, ICAM-1, potently blocks infection of human cells by one of the major causes of the common cold. An immunoadhesin targeting the MERS coronavirus is in an early stage of development. We describe here the unique challenges involved in designing and developing immunoadhesins targeting infectious diseases in the hope of inspiring further research into this promising class of drugs. PMID:26242703

  12. 77 FR 65000 - Drug Safety and Risk Management Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-10-24

    ... HUMAN SERVICES Food and Drug Administration Drug Safety and Risk Management Advisory Committee; Notice... be open to the public. Name of Committee: Drug Safety and Risk Management Advisory Committee. General... Committee (DSaRM). The Agency plans to present information on the risk management of teratogens, some...

  13. 77 FR 34051 - Drug Safety and Risk Management Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-06-08

    ... HUMAN SERVICES Food and Drug Administration Drug Safety and Risk Management Advisory Committee; Notice... be open to the public. Name of Committee: Drug Safety and Risk Management Advisory Committee. General... 29 and 30, 2012, the committee will discuss the public health benefits and risks, including...

  14. 77 FR 43600 - Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-07-25

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee; Notice of... to the public. Name of Committee: Cardiovascular and Renal Drugs Advisory Committee. General...

  15. 77 FR 21982 - Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-04-12

    ... HUMAN SERVICES Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee; Notice of... to the public. Name of Committee: Cardiovascular and Renal Drugs Advisory Committee. General Function... patients with acute coronary syndrome (ACS) [ST elevation myocardial infarction (STEMI), non-ST...

  16. 78 FR 76307 - Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-12-17

    ... HUMAN SERVICES Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee; Notice of... to the public. Name of Committee: Cardiovascular and Renal Drugs Advisory Committee. General Function... atherothrombotic events in patients with a history of myocardial infarction (MI). The applicant also proposes...

  17. 78 FR 76308 - Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-12-17

    ... HUMAN SERVICES Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee; Notice of... to the public. Name of Committee: Cardiovascular and Renal Drugs Advisory Committee. General Function... coronary syndrome [ST elevation myocardial infarction, non-ST elevation myocardial infarction, or...

  18. 76 FR 23324 - Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-04-26

    ... HUMAN SERVICES Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee... be open to the public. Name of Committee: Endocrinologic and Metabolic Drugs Advisory Committee... and coronary heart disease (CHD) or CHD risk equivalent who are on optimal statin therapy to...

  19. 78 FR 50423 - Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-08-19

    ... HUMAN SERVICES Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee... be open to the public. Name of Committee: Endocrinologic and Metabolic Drugs Advisory Committee...) or a CHD risk equivalent. FDA intends to make background material available to the public no...

  20. 76 FR 29766 - Pulmonary-Allergy Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-05-23

    ... HUMAN SERVICES Food and Drug Administration Pulmonary-Allergy Drugs Advisory Committee; Notice of... to the public. Name of Committee: Pulmonary-Allergy Drugs Advisory Committee. General Function of the... (proposed trade name Firazyr), Shire Human Genetic Therapies, for the proposed indication of treatment...

  1. 75 FR 82031 - Pulmonary-Allergy Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-12-29

    ... HUMAN SERVICES Food and Drug Administration Pulmonary-Allergy Drugs Advisory Committee; Notice of... to the public. Name of Committee: Pulmonary-Allergy Drugs Advisory Committee. General Function of the... Pharmaceuticals Corp., for the long-term once daily maintenance bronchodilator treatment of airflow obstruction...

  2. 77 FR 4566 - Pulmonary-Allergy Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-01-30

    ... HUMAN SERVICES Food and Drug Administration Pulmonary-Allergy Drugs Advisory Committee; Notice of... to the public. Name of Committee: Pulmonary-Allergy Drugs Advisory Committee. General Function of the... Laboratories, for the proposed ] indication of long-term maintenance treatment of bronchospasm associated...

  3. 77 FR 69635 - Pulmonary-Allergy Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-11-20

    ... HUMAN SERVICES Food and Drug Administration Pulmonary-Allergy Drugs Advisory Committee; Notice of... to the public. Name of Committee: Pulmonary-Allergy Drugs Advisory Committee. General Function of the... bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease...

  4. 75 FR 9420 - Pulmonary-Allergy Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-03-02

    ... HUMAN SERVICES Food and Drug Administration Pulmonary-Allergy Drugs Advisory Committee; Notice of... to the public. Name of Committee: Pulmonary-Allergy Drugs Advisory Committee. General Function of the... (NDA) 22-522, roflumilast (DAXAS), Forest Research Institute, for the maintenance treatment of...

  5. 75 FR 5334 - Pulmonary-Allergy Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-02-02

    ... HUMAN SERVICES Food and Drug Administration Pulmonary-Allergy Drugs Advisory Committee; Notice of... to the public. Name of Committee: Pulmonary-Allergy Drugs Advisory Committee. General Function of the... in the treatment of asthma in adults, adolescents, and children. FDA intends to make...

  6. 78 FR 46976 - Pulmonary-Allergy Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-08-02

    ... HUMAN SERVICES Food and Drug Administration Pulmonary-Allergy Drugs Advisory Committee; Notice of... to the public. Name of Committee: Pulmonary-Allergy Drugs Advisory Committee. General Function of the... (d/b/a/GSK) for the long-term, once- daily, maintenance treatment of airflow obstruction in...

  7. 77 FR 74486 - Pulmonary-Allergy Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-12-14

    ... HUMAN SERVICES Food and Drug Administration Pulmonary-Allergy Drugs Advisory Committee; Notice of... to the public. Name of Committee: Pulmonary-Allergy Drugs Advisory Committee. General Function of the... (proposed tradename BREO ELLIPTA), sponsored by GlaxoSmithKline, for the long-term maintenance treatment...

  8. 78 FR 63224 - Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-10-23

    ... HUMAN SERVICES Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee... be open to the public. Name of Committee: Endocrinologic and Metabolic Drugs Advisory Committee... Type IVA (Morquio A syndrome). Morquio A syndrome is a rare congenital disorder caused by the...

  9. 75 FR 5333 - Pulmonary-Allergy Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-02-02

    ... pulmonary fibrosis (scarring of the lungs without a known cause) to decrease the decline in lung function... HUMAN SERVICES Food and Drug Administration Pulmonary-Allergy Drugs Advisory Committee; Notice of... to the public. Name of Committee: Pulmonary-Allergy Drugs Advisory Committee. General Function of...

  10. 77 FR 69636 - Pulmonary-Allergy Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-11-20

    ... HUMAN SERVICES Food and Drug Administration Pulmonary-Allergy Drugs Advisory Committee; Notice of... to the public. Name of Committee: Pulmonary-Allergy Drugs Advisory Committee. General Function of the... sponsored by Pharmaxis, for the proposed indication of management of cystic fibrosis in patients aged...

  11. The Food and Drug Administration advisory committees and panels: how they are applied to the drug regulatory process.

    Science.gov (United States)

    Ciociola, Arthur A; Karlstadt, Robyn G; Pambianco, Daniel J; Woods, Karen L; Ehrenpreis, Eli D

    2014-10-01

    Food and Drug Administration (FDA) advisory panels and committees play a critical role in advising the FDA on the safety and efficacy of medical devices and drugs marketed in the US. Advisory panel recommendations are used by the FDA to make decisions regarding medical products. Currently, the FDA utilizes over 50 advisory panels that serve the three major FDA centers, including the Centers for Biologics, Drugs and Device Products. Members of an advisory panel typically include academicians, clinicians, consumers, patients, and industry representatives. The FDA establishes the schedules for advisory panel meetings on an annual basis and a panel usually meets several times a year for two consecutive days in Washington, DC. Typically, the advisory panel discusses issues highlighted by the FDA and is then asked to vote a response to the questions posed in advance by the FDA. Advisory panel recommendations have a strong influence on FDA's decision to approve a product, as evidenced by the 214 Advisory Panels FDA convened between January 2008 to November 2012, during which advisory panel members voted to approve the product (or use of the product) ∼74% of the time, with FDA ultimately approving the medical product (or use of the product) ∼79% of the time. The ACG membership are encouraged to consider serving the public's interest by participating in an FDA advisory panel utilizing their expertise for the evaluation of a new drug or medical device, and providing advice about whether the product should be sold in the US.

  12. 77 FR 61609 - Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-10-10

    ... HUMAN SERVICES Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee... efficacy of new drug applications (NDAs) 203313, insulin degludec/insulin aspart [rDNA origin] injection and 203314, insulin degludec injection, manufactured by Novo Nordisk Inc. The proposed indication...

  13. 78 FR 13348 - Science Board to the Food and Drug Administration Advisory Committee; Amendment of Notice

    Science.gov (United States)

    2013-02-27

    ... HUMAN SERVICES Food and Drug Administration Science Board to the Food and Drug Administration Advisory... Administration (FDA) is announcing an amendment to the notice of meeting of the Science Board to the Food and... that a meeting of the Science Board to the Food and Drug Administration would be held on February...

  14. 76 FR 63929 - Joint Meeting of the Drug Safety and Risk Management Advisory Committee and the Dermatologic and...

    Science.gov (United States)

    2011-10-14

    ... public. Name of Committees: Drug Safety and Risk Management Advisory Committee and Dermatologic and... Management Advisory Committee (DSaRM). On December 1, 2011, the DSaRM and the Dermatologic and Ophthalmic... HUMAN SERVICES Food and Drug Administration Joint Meeting of the Drug Safety and Risk...

  15. 75 FR 56548 - Joint Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee and the Drug...

    Science.gov (United States)

    2010-09-16

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Joint Meeting of the Peripheral and Central Nervous System... the public. Name of Committees: Peripheral and Central Nervous System Drugs Advisory Committee and...

  16. Liposomes as novel anti-infectives targeting bacterial virulence factors?

    Science.gov (United States)

    Azeredo da Silveira, Samareh; Perez, Antonio

    2015-05-01

    A recent report commissioned by Prime Minister David Cameron and chaired by former Goldman Sachs chief economist Jim O'Neill warns that the emergence, persistence and spread of antimicrobial resistance could lead to 10 million deaths per year and cause an economic burden as much as US$100 trillion by 2050. In the midst of this global crisis, unprecedented paths are being explored to combat bacterial infection. Virulence factors, and more particularly pore-forming toxins, play a key role in increasing morbidity and mortality caused by drug-resistant bacterial infections. Novel anti-infective liposomes specifically targeting and neutralizing these cytotoxic toxins are potential game-changers in the fight against deadly infections. PMID:25850805

  17. 75 FR 17417 - Peripheral and Central Nervous System Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-04-06

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Peripheral and Central Nervous System Drugs Advisory...). The meeting will be open to the public. Name of Committee: Peripheral and Central Nervous System...

  18. 76 FR 3912 - Peripheral and Central Nervous System Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-01-21

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Peripheral and Central Nervous System Drugs Advisory...). The meeting will be open to the public. Name of Committee: Peripheral and Central Nervous System...

  19. 78 FR 20328 - Peripheral and Central Nervous System Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-04-04

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Peripheral and Central Nervous System Drugs Advisory...). The meeting will be open to the public. Name of Committee: Peripheral and Central Nervous System...

  20. 78 FR 63478 - Peripheral and Central Nervous System Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-10-24

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Peripheral and Central Nervous System Drugs Advisory...). The meeting will be open to the public. Name of Committee: Peripheral and Central Nervous System...

  1. 76 FR 44595 - Peripheral and Central Nervous System Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-07-26

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Peripheral and Central Nervous System Drugs Advisory...). The meeting will be open to the public. Name of Committee: Peripheral and Central Nervous System...

  2. 75 FR 12768 - Peripheral and Central Nervous System Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-03-17

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Peripheral and Central Nervous System Drugs Advisory...). The meeting will be open to the public. Name of Committee: Peripheral and Central Nervous System...

  3. 77 FR 20037 - Peripheral and Central Nervous System Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-04-03

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Peripheral and Central Nervous System Drugs Advisory...). The meeting will be open to the public. Name of Committee: Peripheral and Central Nervous System...

  4. 75 FR 75681 - Peripheral and Central Nervous System Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-12-06

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Peripheral and Central Nervous System Drugs Advisory...). The meeting will be open to the public. Name of Committee: Peripheral and Central Nervous System...

  5. 78 FR 63481 - Peripheral and Central Nervous System Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-10-24

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Peripheral and Central Nervous System Drugs Advisory...). The meeting will be open to the public. Name of Committee: Peripheral and Central Nervous System...

  6. 75 FR 36428 - Peripheral and Central Nervous System Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-06-25

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Peripheral and Central Nervous System Drugs Advisory...). The meeting will be open to the public. Name of Committee: Peripheral and Central Nervous System...

  7. Marine-Derived Metabolites of S-Adenosylmethionine as Templates for New Anti-Infectives

    Directory of Open Access Journals (Sweden)

    Janice R. Sufrin

    2009-08-01

    Full Text Available S-Adenosylmethionine (AdoMet is a key biochemical co-factor whose proximate metabolites include methylated macromolecules (e.g., nucleic acids, proteins, phospholipids, methylated small molecules (e.g., sterols, biogenic amines, polyamines (e.g., spermidine, spermine, ethylene, and N-acyl-homoserine lactones. Marine organisms produce numerous AdoMet metabolites whose novel structures can be regarded as lead compounds for anti-infective drug design.

  8. 76 FR 45578 - Request for Nominations for Members on a Public Advisory Committee; Medical Imaging Drugs...

    Science.gov (United States)

    2011-07-29

    ... requesting nominations for voting members on the Medical Imaging Drugs Advisory Committee (the Committee... more qualified persons for membership on the Committee. Self-nominations are also accepted. Nominations... committee for which the nominee is recommended. Nominations must also acknowledge that the nominee is...

  9. 75 FR 21000 - Draft Guidance for the Public, Food and Drug Administration Advisory Committee Members, and Food...

    Science.gov (United States)

    2010-04-22

    ... HUMAN SERVICES Food and Drug Administration (formerly Docket No. 02D-0049) Draft Guidance for the Public, Food and Drug Administration Advisory Committee Members, and Food and Drug Administration Staff: Public...) (added by the Food and Drug Administration Amendments Act of 2007, Public Law No. 110-85), and...

  10. 抗感染新药非达霉素的药理作用与临床评价%Pharmacology and clinical evaluation of the new anti-infective drug fidaxomicin

    Institute of Scientific and Technical Information of China (English)

    姜春梅; 刘洋; 王京晶; 张清; 康博欣

    2011-01-01

    Fidaxomicin (edarbi) is the antibiotic with a novel structure of macrolides for the treatment of clostridium difficile-associated diarrhea ( CDAD). Literature was searched from FDA database with the key word edarbi. The pharmacology, pharmacokinetics, clinical evaluation, safety evaluation and drug interactions of fidaxomicin were reviewed.%非达霉素( fidaxomicin)是一种新型的大环内酯类抗生素,适用于艰难梭菌相关性腹泻(clostridium difficile-associated diarrhea,CDAD)的治疗.本文参考美国FDA的相关资料,对非达霉素的药理作用、药动学、临床评价、安全性评价及药物相互作用等进行综述.

  11. 76 FR 82309 - Oncologic Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-12-30

    ... Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 31, rm. 2417, Silver Spring, MD... product is for the treatment of acute myelogenous leukemia (AML) in adults 65 years of age or older...

  12. OxyContin: Prescription Drug Abuse. CSAT Advisory.

    Science.gov (United States)

    Substance Abuse and Mental Health Services Administration (DHHS/PHS), Rockville, MD. Center for Substance Abuse Treatment.

    Recently, the media have issued numerous reports about the apparent increase in OxyContin abuse and addiction. OxyContin has been heralded as a miracle drug that allows patients with chronic pain to resume a normal life. It has also been called pharmaceutical heroin and is thought to have been responsible for a number of deaths and robberies in…

  13. 75 FR 30045 - Oncologic Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-05-28

    ... cancer known as HER2-negative breast cancer, in combination with the chemotherapy drug docetaxel; and (2) first-line treatment of HER2-negative metastatic breast cancer in combination with one of two classes of... for their locally recurrent or metastatic HER2 negative breast cancer. FDA intends to make...

  14. 洋葱伯克霍尔德菌感染家兔抗感染疗效与体外药物敏感性的比较%Comparison of the anti-infective drug sensitivity in rabbit model of Burkholderia cepacia infection and the effect of antimicrobial sensitivity monitoring in vitro

    Institute of Scientific and Technical Information of China (English)

    吕火祥; 胡庆丰; 沈蓓琼; 杨广宇; 俞赛

    2011-01-01

    rabbit in Group A was injected 1 mL of 2 g/mL Piperacillin-Tazobactam, each rabbit in Group B was injected 1 mL of 0.6 g/mL Ticarcillin-clavulanate, and each rabbits in Group C with 1 mL of 0. 1 g/mL Cefepime. The sensitivity test results by MIC method, disc agar diffusion method ( KB method) and VITEK method and their relationship with the efficacy of treatment were compared. Results The consistency of K-B assay results of Piperacillin/tazobactam treatment group ( group A) with the treatment of infection model was 72.2%, while that of MIC method was 66.7%, and that of VITEK method was 66.7% as well. In Ticarcillin/clavulanic acid treatment group (group B), the consistency of MIC method was 83.3%, that of VITEK method was 77.8%, and that of K-B method was 50.0%. In Cefepime treatment group (group C), the consistency of MIC method was 88.9%, that of VITEK method was 77.8%, and that of K-B method was 72.2%. Conclusion Among the 3 antimicrobial sensitivity test methods, the KB result of piperacillin/tazobactam was the closest to the results of anti-infective efficacy in infected rabbits,while the MIC results of ticarcillin/clavulanic acid and cefepime were the closest to the results of anti-infective efficacy; For the treatment of Burkholderia cepacia infection, it is suggested to determine the drug sensitivity in vitro using different methods.

  15. Screening for potential anti-infective agents towards Burkholderia pseudomallei infection

    Science.gov (United States)

    Eng, Su Anne; Nathan, Sheila

    2014-09-01

    The established treatment for melioidosis is antibiotic therapy. However, a constant threat to this form of treatment is resistance development of the causative agent, Burkholderia pseudomallei, towards antibiotics. One option to circumvent this threat of antibiotic resistance is to search for new alternative anti-infectives which target the host innate immune system and/or bacterial virulence. In this study, 29 synthetic compounds were evaluated for their potential to increase the lifespan of an infected host. The nematode Caenorhabditis elegans was adopted as the infection model as its innate immune pathways are homologous to humans. Screens were performed in a liquid-based survival assay containing infected worms exposed to individual compounds and survival of untreated and compound-treated worms were compared. A primary screen identified nine synthetic compounds that extended the lifespan of B. pseudomallei-infected worms. Subsequently, a disc diffusion test was performed on these selected compounds to delineate compounds into those that enhanced the survival of worms via antimicrobial activity i.e. reducing the number of infecting bacteria, or into those that did not target pathogen viability. Out of the nine hits selected, two demonstrated antimicrobial effects on B. pseudomallei. Therefore, the findings from this study suggest that the other seven identified compounds are potential anti-infectives which could protect a host against B. pseudomallei infection without developing the risk of drug resistance.

  16. 78 FR 69991 - Advisory Committee; Veterinary Medicine Advisory Committee; Termination

    Science.gov (United States)

    2013-11-22

    ... HUMAN SERVICES Food and Drug Administration 21 CFR Part 14 Advisory Committee; Veterinary Medicine... Food and Drug Administration (FDA) is announcing the termination of the Veterinary Medicine Advisory... Michael.Ortwerth@fda.hhs.gov . SUPPLEMENTARY INFORMATION: The Veterinary Medicine Committee...

  17. 75 FR 35496 - Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-06-22

    ... Inn and Conference Center, University of Maryland University College, 3501 University Blvd. East... attendance of the public at its advisory committee meetings and will make every effort to accommodate...

  18. 75 FR 57474 - Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-09-21

    ... Marriott Inn and Conference Center, University of Maryland University College, 3501 University Boulevard... attendance of the public at its advisory committee meetings and will make every effort to accommodate...

  19. 76 FR 30176 - Dermatologic and Ophthalmic Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-05-24

    ... Marriott Inn and Conference Center, University of Maryland University College (UMUC), 3501 University Blvd... attendance of the public at its advisory committee meetings and will make every effort to accommodate...

  20. Anti-infective potential of hot-spring bacteria

    Directory of Open Access Journals (Sweden)

    Pallavi Pednekar

    2011-01-01

    Full Text Available Aim and Background: Antibiotic resistance currently spans most of the known classes of natural and synthetic antibiotics; limiting our options for treatment of infections and demanding discovery of new classes of antibiotics. Much effort is being directed towards developing new antibiotics to overcome this problem. Success in getting novel chemical entities from microbial sources depends essentially on novelty of its habitat. The diversity of geographical location decides the type of micro-flora. In the past various terrestrial and aqueous microorganisms have provided several novel bioactive secondary metabolites of pharmaceutical importance. Hot-springs have not been as extensively exploited as other terrestrial resources. However, perseverance with such microbes augment the probability of getting novel bioactive compounds. Materials and Methods: Hot-springs soil samples were collected from Hot-springs in Maharashtra. Actinomycetes and other eubacteria were isolated from these soil samples by selective methods and purified. They were classified based on gram′s nature and morphology. Six representative morphological strains were screened for their anti-infective potential by agar well diffusion method as reported by Nathan P. et al (1974. The bioactivity of the active microbes was confirmed. Results: Seventy three strains of bacteria encompassing eight actinomycetes, and 65 eubacteria were isolated and purified. Among the actives eubacteria PPVWK106001 showed broad spectrum antibacterial activity encompassing both gram positive and gram negative bacterial test models. The extract was active against resistant bacteria such as MRSA and VREs. Activity was very specific as there was no activity against fungi even at 100 fold concentration. The active principle was extractable in butanol. Conclusions: The study showed that Hot-springs exhibit diverse bacteria and it serves as potential reservoirs for bacteria of antimicrobial importance with

  1. 76 FR 59143 - Joint Meeting of the Advisory Committee for Reproductive Health Drugs and the Drug Safety and...

    Science.gov (United States)

    2011-09-23

    ..., from 8 a.m. to 5 p.m. Location: The Marriott Inn and Conference Center, University of Maryland University College, The Ballroom, 3501 University Blvd. East, Adelphi, MD. The conference center telephone... welcomes the attendance of the public at its advisory committee meetings and will make every effort...

  2. 76 FR 59142 - Joint Meeting of the Advisory Committee for Reproductive Health Drugs and the Drug Safety and...

    Science.gov (United States)

    2011-09-23

    ..., from 8 a.m. to 5 p.m. Location: The Marriott Inn and Conference Center, University of Maryland University College (UMUC), The Ballroom, 3501 University Blvd., ] East, Adelphi, MD. The conference center... welcomes the attendance of the public at its advisory committee meetings and will make every effort...

  3. 75 FR 32188 - Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and...

    Science.gov (United States)

    2010-06-07

    ... 23, 2010, from 8 a.m. to 4:30 p.m. Location: The Marriott Inn and Conference Center, University of Maryland University College, 3501 University Boulevard East, Adelphi, MD. The conference center telephone... attendance of the public at its advisory committee meetings and will make every effort to accommodate...

  4. Silver Nanoparticles/Ibuprofen-Loaded Poly(l-lactide Fibrous Membrane: Anti-Infection and Anti-Adhesion Effects

    Directory of Open Access Journals (Sweden)

    Shuai Chen

    2014-08-01

    Full Text Available Infection caused by bacteria is one of the crucial risk factors for tendon adhesion formation. Silver nanoparticles (AgNP-loaded physical barriers were reported to be effective in anti-infection and anti-adhesion. However, high silver load may lead to kidney and liver damages. This study was designed for Ibuprofen (IBU-loaded poly(l-lactide (PLLA electrospun fibrous membranes containing a low dosage of Ag to evaluate its potential in maintaining suitable anti-infection and good anti-adhesion effects. The in vitro drug release study showed a sustained release of Ag ions and IBU from the membrane. Inferior adherence and proliferation of fibroblasts were found on the Ag4%–IBU4%-loaded PLLA electrospun fibrous membranes in comparison with pure PLLA and 4% Ag-loaded PLLA membranes. In the antibacterial test, all Ag-loaded PLLA electrospun fibrous membranes prevented the adhesion of Staphylococcus aureus and Staphylococcus epidermidis. Taken together, these results demonstrate that Ibuprofen is effective in enhancing the anti-adhesion and anti-proliferation effects of 4% Ag-loaded PLLA fibrous membrane. The medical potential of infection reduction and adhesion prevention of Ag4%–IBU4%-loaded PLLA electrospun fibrous membrane deserves to be further studied.

  5. 78 FR 37821 - Joint Meeting of the Risk Communication Advisory Committee and Tobacco Products Scientific...

    Science.gov (United States)

    2013-06-24

    ...: Risk Communication Advisory Committee and Tobacco Products Scientific Advisory Committee. General... HUMAN SERVICES Food and Drug Administration Joint Meeting of the Risk Communication Advisory Committee and Tobacco Products Scientific Advisory Committee; Notice of Joint Meeting AGENCY: Food and...

  6. Anti-infectives for systemic use prescribed in a Spanish hospital between 2009-2013.

    Science.gov (United States)

    March Rosselló, Gabriel Alberto; Mora, Arturo Artero; Pérez Rubio, Alberto; Eiros Bouza, José María

    2016-01-01

    The overuse and misuse of antimicrobials contribute to the emergence of antibiotic-resistant bacteria. The aim of this work was to analyse all the anti-infectives for systemic use (J ATC group) prescribed at the University Clinic Hospital of Valladolid (Spain) for the years 2009-2013. Amounts of anti-infectives (antibacterials, antifungals and antivirals) used in the period 2009-2013 were expressed as defined daily doses (DDDs) and as total expenditure, and the significance of the difference in consumption of anti-infectives and the relevant expenditure between years was evaluated from the overlapping of the corresponding confidence intervals at 95% confidence level of DDDs and expenditure. The results obtained showed that DDDs and expenditure of antibacterials decreased in the period 2009-2013. Antimycotics showed an upward trend in expenditure and DDDs in the five-year study period, but with major oscillations. The consumption of antivirals was practically constant in the period 2009-2011; in 2012, a significant reduction was observed and this reduction was conserved in 2013, although their expenditure increased year by year. In conclusion, in the period 2009-2013, expenditure on anti-infectives increased year to year. However, this increase in expenditure resulted in a downward trend of DDDs. PMID:27031892

  7. Preliminary study of anti-infective function of a copper-bearing stainless steel

    International Nuclear Information System (INIS)

    In this study the copper (Cu)-bearing stainless steel was developed to reduce the incidence of implant-associated infections in clinical areas. A 317L austenitic stainless steel containing 4.5% Cu (317L-Cu SS) was designed and fabricated, and its anti-infective function was preliminarily studied both in vitro and in vivo by means of antibacterial test, confocal laser scanning microscope (CLSM) and scanning electron microscopy (SEM) observations, and animal implantation. The results indicated that the 317L-Cu SS possessed strong antibacterial rates against both Escherichia coli and Staphylococcus aureus, and showed anti-infective ability by inhibiting the formation of bacterial bio-film on surface of the steel due to the release of Cu ions from the steel surface. The microbiological and histological evaluations from animal implantation further proved that the 317L-Cu SS could obviously reduce the happening of bacterial infection, and is potential to be used as a new class of surgical implant material with anti-infective function. - Highlights: ► 317L stainless steel containing 4.5% Cu (317L-Cu SS) showed strong antibacterial role. ► 317L-Cu SS could inhibit the formation of bacterial bio-film on its surface. ► 317L-Cu SS showed anti-infective role in vivo.

  8. Anti-infective bovine colostrum oligosaccharides: Campylobacter jejuni as a case study.

    Science.gov (United States)

    Lane, Jonathan A; Mariño, Karina; Naughton, Julie; Kavanaugh, Devon; Clyne, Marguerite; Carrington, Stephen D; Hickey, Rita M

    2012-07-01

    Campylobacter jejuni is the leading cause of acute bacterial infectious diarrhea in humans. Unlike in humans, C. jejuni is a commensal within the avian host. Heavily colonized chickens often fail to display intestinal disease, and no cellular attachment or invasion has been demonstrated in-vivo. Recently, researchers have shown that the reason for the attenuation of C. jejuni virulence may be attributed to the presence of chicken intestinal mucus and more specifically chicken mucin. Since mucins are heavily glycosylated molecules this observation would suggest that glycan-based compounds may act as anti-infectives against C. jejuni. Considering this, we have investigated naturally sourced foods for potential anti-infective glycans. Bovine colostrum rich in neutral and acidic oligosaccharides has been identified as a potential source of anti-infective glycans. In this study, we tested oligosaccharides isolated and purified from the colostrum of Holstein Friesian cows for anti-infective activity against a highly invasive strain of C. jejuni. During our initial studies we structurally defined 37 bovine colostrum oligosaccharides (BCO) by HILIC-HPLC coupled with exoglycosidase digests and off-line mass spectroscopy, and demonstrated the ability of C. jejuni to bind to some of these structures, in-vitro. We also examined the effect of BCO on C. jejuni adhesion to, invasion of and translocation of HT-29 cells. BCO dramatically reduced the cellular invasion and translocation of C. jejuni, in a concentration dependent manner. Periodate treatment of the BCO prior to inhibition studies resulted in a loss of the anti-infective activity of the glycans suggesting a direct oligosaccharide-bacterial interaction. This was confirmed when the BCO completely prevented C. jejuni binding to chicken intestinal mucin, in-vitro. This study builds a strong case for the inclusion of oligosaccharides sourced from cow's milk in functional foods. However, it is only through further

  9. Recent advances in design of potential quinoxaline anti-infectives.

    Science.gov (United States)

    Jampilek, Josef

    2014-01-01

    Antimicrobial diazanaphthalenes are indispensable in the treatment of various infections. The quinoxaline scaffold possesses unique physicochemical properties and provides a possibility of a great number of targeted modifications. Quinoxaline-based compounds have a wide range of promising biological properties; therefore a special attention is paid to them for research and designing of new drugs. In fact, quinoxaline can be considered as a privileged structure. The scaffold can be easily and rapidly constructed, which emphasizes the significance of this favourable structure. The review is focused on recently reported potential antibacterial, antimycobacterial, antifungal and antiprotozoal agents derived from the quinoxaline scaffold, their mechanism of action and structure-activity relationships. A brief classification of synthetic pathways of quinoxaline derivatives is provided too.

  10. Nanotechnology based anti-infectives to fight microbial intrusions.

    Science.gov (United States)

    Rai, M; Ingle, A P; Gaikwad, S; Gupta, I; Gade, A; Silvério da Silva, S

    2016-03-01

    With the rise in human population across the globe especially in developing countries, the incidence of microbial infections are increasing with greater pace. On the other hand, available medication and therapies are found to be insufficient for the complete cure of such microbial infections due to the development of resistance against various antibiotics. Therefore, to cope up the menace of microbial infections and drug resistance, there is demand for new and compelling technology, which has the ability to impede these problems. Many research groups worldwide are finding a ray of hope in nanomaterials owing to their unique properties. In the present review we have discussed the reasons behind the development of new materials based on nanotechnology. It is mainly focused on pioneering studies on application of nanomaterials like carbon nanotube, fullerene, dendrimers, nanocomposite and metal nanoparticles in combating dreadful pathogens. Moreover, the concerns about their toxicity have also been discussed. PMID:26599354

  11. 78 FR 63222 - Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-10-23

    ... HUMAN SERVICES Food and Drug Administration Pediatric Oncology Subcommittee of the Oncologic Drugs... ] (FDA). The meeting will be open to the public. Name of Committee: Pediatric Oncology Subcommittee of... relevance and potential use of such measures in the pediatric development plans of oncology products....

  12. 75 FR 66773 - Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-10-29

    ... HUMAN SERVICES Food and Drug Administration Pediatric Oncology Subcommittee of the Oncologic Drugs... (FDA). The meeting will be open to the public. Name of Committee: Pediatric Oncology Subcommittee of... were either recently approved by FDA or, are in late stage development for an adult oncology...

  13. 78 FR 63224 - Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-10-23

    ... HUMAN SERVICES Food and Drug Administration Pediatric Oncology Subcommittee of the Oncologic Drugs... (FDA). The meeting will be open to the public. Name of Committee: Pediatric Oncology Subcommittee of... late stage development for various adult oncology indications. The subcommittee will consider...

  14. 76 FR 58520 - Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-09-21

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Pediatric Oncology Subcommittee of the Oncologic Drugs... (FDA). The meeting will be open to the public. Name of Committee: Pediatric Oncology Subcommittee...

  15. 77 FR 57095 - Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-09-17

    ... HUMAN SERVICES Food and Drug Administration Pediatric Oncology Subcommittee of the Oncologic Drugs... (FDA). The meeting will be open to the public. Name of Committee: Pediatric Oncology Subcommittee of... plans for four products that are in development for an adult oncology indication. The subcommittee...

  16. 77 FR 6567 - Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-02-08

    ... the heading ``Resources for You,'' click on ``Public Meetings at the FDA White Oak Campus.'' Please... enough to provide timely notice. Therefore, you should always check the Agency's Web site and call the... preapproval and postapproval settings for drugs and biologics developed for the treatment of obesity....

  17. 78 FR 17414 - Risk Communications Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-03-21

    ...: Luis G. Bravo, Designated Federal Officer, Risk Communication Staff, Office of Planning, Food and Drug... HUMAN SERVICES Food and Drug Administration Risk Communications Advisory Committee; Notice of Meeting... the public. Name of Committee: Risk Communications Advisory Committee. General Function of...

  18. Chinese patent of anti-infective urinary catheter%抗感染尿管获中国专利现况

    Institute of Scientific and Technical Information of China (English)

    熊国兵; 王寓; 邱明星

    2015-01-01

    application. METHODS:Al related Chinese patent papers of anti-infective urinary catheters were retrieved by Google’s proprietary search platform (http://www.google.com/advanced_patent_search) until the deadline of March 26, 2014, with the search strategy of‘Return the patents with the fol owing proprietary name:urinary catheter’. RESULTS AND CONCLUSION:According to the predefined search strategy, 949 potential y relevant patent papers were screened out for further identification, and 23 papers referred to anti-infective catheters that were obviously eligible were included. The analyses showed that:(1) The antibacterial coating agents of the majority of papers were antibacterial agents of nano-inorganic metal cations, only four papers used antibiotic coated. (2) The drug-eluting catheters were mainly composite-coated. (3) The drug release modes from coating were mainly extended-release but release mechanism was not clarified. (4) The preparation process was chemical bond or ionic bond in one paper, blending methods in one paper, repeated electroplating in one paper, electrospinning technology in one paper, and physical impregnation methods in 12 papers (52.17%). (5) The antimicrobial mode was ultrasonic-antibacterial method in two patent papers, sterile sleeve in one paper, hydrophilic coating in one paper, catheter made by blending polymer material and anti-infective agents in one paper, drug coated films made by coating with antimicrobial drug liquid and drying process in 20 papers (82.61%). In conclusion, there have been no translational and applied clinical researches about the anti-infective urinary catheter, and the relevant researches were only at the laboratory level. The research methods of Chinese patent for anti-infective urinary catheter were limited, and need to be further improved.

  19. 76 FR 78931 - Advisory Committees; Tentative Schedule of Meetings for 2012

    Science.gov (United States)

    2011-12-20

    ... Advisory Committee..... May 16-17. Arthritis Advisory Committee March 12. Cardiovascular and Renal Drugs...-6. Ophthalmic Devices Panel November 8-9. Orthopedic and Rehabilitation Devices September...

  20. Future potential for anti-infectives from bacteria - how to exploit biodiversity and genomic potential.

    Science.gov (United States)

    Müller, Rolf; Wink, Joachim

    2014-01-01

    The early stages of antibiotic development include the identification of novel hit compounds. Since actinomycetes and myxobacteria are still the most important natural sources of active metabolites, we provide an overview on these producers and discuss three of the most promising approaches toward finding novel anti-infectives from microorganisms. These are defined as the use of biodiversity to find novel producers, the variation of culture conditions and induction of silent genes, and the exploitation of the genomic potential of producers via "genome mining". Challenges that exist beyond compound discovery are outlined in the last section. PMID:24119567

  1. 78 FR 70954 - Risk Communications Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-11-27

    ... the free Webcast. Visit the Risk Communication Advisory Committee Web site at http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/RiskCommunicationAdvisoryCommittee/default.htm . The link... HUMAN SERVICES Food and Drug Administration Risk Communications Advisory Committee; Notice of...

  2. From Pichia anomala killer toxin through killer antibodies to killer peptides for a comprehensive anti-infective strategy.

    Science.gov (United States)

    Polonelli, Luciano; Magliani, Walter; Ciociola, Tecla; Giovati, Laura; Conti, Stefania

    2011-01-01

    "Antibiobodies", antibodies (Abs) with antibiotic activity, internal image of a Pichia anomala killer toxin (PaKT) characterized by microbicidal activity against microorganisms expressing β-glucans cell-wall receptors (PaKTRs), were produced by idiotypic vaccination with a PaKT-neutralizing monoclonal Ab (PaKT-like Abs) or induced by a protein-conjugated β-glucan. Human natural PaKT-like Abs (PaKTAbs) were found in the vaginal fluid of women infected with KT-sensitive microorganisms. Monoclonal and recombinant PaKT-like Abs, and PaKTAbs proved to be protective against experimental candidiasis, cryptococcosis and aspergillosis. A killer decapeptide (KP), synthesized from the sequence of a recombinant PaKT-like Ab or produced in transgenic plants, showed a microbicidal activity in vitro, neutralized by β-glucans, a therapeutic effect in vivo, against experimental mucosal and systemic mycoses, and a prophylactic role in planta, against phytopathogenic microorganisms, respectively. KP showed fungicidal properties against all the defective mutants of a Saccharomyces cerevisiae library, inclusive of strains recognized to be resistant to conventional antifungal drugs. KP inhibited in vitro, ex vivo and/or in vivo HIV-1 and Influenza A virus replication, owing to down-regulation of CCR5 co-receptors, physical block of the gp120-receptor interaction and reduction in the synthesis of glycoproteins, HA and M1 in particular. KP modulated the expression of costimulatory and MHC molecules on murine dendritic cells, improving their capacity to induce lymphocyte proliferation. KP, proven to be devoid of cytotoxicity on human cells, showed self-assembly-releasing hydrogel-like properties, catalyzed by β 1,3 glucan. PaKT's biotechnological derivatives may represent the prototypes of novel antifungal vaccines and anti-infective drugs characterized by different mechanisms of action. PMID:20714805

  3. The anti-infective activity of punicalagin against Salmonella enterica subsp. enterica serovar typhimurium in mice.

    Science.gov (United States)

    Li, Guanghui; Feng, Yuqing; Xu, Yunfeng; Wu, Qian; Han, Qi'an; Liang, Xiujun; Yang, Baowei; Wang, Xin; Xia, Xiaodong

    2015-07-01

    Punicalagin, a major bioactive component of pomegranate peel, has been proven to have antioxidant, antiviral, anti-apoptosis, and hepatoprotective properties. The aim of this study was to investigate the anti-infective activity of punicalagin in a mouse model. C57BL/6 mice were initially challenged with Salmonella enterica subsp. enterica serovar typhimurium (S. typhimurium) and then treated with punicalagin. Food and water consumption and body weight were recorded daily. On day 8 post infection, the mice were sacrificed to examine pathogen counts in tissues, hematological parameters, cytokine levels, and histological changes. Compared to mice only infected with S. typhimurium, punicalagin-treated mice had more food consumption and less weight loss. A higher survival rate and lower counts of viable S. typhimurium in feces, liver, spleen, and kidney were found in the punicalagin-treated mice. The enzyme linked immunosorbent assay showed that the levels of IL-6, IL-10, and IFN-γ in serum and the spleen and TNF-α in serum, the spleen and the liver were reduced by punicalagin. Moreover, more neutrophils and higher neutrophil-to-mononuclear cell ratios in the punicalagin-treated mice were observed. Histological examination showed that punicalagin protected cells in the liver and spleen from hemorrhagic necrosis. It is concluded that punicalagin has a beneficial effect against S. typhimurium infection in mice. The anti-infective properties, together with other nutritionally beneficial effects, make punicalagin a promising supplement in human food or animal feeds to prevent disease associated with S. typhimurium.

  4. Solvothermal synthesis of ZnO nanoparticles and anti-infection application in vivo.

    Science.gov (United States)

    Bai, Xiangyang; Li, Linlin; Liu, Huiyu; Tan, Longfei; Liu, Tianlong; Meng, Xianwei

    2015-01-21

    Zinc oxide nanoparticles (ZnONPs) have been widely studied as the bacteriostatic reagents. However, synthesis of small ZnO nanoparticles with good monodispersion and stability in aqueous solution is still a challenge. Anti-infection research of ZnONPs used as antibacterial agent in vivo is rare. In this paper, a novel, sustainable, and simple method to synthesize ZnO nanoparticles with good monodispersion in aqueous low-temperature conditions and with a small molecule agent is reported. Inhibition zone test and the minimum inhibitory concentration test were performed to examine the antibacterial activity of ZnONPs against bacteria Staphylococcus aureus and Escherichia coli in vitro. For further application in vivo, low cytotoxicity and low acute toxicity in mice of ZnO were demonstrated. Finally, 4 nm ZnONPs combined with poly(vinyl alcohol) gel was used as antibacterial agent in rodent elytritis model, and significant anti-infection effect was proven. In one word, the present research would shed new light on the designing of antibacterial materials like ZnO with promising application in disinfection.

  5. Identification of potential anti-infectives against Staphylococcus aureus using a Caenorhabditis elegans infection model

    Science.gov (United States)

    Kong, Cin; Rahman, Noorsaadah Abd; Nathan, Sheila

    2014-09-01

    The alarming increase of antibiotic-resistant Staphylococcus aureus and a delay in antibiotics development point to the need for novel therapeutic approaches to combat infection. To discover novel anti-infective agents, we screened a number of synthetic compounds comprising mainly of chalcone derivatives to explore their potential in promoting the survival of the nematode Caenorhabditis elegans upon infection by S. aureus. Screening of seven chalcone derivatives using both agar- and liquid-based assays revealed three positive hits that significantly prolonged the survival of S. aureus-infected nematodes. All the hits did not interfere with bacterial growth in vitro, proposing that the three compounds identified most probably act through mechanisms distinct from conventional antibiotics that target bacterial replication.

  6. Bacteriophages as anti-infective agents: recent developments and regulatory challenges.

    Science.gov (United States)

    Gilmore, Brendan F

    2012-05-01

    The biennial meeting on 'Exploiting Bacteriophages for Bioscience, Biotechnology and Medicine', held in London, UK, on 20 January 2012, and chaired by George Salmond (University of Cambridge, UK) hosted over 50 participants representing 13 countries. The highly multidisciplinary meeting covered a diverse range of topics, reflecting the current expansion of interest in this field, including the use of bacteriophages as the source of biochemical reagents for molecular biology, bacteriophages for the treatment of human and animal diseases, bacteriophage-based diagnostics and therapeutic delivery technologies and necessity for, and regulatory challenges associated with, robust clinical trials of phage-based therapeutics. This report focuses on a number of presentations from the meeting relating to cutting-edge research on bacteriophages as anti-infective agents.

  7. Using antimicrobial host defense peptides as anti-infective and immunomodulatory agents.

    Science.gov (United States)

    Kruse, Thomas; Kristensen, Hans-Henrik

    2008-12-01

    Virtually all life forms express short antimicrobial cationic peptides as an important component of their innate immune defenses. They serve as endogenous antibiotics that are able to rapidly kill an unusually broad range of bacteria, fungi and viruses. Consequently, considerable efforts have been expended to exploit the therapeutic potential of these antimicrobial peptides. Within the last couple of years, it has become increasingly clear that many of these peptides, in addition to their direct antimicrobial activity, also have a wide range of functions in modulating both innate and adaptive immunity. For one class of antimicrobial peptides, such as the human defensins, their primary role may even be as immunomodulators. These properties potentially provide entirely new therapeutic approaches to anti-infective therapy.

  8. 77 FR 70450 - Risk Communication Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-11-26

    ... HUMAN SERVICES Food and Drug Administration Risk Communication Advisory Committee; Notice of Meeting... the public. Name of Committee: Risk Communication Advisory Committee. General Function of the... Campus must enter through Building 1. Contact Person: Lee L. Zwanziger, Risk Communication Staff,...

  9. 75 FR 57279 - Risk Communication Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-09-20

    ... HUMAN SERVICES Food and Drug Administration Risk Communication Advisory Committee; Notice of Meeting... the public. Name of Committee: Risk Communication Advisory Committee. General Function of the... programs, such as FDA's Strategic Plan for Risk Communication, FDA's Transparency Initiative, and...

  10. 77 FR 62242 - Risk Communication Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-10-12

    ... HUMAN SERVICES Food and Drug Administration Risk Communication Advisory Committee; Notice of Meeting... the public. Name of Committee: Risk Communication Advisory Committee. General Function of the... enter through Building 1. Contact Person: Lee L. Zwanziger, Risk Communication Staff, Office of...

  11. 77 FR 31025 - Risk Communication Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-05-24

    ... HUMAN SERVICES Food and Drug Administration Risk Communication Advisory Committee; Notice of Meeting... the public. Name of Committee: Risk Communication Advisory Committee. General Function of the... enter through Building 1. Contact Person: Lee L. Zwanziger, Risk Communication Staff, Office of...

  12. 75 FR 52605 - Veterinary Medicine Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-08-26

    ... HUMAN SERVICES Food and Drug Administration Veterinary Medicine Advisory Committee; Notice of Meeting... the public. Name of Committee: Veterinary Medicine Advisory Committee. General Function of the...-1100. Contact Person: Aleta Sindelar, Center for Veterinary Medicine (HFV-3), Food and...

  13. Screening for anti-infective properties of several medicinal plants of the Mauritians flora.

    Science.gov (United States)

    Rangasamy, Oumadevi; Raoelison, Guy; Rakotoniriana, Francisco E; Cheuk, Kiban; Urverg-Ratsimamanga, Suzanne; Quetin-Leclercq, Joelle; Gurib-Fakim, Ameenah; Subratty, Anwar Hussein

    2007-01-19

    Several plants of the Mauritian flora alleged to possess anti-infective properties were studied against different strains of pathogenic bacteria and fungi. The grounded dried plant materials were extracted with different extractants and screened for anti-microbial activity using the disk diffusion and the micro-dilution techniques. Preliminary screening revealed that the methanol extracts were most active. Salmonella enteritidis, Enterobacter cloacae and Bacillus subtilis were the three test organisms, which were found to be susceptible to all the crude methanolic extracts of the different plants investigated (100% susceptibility), followed by Escherichia coli (57.1%) and Pseudomonas aeruginosa (57.1%), and Staphylococcus aureus (28.6%). The lowest minimum inhibitory concentration recorded for the different crude methanol extracts against Staphylococcus aureus, Escherichia coli, Salmonella enteritidis, Enterobacter cloacae, Bacillus subtilis and the mould fungus Candida albicans were 500, 1000, 125, 250, 1000 and 125 micro g/ml, respectively. Bioautography using Cladosporium cucumerinum revealed that dichloromethane (DCM) extracts had the highest activity against the phytopathogenic fungus. It was also noted that the DCM extracts of Michelia champaca and Antidesma madagascariense yielded the maximum number of growth inhibiting compounds against Cladosporium cucumerinum. Activity of the different crude extracts was also investigated against several phytopathogenic filamentous fungi, Colletotrichum glocosporoides, Rhizoctonia solani, Sclerotinia sclerotium, Guignardia sp. and Fusarium oxysporum. It was found that crude hexane extracts as well as crude DCM extracts exhibited marked activity against several strains of fungi, especially Colletotrichum glocosporoides, Sclerotinia sclerotium and Guignardia sp. PMID:17011733

  14. 21 CFR 14.142 - Functions of a color additive advisory committee.

    Science.gov (United States)

    2010-04-01

    ... 21 Food and Drugs 1 2010-04-01 2010-04-01 false Functions of a color additive advisory committee. 14.142 Section 14.142 Food and Drugs FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES GENERAL PUBLIC HEARING BEFORE A PUBLIC ADVISORY COMMITTEE Color Additive Advisory Committees §...

  15. 21 CFR 14.147 - Membership of a color additive advisory committee.

    Science.gov (United States)

    2010-04-01

    ... 21 Food and Drugs 1 2010-04-01 2010-04-01 false Membership of a color additive advisory committee. 14.147 Section 14.147 Food and Drugs FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES GENERAL PUBLIC HEARING BEFORE A PUBLIC ADVISORY COMMITTEE Color Additive Advisory Committees §...

  16. 21 CFR 14.145 - Procedures of a color additive advisory committee.

    Science.gov (United States)

    2010-04-01

    ... 21 Food and Drugs 1 2010-04-01 2010-04-01 false Procedures of a color additive advisory committee. 14.145 Section 14.145 Food and Drugs FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES GENERAL PUBLIC HEARING BEFORE A PUBLIC ADVISORY COMMITTEE Color Additive Advisory Committees §...

  17. 21 CFR 14.140 - Establishment of a color additive advisory committee.

    Science.gov (United States)

    2010-04-01

    ... 21 Food and Drugs 1 2010-04-01 2010-04-01 false Establishment of a color additive advisory committee. 14.140 Section 14.140 Food and Drugs FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES GENERAL PUBLIC HEARING BEFORE A PUBLIC ADVISORY COMMITTEE Color Additive Advisory Committees §...

  18. Cytocompatibility with osteogenic cells and enhanced in vivo anti-infection potential of quaternized chitosan-loaded titania nanotubes.

    Science.gov (United States)

    Yang, Ying; Ao, Haiyong; Wang, Yugang; Lin, Wentao; Yang, Shengbing; Zhang, Shuhong; Yu, Zhifeng; Tang, Tingting

    2016-01-01

    Infection is one of the major causes of failure of orthopedic implants. Our previous study demonstrated that nanotube modification of the implant surface, together with nanotubes loaded with quaternized chitosan (hydroxypropyltrimethyl ammonium chloride chitosan, HACC), could effectively inhibit bacterial adherence and biofilm formation in vitro. Therefore, the aim of this study was to further investigate the in vitro cytocompatibility with osteogenic cells and the in vivo anti-infection activity of titanium implants with HACC-loaded nanotubes (NT-H). The titanium implant (Ti), nanotubes without polymer loading (NT), and nanotubes loaded with chitosan (NT-C) were fabricated and served as controls. Firstly, we evaluated the cytocompatibility of these specimens with human bone marrow-derived mesenchymal stem cells in vitro. The observation of cell attachment, proliferation, spreading, and viability in vitro showed that NT-H has improved osteogenic activity compared with Ti and NT-C. A prophylaxis rat model with implantation in the femoral medullary cavity and inoculation with methicillin-resistant Staphylococcus aureus was established and evaluated by radiographical, microbiological, and histopathological assessments. Our in vivo study demonstrated that NT-H coatings exhibited significant anti-infection capability compared with the Ti and NT-C groups. In conclusion, HACC-loaded nanotubes fabricated on a titanium substrate show good compatibility with osteogenic cells and enhanced anti-infection ability in vivo, providing a good foundation for clinical application to combat orthopedic implant-associated infections. PMID:27672479

  19. 75 FR 5335 - Risk Communication Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-02-02

    ... HUMAN SERVICES Food and Drug Administration Risk Communication Advisory Committee; Notice of Meeting... the public. Name of Committee: Risk Communication Advisory Committee. General Function of the... and call the appropriate advisory committee hot line/phone line to learn about possible...

  20. 76 FR 16427 - Risk Communication Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-03-23

    ... HUMAN SERVICES Food and Drug Administration Risk Communication Advisory Committee; Notice of Meeting... the public. Name of Committee: Risk Communication Advisory Committee. General Function of the... appropriate advisory committee hot line/phone line to learn about possible modifications before coming to...

  1. Drug: D00830 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D00830 Drug Furazolidone (USP/INN); Furoxone (TN) C8H7N3O5 225.0386 225.1583 D00830.gif Anti-infective, topi...cal; Antiprotozoal [trichomonas, topical] Same as: C07999 ATC code: G01AX06 Anatomi

  2. Are Cancer Drugs Less Likely to be Recommended for Listing by the Pharmaceutical Benefits Advisory Committee in Australia?

    OpenAIRE

    Lesley Chim; Kelly, Patrick J; Glenn Salkeld; Stockler, Martin R.

    2010-01-01

    Background: The hurdle of cost effectiveness for the selection and reimbursement of drugs in Australia limits access to new medicines based on an assessment of cost relative to clinical benefit. Those drugs that are expensive and provide modest benefits will be less likely to receive a government price subsidy. There is concern that the cost-effectiveness hurdle will limit access to new cancer treatments because of their high costs and modest benefits. Objective: To test the hypothesis that C...

  3. Analysis of Anti-infection in One Case of Pulmonary Abscess%一例肺脓肿患者的抗感染方案分析

    Institute of Scientific and Technical Information of China (English)

    金旭辉; 裴素娟; 柳小飞

    2016-01-01

    Objective: To investigate the effect of clinical pharmacists in the clinical treatment of a case of pulmonary abscess by clinical pharmacists. Methods: Pharmacistsparticipatedand assisted doctors in a case of patients with lung abscesses, for theanti-infection treatment.Results: The clinical pharmacists involved in the treatment of patients with anti-infection treatment, and improved the effect of drug treatment.Conclusion: Clinical pharmacists directly participated in the formulation and adjustment of the treatment plan, andpromoted the clinical rational drug use.%目的:通过临床药师参与并分析对一例肺脓肿患者抗感染治疗,探讨临床药师在临床治疗中发挥的作用。方法:药师通过参与一例完整的肺脓肿病例的治疗,与临床医生一起制定抗感染治疗方案并协助医生及时调整。结果:该患者在临床医生与临床药师一起的抗感染治疗下,获得了很好的治疗效果,临床治愈出院。结论:临床药师直接参与医生治疗方案的制定与调整可促进临床合理用药。

  4. Effect of Winemaking on the Composition of Red Wine as a Source of Polyphenols for Anti-Infective Biomaterials

    Directory of Open Access Journals (Sweden)

    Arianna Di Lorenzo

    2016-04-01

    Full Text Available Biomaterials releasing bactericides have currently become tools for thwarting medical device-associated infections. The ideal anti-infective biomaterial must counteract infection while safeguarding eukaryotic cell integrity. Red wine is a widely consumed beverage to which many biological properties are ascribed, including protective effects against oral infections and related bone (osteoarthritis, osteomyelitis, periprosthetic joint infections and cardiovascular diseases. In this study, fifteen red wine samples derived from grapes native to the Oltrepò Pavese region (Italy, obtained from the winemaking processes of “Bonarda dell’Oltrepò Pavese” red wine, were analyzed alongside three samples obtained from marc pressing. Total polyphenol and monomeric anthocyanin contents were determined and metabolite profiling was conducted by means of a chromatographic analysis. Antibacterial activity of wine samples was evaluated against Streptococcus mutans, responsible for dental caries, Streptococcus salivarius, and Streptococcus pyogenes, two oral bacterial pathogens. Results highlighted the winemaking stages in which samples exhibit the highest content of polyphenols and the greatest antibacterial activity. Considering the global need for new weapons against bacterial infections and alternatives to conventional antibiotics, as well as the favorable bioactivities of polyphenols, results point to red wine as a source of antibacterial substances for developing new anti-infective biomaterials and coatings for biomedical devices.

  5. 76 FR 44017 - Risk Communication Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-07-22

    ... HUMAN SERVICES Food and Drug Administration Risk Communication Advisory Committee; Notice of Meeting... the public. Name of Committee: Risk Communication Advisory Committee. General Function of the... Person: Lee L. Zwanziger, Office of Policy, Planning and Budget, Food and Drug Administration, 10903...

  6. 75 FR 74735 - Food Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-12-01

    ...'s consumption of synthetic color additives in food and adverse effects on behavior. FDA intends to... HUMAN SERVICES Food and Drug Administration Food Advisory Committee; Notice of Meeting AGENCY: Food and... advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public....

  7. 75 FR 65640 - Cellular, Tissue and Gene Therapies Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-10-26

    ... HUMAN SERVICES Food and Drug Administration Cellular, Tissue and Gene Therapies Advisory Committee... and Gene Therapies Advisory Committee. General Function of the Committee: To provide advice and... Tumor Vaccines and Biotechnology Branch, Office of Cellular, Tissue and Gene Therapies, Center...

  8. 77 FR 73472 - Cellular, Tissue and Gene Therapies Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-12-10

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Cellular, Tissue and Gene Therapies Advisory Committee... and Gene Therapies Advisory Committee. General Function of the Committee: To provide advice...

  9. 78 FR 12068 - Device Good Manufacturing Practice Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-02-21

    ... HUMAN SERVICES Food and Drug Administration Device Good Manufacturing Practice Advisory Committee... meeting will be open to the public. Name of Committee: Device Good Manufacturing Practice Advisory... effects of extreme weather and natural disasters on medical device manufacturing chain processes...

  10. Anti-Infective Metabolites of a Newly Isolated Bacillus thuringiensis KL1 Associated with Kalmegh (Andrographis paniculata Nees.), a Traditional Medicinal Herb.

    Science.gov (United States)

    Roy, Sudipta; Yasmin, Sahana; Ghosh, Subhadeep; Bhattacharya, Somesankar; Banerjee, Debdulal

    2016-01-01

    This study was conducted to isolate endophytic bacteria possessing anti-infective property from Kalmegh (Andrographis paniculata Nees.), a well-known medicinal plant. A total of 23 strains were isolated from this plant among which the strain KL1, isolated from surface-sterilized leaf of this medicinal herb, showed broad-spectrum antagonism against an array of Gram-positive and -negative bacterial pathogens. Ethyl acetate extract of KL1-fermented media yielded a greenish amorphous substance retaining anti-infective property. Solvent-extracted crude material was separated by thin-layer chromatography, and the active ingredient was located by autobiogram analysis. The purified anti-infective compound was found as anthracene derivative as analyzed by ultraviolet and Fourier transform infrared spectroscopy. The strain was identified as Bacillus thuringiensis KL1 from cultural, physiochemical, and molecular aspects. The above results indicate the pharmaceutical potential of the candidate isolate. PMID:26997870

  11. Anti-Infective Metabolites of a Newly Isolated Bacillus thuringiensis KL1 Associated with Kalmegh (Andrographis paniculata Nees.), a Traditional Medicinal Herb.

    Science.gov (United States)

    Roy, Sudipta; Yasmin, Sahana; Ghosh, Subhadeep; Bhattacharya, Somesankar; Banerjee, Debdulal

    2016-01-01

    This study was conducted to isolate endophytic bacteria possessing anti-infective property from Kalmegh (Andrographis paniculata Nees.), a well-known medicinal plant. A total of 23 strains were isolated from this plant among which the strain KL1, isolated from surface-sterilized leaf of this medicinal herb, showed broad-spectrum antagonism against an array of Gram-positive and -negative bacterial pathogens. Ethyl acetate extract of KL1-fermented media yielded a greenish amorphous substance retaining anti-infective property. Solvent-extracted crude material was separated by thin-layer chromatography, and the active ingredient was located by autobiogram analysis. The purified anti-infective compound was found as anthracene derivative as analyzed by ultraviolet and Fourier transform infrared spectroscopy. The strain was identified as Bacillus thuringiensis KL1 from cultural, physiochemical, and molecular aspects. The above results indicate the pharmaceutical potential of the candidate isolate.

  12. Advisory Committees.

    Science.gov (United States)

    ERIC Clearinghouse on Educational Management, Eugene, OR.

    This chapter of "The Best of the Best of ERIC," Volume 2, contains 14 summaries of documents and journal articles on citizen advisory committees, all of which are indexed in either "Resources in Education" or "Current Index to Journals in Education." The materials included deal with various aspects of this topic, such as the role of the school…

  13. 终末期肺癌127例抗感染治疗分析%Analysis of 127 Cases of Terminal Lung Cancer Patients with Anti-infection Treatment

    Institute of Scientific and Technical Information of China (English)

    吴晓安; 邱钧; 钟小红; 康美玲; 陈建清

    2012-01-01

    Objective To investigate the incidence of terminal lung cancer patients with lung infection and anti-infection treatment. Methods To retrospectively analyze the clinical cases of 127 patients of terminal lung cancer with pulmonary infection and antimicrobial drug used in our hospital for the past three years. Results In the 127 cases of terminal lung cancer patients with pulmonary infection in 112 cases ( 88. 2% ),of which 103 patients( 81. 1% ) who died within 1 month were given anti-infection treatment, all patients were not meet clinical symptoms improved. Conclusion Terminal lung cancer patients are with a high proportion of lung infection,antibiotics are widely used,and there is abuse.%目的 探讨终末期肺癌患者的抗感染治疗.方法 对近3年来我院收治的127例终末期肺癌患者临床表现、合并肺部感染及抗菌药物应用和获益等情况进行回顾性分析.结果 127例终末期肺癌患者中合并肺部感染者112例(88.2%),其中103例(81.1%)患者给予抗感染治疗后症状均未改善,且均于1个月内死亡.结论 终末期肺癌患者合并感染率高,抗菌药物应用品种广泛,但效果差.

  14. Population-based cohort study of anti-infective medication use before and after the onset of type 1 diabetes in children and adolescents

    NARCIS (Netherlands)

    Fazeli Farsani, Soulmaz; Souverein, Patrick C; van der Vorst, Marja M J; Knibbe, Catherijne A J; de Boer, Anthonius; Mantel-Teeuwisse, Aukje K

    2014-01-01

    A population-based cohort study was conducted in the Dutch PHARMO database to investigate prevalence and patterns of anti-infective medication use in children and adolescents with type 1 diabetes (T1D) before and after the onset of this disease. All patients <19 years with at least 2 insulin prescri

  15. Anti-infective mannose receptor immune mechanism in large yellow croaker (Larimichthys crocea).

    Science.gov (United States)

    Dong, Xiangli; Li, Jiji; He, Jianyu; Liu, Wei; Jiang, Lihua; Ye, Yingying; Wu, Changwen

    2016-07-01

    Mannose receptor (MR) is a pattern recognition receptor (PRR) that plays a significant role in immunity responses. Its role has been described extensively in mammals, but very rarely in fish. Recently, with the rapid development of an aquaculture industry cultivating large yellow croaker (Larimichthys crocea), infectious diseases caused by viruses, bacteria and parasites are becoming more frequent and more severe, in particular bacterial infections caused by Vibrio anguillarum, resulting in great economical losses. Extensive use of antibiotics as conventional treatment has led to microenvironment imbalances, development of drug-resistant bacteria and deposition of drug residues, which cause environmental pollution and ultimately affect human health. The purpose of this pilot study was to detect the transcriptional levels of C-type mannose receptor genes MRC1 (4710-bp ORF; encoding 1437 aa; a signal peptide, a SMART RICIN domain, a SMART FN2 domain, eight SMART CLECT domain, and a transmembrane helix region) and MRC2 (3996-bp ORF; encoding 1484 aa; a SMART FN2 domain, eight SMART CLECT domains, and a transmembrane region) in the liver, kidney and spleen tissues of L. crocea challenged by V. anguillarum, to explore the effective domain and the molecular response mechanisms of MRC1 and MRC2, and, ultimately, to explore the possibility of developing a vaccine targeting V. anguillarum infections. PMID:27071518

  16. 76 FR 12973 - Neurological Devices Panel of the Medical Devices Advisory Committee; Amendment of Notice

    Science.gov (United States)

    2011-03-09

    ... HUMAN SERVICES Food and Drug Administration Neurological Devices Panel of the Medical Devices Advisory... Medical Devices Advisory Committee. This meeting was announced in the Federal Register of February 7, 2011... meeting of the Neurological Devices Panel of the Medical Devices Advisory Committee would be held on...

  17. 75 FR 58414 - Dental Products Panel of the Medical Devices Advisory Committee; Amendment of Notice

    Science.gov (United States)

    2010-09-24

    ... HUMAN SERVICES Food and Drug Administration Dental Products Panel of the Medical Devices Advisory... Medical Devices Advisory Committee. This meeting was announced in the Federal Register of June 11, 2010... announced that a meeting of the Dental Products Panel of the Medical Devices Advisory Committee would...

  18. 76 FR 80949 - Request for Nominations for Voting Members on Public Advisory Panels or Committees

    Science.gov (United States)

    2011-12-27

    ... include experience in medical practice, teaching, and/or research relevant to the field of activity of the... Manufacturing Practice Advisory Committee, certain device panels of the Medical Devices Advisory Committee, and... Device Good Manufacturing and Radiological Health, Food and Drug Practice Advisory...

  19. 21 CFR 14.155 - Fees and compensation pertaining to a color additive advisory committee.

    Science.gov (United States)

    2010-04-01

    ... 21 Food and Drugs 1 2010-04-01 2010-04-01 false Fees and compensation pertaining to a color additive advisory committee. 14.155 Section 14.155 Food and Drugs FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES GENERAL PUBLIC HEARING BEFORE A PUBLIC ADVISORY COMMITTEE Color...

  20. Genetic and chemical knockdown: a complementary strategy for evaluating an anti-infective target

    Directory of Open Access Journals (Sweden)

    Ramachandran V

    2013-02-01

    Full Text Available Vasanthi Ramachandran,1,* Ragini Singh,2,* Xiaoyu Yang,1 Ragadeepthi Tunduguru,1 Subrat Mohapatra,2 Swati Khandelwal,2 Sanjana Patel,2 Santanu Datta21AstraZeneca India R&D, Bangalore, India; 2Cellworks India, Bangalore, India *These authors contributed equally to this workAbstract: The equity of a drug target is principally evaluated by its genetic vulnerability with tools ranging from antisense- and microRNA-driven knockdowns to induced expression of the target protein. In order to upgrade the process of antibacterial target identification and discern its most effective type of inhibition, an in silico toolbox that evaluates its genetic and chemical vulnerability leading either to stasis or cidal outcome was constructed and validated. By precise simulation and careful experimentation using enolpyruvyl shikimate-3-phosphate synthase and its specific inhibitor glyphosate, it was shown that genetic knockdown is distinct from chemical knockdown. It was also observed that depending on the particular mechanism of inhibition, viz competitive, uncompetitive, and noncompetitive, the antimicrobial potency of an inhibitor could be orders of magnitude different. Susceptibility of Escherichia coli to glyphosate and the lack of it in Mycobacterium tuberculosis could be predicted by the in silico platform. Finally, as predicted and simulated in the in silico platform, the translation of growth inhibition to a cidal effect was able to be demonstrated experimentally by altering the carbon source from sorbitol to glucose.Keywords: knockdown, inhibition, in silico, vulnerability

  1. Display technology on filamentous phage in the search for anti-infective biological agents

    Directory of Open Access Journals (Sweden)

    Nelson Santiago Vispo

    2016-01-01

    Full Text Available Introduction: The causes of antibiotic resistance are complex. The phage display technology has been used mainly to produce monoclonal antibodies (MAbs and peptides directed against cancer or inflammatory disease targets. Today, this technology is recognized as a powerful tool for selecting novel peptides and antibodies that can bind to a wide range of antigens, ranging from whole cells to proteins and lipid targets. In this review, we highlight research that exploits the phage display technology to discover new drugs against infectious diseases, with a focus on antimicrobial peptides and antibodies. Methods: Basic and recent literature review was made, mainly focused on general aspects of phage display technology and the application in the search of new peptides or antibodies of pharmaceutical use to combat the infectious diseases transmitted by bacteria and virus. Results: Updated information on the selected topics is shown, with a guiding and practical approach aimed at researchers in the field of molecular biology to continue deepening the technology with special emphasis in the applications that have been developed in Cuba. Conclusions: Advances in methods of screening, manufacturing, and humanization technologies show that phage display technology can significantly contribute in the fight against clinically important pathogens.

  2. Anti-infective efficacy of the lactoferrin-derived antimicrobial peptide HLR1r.

    Science.gov (United States)

    Björn, Camilla; Mahlapuu, Margit; Mattsby-Baltzer, Inger; Håkansson, Joakim

    2016-07-01

    Antimicrobial peptides (AMPs) have emerged as a new class of drug candidates for the treatment of infectious diseases. Here we describe a novel AMP, HLR1r, which is structurally derived from the human milk protein lactoferrin and demonstrates a broad spectrum microbicidal action in vitro. The minimum concentration of HLR1r needed for killing ≥99% of microorganisms in vitro, was in the range of 3-50μg/ml for common Gram-negative and Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), and for the yeast Candida albicans, when assessed in diluted brain-heart infusion medium. We found that HLR1r also possesses anti-inflammatory properties as evidenced by inhibition of tumor necrosis factor alpha (TNF-α) secretion from human monocyte-derived macrophages and by repression of interleukin-6 (IL-6) and plasminogen activator inhibitor-1 (PAI-1) secretion from human mesothelial cells, without any cytotoxic effect observed at the concentration range tested (up to 400μg/ml). HLR1r demonstrated pronounced anti-infectious effect in in vivo experimental models of cutaneous candidiasis in mice and of excision wounds infected with MRSA in rats as well as in an ex vivo model of pig skin infected with S. aureus. In conclusion, HLR1r may constitute a new therapeutic alternative for local treatment of skin infections. PMID:27155369

  3. INFECTIOUS AETIOLOGY OF MARGINAL ZONE LYMPHOMA AND ROLE OF ANTI-INFECTIVE THERAPY

    Directory of Open Access Journals (Sweden)

    Salvatore Perrone

    2016-01-01

    Full Text Available Marginal zone lymphomas have been associated with several infectious agents covering both viral and bacterial pathogens and in some cases a clear aetiological role has been established. Pathogenetic mechanisms are currently not completely understood, however the role of chronic stimulation of the host immune response with persistent lymphocyte activation represents the most convincing explanation for lymphoproliferation. Gastric MALT lymphoma is strictly associated with Helicobacter pylori infection and various eradicating protocols, developed due to increasing antibiotic resistance, represent the first line therapy. The response rate to eradication is good with 80% of response at 1 year; this finding is also noteworthy because recapitulates a cancer cured only by antibacterial approach and it satisfies the Koch postulates of causation, establishing a causative relationship between Hp and gastric MALT lymphoma. Patients with chronic HCV infection have 5 times higher risk to develop MZL, in particular an association with splenic and nodal MZL has been shown in several studies. Moreover, there is evidence of lymphoma regression after antiviral therapy with interferon+ribavirin, thus rising hope that new available drugs, extremely effective against HCV replication, could improve outcome also in HCV-driven lymphomas. The rare cases of MZL localized to orbital fat and eye conjunctivas have been associated with Chlamydia psittaci infection carried by birds. Efficacy of antibacterial therapy against C. psittaci are conflicting and generally poorer thain gastric MALT. Finally some case-reports will cover the relationship between primary cutaneous B-cell Lymphomas and Borrelia Burgdorferi.

  4. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies.

    Science.gov (United States)

    Hancock, Robert E W; Sahl, Hans-Georg

    2006-12-01

    Short cationic amphiphilic peptides with antimicrobial and/or immunomodulatory activities are present in virtually every life form, as an important component of (innate) immune defenses. These host-defense peptides provide a template for two separate classes of antimicrobial drugs. Direct-acting antimicrobial host-defense peptides can be rapid-acting and potent, and possess an unusually broad spectrum of activity; consequently, they have prospects as new antibiotics, although clinical trials to date have shown efficacy only as topical agents. But for these compounds to fulfill their therapeutic promise and overcome clinical setbacks, further work is needed to understand their mechanisms of action and reduce the potential for unwanted toxicity, to make them more resistant to protease degradation and improve serum half-life, as well as to devise means of manufacturing them on a large scale in a consistent and cost-effective manner. In contrast, the role of cationic host-defense peptides in modulating the innate immune response and boosting infection-resolving immunity while dampening potentially harmful pro-inflammatory (septic) responses gives these peptides the potential to become an entirely new therapeutic approach against bacterial infections.

  5. 75 FR 65641 - Risk Communication Advisory Committee; Amendment of Notice

    Science.gov (United States)

    2010-10-26

    ... HUMAN SERVICES Food and Drug Administration Risk Communication Advisory Committee; Amendment of Notice... announcing an amendment to the notice of meeting of the Risk Communication Advisory Committee. This meeting was announced in the Federal Register of September 20, 2010 (75 FR 57279). The amendment is being...

  6. 78 FR 42087 - Risk Communications Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-07-15

    ... the White Oak Campus must enter through Building 1. Contact Person: Luis G. Bravo, Risk Communication... HUMAN SERVICES Food and Drug Administration Risk Communications Advisory Committee; Notice of Meeting... the public. Name of Committee: Risk Communications Advisory Committee. General Function of...

  7. 75 FR 20608 - Risk Communication Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-04-20

    ... HUMAN SERVICES Food and Drug Administration Risk Communication Advisory Committee; Notice of Meeting... the public. Name of Committee: Risk Communication Advisory Committee. General Function of the... current research in a range of fields relevant to improving risk communication at FDA, and...

  8. 78 FR 33423 - Arthritis Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-06-04

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Arthritis Advisory Committee; Notice of Meeting AGENCY: Food... of Committee: Arthritis Advisory Committee. General Function of the Committee: To provide advice...

  9. 77 FR 14529 - Arthritis Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-03-12

    ... HUMAN SERVICES Food and Drug Administration Arthritis Advisory Committee; Notice of Meeting AGENCY: Food... of Committee: Arthritis Advisory Committee. General Function of the Committee: To provide advice and... moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more...

  10. 76 FR 42715 - Arthritis Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-07-19

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Arthritis Advisory Committee; Notice of Meeting AGENCY: Food... of Committee: Arthritis Advisory Committee. General Function of the Committee: To provide advice...

  11. 76 FR 29767 - Arthritis Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-05-23

    ... HUMAN SERVICES Food and Drug Administration Arthritis Advisory Committee; Notice of Meeting AGENCY: Food... of Committee: Arthritis Advisory Committee. General Function of the Committee: To provide advice and... arthritis attacks. ILARIS has also been shown to extend the time to the next attack and reduce the...

  12. 75 FR 55805 - Arthritis Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-09-14

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Arthritis Advisory Committee; Notice of Meeting AGENCY: Food... of Committee: Arthritis Advisory Committee. General Function of the Committee: To provide advice...

  13. 77 FR 64524 - Arthritis Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-10-22

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Arthritis Advisory Committee; Notice of Meeting AGENCY: Food... of Committee: Arthritis Advisory Committee. General Function of the Committee: To provide advice...

  14. 78 FR 32403 - Arthritis Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-05-30

    ... HUMAN SERVICES Food and Drug Administration Arthritis Advisory Committee; Notice of Meeting AGENCY: Food... of Committee: Arthritis Advisory Committee. General Function of the Committee: To provide advice and... meeting. Agenda: On July 22, 2013, the committee will discuss the Assessment of...

  15. 77 FR 1697 - Arthritis Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-01-11

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Arthritis Advisory Committee; Notice of Meeting AGENCY: Food... of Committee: Arthritis Advisory Committee. General Function of the Committee: To provide advice...

  16. 75 FR 4576 - Veterinary Medicine Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-01-28

    ... HUMAN SERVICES Food and Drug Administration Veterinary Medicine Advisory Committee; Notice of Meeting... the public. Name of Committee: Veterinary Medicine Advisory Committee. General Function of the... PROHEART 6 (NADA 141-189), the subsequent safety data collected under the Center for Veterinary...

  17. The Quest for Anti-inflammatory and Anti-infective Biomaterials in Clinical Translation.

    Science.gov (United States)

    Griffith, May; Islam, Mohammad M; Edin, Joel; Papapavlou, Georgia; Buznyk, Oleksiy; Patra, Hirak K

    2016-01-01

    Biomaterials are now being used or evaluated clinically as implants to supplement the severe shortage of available human donor organs. To date, however, such implants have mainly been developed as scaffolds to promote the regeneration of failing organs due to old age or congenital malformations. In the real world, however, infection or immunological issues often compromise patients. For example, bacterial and viral infections can result in uncontrolled immunopathological damage and lead to organ failure. Hence, there is a need for biomaterials and implants that not only promote regeneration but also address issues that are specific to compromised patients, such as infection and inflammation. Different strategies are needed to address the regeneration of organs that have been damaged by infection or inflammation for successful clinical translation. Therefore, the real quest is for multifunctional biomaterials with combined properties that can combat infections, modulate inflammation, and promote regeneration at the same time. These strategies will necessitate the inclusion of methodologies for management of the cellular and signaling components elicited within the local microenvironment. In the development of such biomaterials, strategies range from the inclusion of materials that have intrinsic anti-inflammatory properties, such as the synthetic lipid polymer, 2-methacryloyloxyethyl phosphorylcholine (MPC), to silver nanoparticles that have antibacterial properties, to inclusion of nano- and micro-particles in biomaterials composites that deliver active drugs. In this present review, we present examples of both kinds of materials in each group along with their pros and cons. Thus, as a promising next generation strategy to aid or replace tissue/organ transplantation, an integrated smart programmable platform is needed for regenerative medicine applications to create and/or restore normal function at the cell and tissue levels. Therefore, now it is of utmost

  18. The Quest for Anti-inflammatory and Anti-infective Biomaterials in Clinical Translation

    Science.gov (United States)

    Griffith, May; Islam, Mohammad M.; Edin, Joel; Papapavlou, Georgia; Buznyk, Oleksiy; Patra, Hirak K.

    2016-01-01

    Biomaterials are now being used or evaluated clinically as implants to supplement the severe shortage of available human donor organs. To date, however, such implants have mainly been developed as scaffolds to promote the regeneration of failing organs due to old age or congenital malformations. In the real world, however, infection or immunological issues often compromise patients. For example, bacterial and viral infections can result in uncontrolled immunopathological damage and lead to organ failure. Hence, there is a need for biomaterials and implants that not only promote regeneration but also address issues that are specific to compromised patients, such as infection and inflammation. Different strategies are needed to address the regeneration of organs that have been damaged by infection or inflammation for successful clinical translation. Therefore, the real quest is for multifunctional biomaterials with combined properties that can combat infections, modulate inflammation, and promote regeneration at the same time. These strategies will necessitate the inclusion of methodologies for management of the cellular and signaling components elicited within the local microenvironment. In the development of such biomaterials, strategies range from the inclusion of materials that have intrinsic anti-inflammatory properties, such as the synthetic lipid polymer, 2-methacryloyloxyethyl phosphorylcholine (MPC), to silver nanoparticles that have antibacterial properties, to inclusion of nano- and micro-particles in biomaterials composites that deliver active drugs. In this present review, we present examples of both kinds of materials in each group along with their pros and cons. Thus, as a promising next generation strategy to aid or replace tissue/organ transplantation, an integrated smart programmable platform is needed for regenerative medicine applications to create and/or restore normal function at the cell and tissue levels. Therefore, now it is of utmost

  19. Mussel-inspired alginate gel promoting the osteogenic differentiation of mesenchymal stem cells and anti-infection.

    Science.gov (United States)

    Zhang, Shiwen; Xu, Kaige; Darabi, Mohammad Ali; Yuan, Quan; Xing, Malcolm

    2016-12-01

    Alginate hydrogels have been used in cell encapsulation for many years but a prevalent issue with pure alginates is that they are unable to provide enough bioactive properties to interact with mammalian cells. This paper discusses the modification of alginate with mussel-inspired dopamine for cell loading and anti-infection. Mouse bone marrow stem cells were immobilized into alginate and alginate-dopamine beads and fibers. Through live-dead and MTT assay, alginates modified by dopamine promoted cell viability and proliferation. In vitro cell differentiation results showed that such an alginate-dopamine gel can promote the osteogenic differentiation of mesenchymal stem cell after PCR and ALP assays. In addition to that, the adhesive prosperities of dopamine allowed for coating the surface of alginate-dopamine gel with silver nanoparticles, which provided the gel with significant antibacterial characteristics. Overall, these results demonstrate that a dopamine-modified alginate gel can be a great tool for cell encapsulation to promote cell proliferation and can be applied to bone regeneration, especially in contaminated bone defects. PMID:27612740

  20. 21 CFR 861.38 - Standards advisory committees.

    Science.gov (United States)

    2010-04-01

    ... Development and Publication § 861.38 Standards advisory committees. (a) The Food and Drug Administration will... the proposed regulation which requires the exercise of scientific judgment if: (1) The Food and...

  1. Anti-Infective Metabolites of a Newly Isolated Bacillus thuringiensis KL1 Associated with Kalmegh (Andrographis paniculata Nees.), a Traditional Medicinal Herb

    OpenAIRE

    Sudipta Roy; Sahana Yasmin; Subhadeep Ghosh; Somesankar Bhattacharya; Debdulal Banerjee

    2016-01-01

    This study was conducted to isolate endophytic bacteria possessing anti-infective property from Kalmegh (Andrographis paniculata Nees.), a well-known medicinal plant. A total of 23 strains were isolated from this plant among which the strain KL1, isolated from surface-sterilized leaf of this medicinal herb, showed broad-spectrum antagonism against an array of Gram-positive and -negative bacterial pathogens. Ethyl acetate extract of KL1-fermented media yielded a greenish amorphous substance re...

  2. Extract of Pelargonium sidoides (EPs 7630) displays anti-infective properties by enhanced phagocytosis and differential modulation of host-bacteria interactions.

    Science.gov (United States)

    Conrad, Andreas; Frank, Uwe

    2008-05-01

    EPs 7630 is an aqueous-ethanolic extract of the roots of PELARGONIUM SIDOIDES that displays well-documented benefits in the treatment of upper respiratory tract infections (URTI). IN VITRO and animal investigations have revealed various anti-infective properties of EPs 7630. The present review sums up recently published IN VITRO investigations that have shown positive effects on the activity of human peripheral blood phagocytes (PBP) and differential modulation of the interactions between group A streptococci and the host's epithelial barrier.

  3. Population-based cohort study of anti-infective medication use before and after the onset of type 1 diabetes in children and adolescents.

    Science.gov (United States)

    Fazeli Farsani, Soulmaz; Souverein, Patrick C; van der Vorst, Marja M J; Knibbe, Catherijne A J; de Boer, Anthonius; Mantel-Teeuwisse, Aukje K

    2014-08-01

    A population-based cohort study was conducted in the Dutch PHARMO database to investigate prevalence and patterns of anti-infective medication use in children and adolescents with type 1 diabetes (T1D) before and after the onset of this disease. All patients <19 years with at least 2 insulin prescriptions (1999 to 2009) were identified (T1D cohort) and compared with an age- and sex-matched (ratio: 1 up to 4) diabetes-free reference group. The prevalence and average number of anti-infective use was studied from (up to) 8 years before until a maximum of 4 years after the onset of T1D. A total of 925 patients with T1D and 3,591 children and adolescents in the reference cohort (51% boys, mean age of 10.1 [standard deviation, 4.5] years) were included. The overall prevalence of anti-infective use (62.6 compared to 52.6%, P < 0.001) and average number of prescriptions (2.71 compared to 1.42 per child, P < 0.001) in the T1D cohort were significantly higher than those in the reference cohort after the onset of diabetes. This pattern was consistent across sex and age categories and already observed in the year before the onset of type 1 diabetes. Patients in the T1D cohort received more antibacterials (49.8 compared to 40%, P < 0.001), antimycotics (4.0 compared to 1.3%, P < 0.001), antivirals (2.5 compared to 0.4%, P < 0.001), and second-line antibiotics, such as aminoglycosides, quinolones, and third-generation cephalosporins and carbapenems. Our findings that elevated anti-infective use in the T1D cohort exists in the period before the onset of type 1 diabetes and the consumption of more second-line anti-infective compounds in this time period warrant further research.

  4. 75 FR 65497 - Science Board Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-10-25

    ... HUMAN SERVICES Food and Drug Administration Science Board Advisory Committee; Notice of Meeting AGENCY: Food and Drug Administration, HHS. ACTION: Notice of meeting. This notice announces a forthcoming... Science Board to the Food and Drug Administration and provide an overview of its strategic plan....

  5. 78 FR 66942 - Orthopaedic and Rehabilitation Devices Panel of the Medical Devices Advisory Committee; Notice of...

    Science.gov (United States)

    2013-11-07

    ... HUMAN SERVICES Food and Drug Administration Orthopaedic and Rehabilitation Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting AGENCY: Food and Drug Administration, HHS. ACTION: Notice. This notice announces a forthcoming meeting of a public advisory committee of the Food and...

  6. 76 FR 17422 - Orthopaedic and Rehabilitation Devices Panel of the Medical Devices Advisory Committee; Notice of...

    Science.gov (United States)

    2011-03-29

    ... HUMAN SERVICES Food and Drug Administration Orthopaedic and Rehabilitation Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting AGENCY: Food and Drug Administration, HHS. ACTION: Notice. This notice announces a forthcoming meeting of a public advisory committee of the Food and...

  7. 75 FR 36660 - Orthopaedic and Rehabilitation Devices Panel of the Medical Devices Advisory Committee; Notice of...

    Science.gov (United States)

    2010-06-28

    ... HUMAN SERVICES Food and Drug Administration Orthopaedic and Rehabilitation Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting AGENCY: Food and Drug Administration, HHS. ACTION: Notice. This notice announces a forthcoming meeting of a public advisory committee of the Food and...

  8. Preparation and Anti-Infective Activity of Houttuynia cordata Topical Cream%鱼腥草外用抗菌霜剂的制备及局部皮肤抗感染研究

    Institute of Scientific and Technical Information of China (English)

    梁菊; 陈姗; 刘秋伟; 池志娟

    2011-01-01

    以系统溶剂法分别制备了鱼腥草的石油醚提取物、氯仿提取物、乙酸乙酯提取物、正丁醇提取物和水提取物.各提取物的体外抑菌实验表明,鱼腥草的氯仿提取物对金黄色葡萄球菌、苏云金杆菌、大肠杆菌、枯草芽孢杆菌和白色葡萄球菌的生长具有很好的抑制作用.以该提取物为主要成分,制作了一种鱼腥草的外用抗菌霜剂.豚鼠皮肤刺激实验表明,该霜剂对皮肤无刺激性.豚鼠皮内注射金黄色葡萄球菌皮肤局部感染模型的建立及抗感染实验结果表明,该霜剂对金黄色葡萄球菌引起的皮肤局部感染有明显的治疗效果,每天给药3次,每次给药0.1 g(区域面积20 m%Five extracts of Houttuynia cordata was obtained using petroleum ether,chloroform,ethyl acetate,n-butanol and water as the solvents.The results of antibacterial experiments in vitro showed that chloroform fraction has strong antibacterial activity against Staphylococcus aureus,Bacillus thuringiensis,Escherichia coli,Bacillus subtilis,and Staphylococcus albus.A topical cream was prepared with chloroform extract as the main ingredient and was evaluated by acute skin irritancy in which the cream showed less irritant and safety for topical application.The guinea pig model of Staphylococcus aureus intradermal infection was then established and used for testing anti-infective activity of the cream.Skin redness and swelling disappeared after dermic administration 7 days with 0.1 g of the cream(20 mm×30 mm) three times a day.And the injected area has no bacteria survival by the bacterial culture of local skin in media.Those results hinted that Houttuynia cordata topical cream might be developed for potential clinical anti-infection drug.

  9. 76 FR 18757 - Monthly Public Meetings of the Local Government Advisory Committee's Small Community Advisory...

    Science.gov (United States)

    2011-04-05

    ... AGENCY Monthly Public Meetings of the Local Government Advisory Committee's Small Community Advisory... Advisory Committee Act, the U.S. Environmental Protection Agency's Local Government Advisory Committee's... the Local Government Advisory Committee. BILLING CODE 6560-50-P...

  10. 77 FR 71591 - Meetings of the Local Government Advisory Committee and the Small Communities Advisory Subcommittee

    Science.gov (United States)

    2012-12-03

    ... AGENCY Meetings of the Local Government Advisory Committee and the Small Communities Advisory... environmental issues affecting small communities. The Local Government Advisory Committee (LGAC) will meet in... INFORMATION CONTACT: Local Government Advisory Committee (LGAC) and Small Communities Advisory...

  11. Citizens Advisory Committees.

    Science.gov (United States)

    Stemnock, Suzanne K.

    1968-01-01

    This document contains the results of a national survey designed to determine the composition and location of permanent citizens advisory committees operating within the nation's school districts. The 52 district-wide, continuing citizens advisory bodies identified by 290 responding school systems are listed alphabetically by State. The following…

  12. 临床药师参与2例产ESBLs大肠埃希菌抗感染治疗病例分析%Clinical pharmacists participating in Anti-infective treatment:Analysis of two gynecological cases of patients with ESBLs-producing bacte-ria-Escherichia coli infection

    Institute of Scientific and Technical Information of China (English)

    桂洪芹; 宁颖

    2016-01-01

    目的:探讨临床药师如何在妇产科产超广谱β-内酰胺酶(ESBLs)大肠埃希菌抗感染治疗中发挥作用。方法临床药师参与剖宫产术后切口感染及子宫次全切除术后宫颈残端感染各1例治疗过程,协助医生调整抗感染治疗方案。结果临床药师建议被采纳,2例患者均痊愈出院。结论临床药师利用药学专业知识协助妇产科医师多次调整用药方案,对治疗效果进行评估,提高治疗成功率。%Objective To investigate the clinical pharmacists how to play a role in anti-infection treatment. Methods Clinical pharmacists participate in treatment process of two cases of patients with ESBLs-producing bacteria-Escherichia coli infection,and one was incision infection after cesarean section,the other was cervical stump infection after subtotal hysterectomy. And in the treatment,Clinical pharmacists helped the doctor to adjust the drug use of anti-in-fection treatment. Results Clinical pharmacists proposals are adopted,and two patients were recovered. Conclusion Clinical pharmacists’pharmaceutical professional knowledge could help the doctor to adjust the drug use of anti-infection treatment and improve the treatment effecacy.

  13. 76 FR 8715 - Technology Advisory Committee

    Science.gov (United States)

    2011-02-15

    ... COMMISSION Technology Advisory Committee AGENCY: Commodity Futures Trading Commission (``CFTC''). ACTION: Notice of meeting of Technology Advisory Committee. SUMMARY: The Technology Advisory Committee will hold...: Office of the Secretary. Please use the title ``Technology Advisory Committee'' in any written...

  14. 75 FR 17929 - Vaccines and Related Biological Products Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-04-08

    ... will review and discuss available data regarding the unexpected finding of DNA originating from porcine... HUMAN SERVICES Food and Drug Administration Vaccines and Related Biological Products Advisory Committee... be open to the public. Name of Committee: Vaccines and Related Biological Products Advisory...

  15. 77 FR 65693 - Cellular, Tissue and Gene Therapies Advisory Committee; Amendment of Notice

    Science.gov (United States)

    2012-10-30

    ... HUMAN SERVICES Food and Drug Administration Cellular, Tissue and Gene Therapies Advisory Committee... Therapies Advisory Committee. This meeting was announced in the Federal Register of October 17, 2012 (77 FR... Register of October 17, 2012, FDA announced that a meeting of the Cellular, Tissue and Gene...

  16. 75 FR 66381 - Cellular, Tissue and Gene Therapies Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-10-28

    ... HUMAN SERVICES Food and Drug Administration Cellular, Tissue and Gene Therapies Advisory Committee... be open to the public. Name of Committee: Cellular, Tissue and Gene Therapies Advisory Committee... Lentiviral Vector Based Gene Therapy Products. FDA intends to make background material available to...

  17. 77 FR 63840 - Cellular, Tissue and Gene Therapies Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-10-17

    ... HUMAN SERVICES Food and Drug Administration Cellular, Tissue and Gene Therapies Advisory Committee..., Tissue and Gene Therapies Advisory Committee. General Function of the Committee: To provide advice and..., Office of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research, and...

  18. 78 FR 44133 - Cellular, Tissue and Gene Therapies Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-07-23

    ... HUMAN SERVICES Food and Drug Administration Cellular, Tissue and Gene Therapies Advisory Committee... be open to the public. Name of Committee: Cellular, Tissue and Gene Therapies Advisory Committee... on guidance documents issued from the Office of Cellular, Tissue and Gene Therapies, Center...

  19. 76 FR 49774 - Cellular, Tissue and Gene Therapies Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-08-11

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Cellular, Tissue and Gene Therapies Advisory Committee... be open to the public. Name of Committee: Cellular, Tissue and Gene Therapies Advisory...

  20. 78 FR 79699 - Cellular, Tissue, and Gene Therapies Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-12-31

    ... HUMAN SERVICES Food and Drug Administration Cellular, Tissue, and Gene Therapies Advisory Committee... be open to the public. Name of Committee: Cellular, Tissue, and Gene Therapies Advisory Committee..., Tissue, and Gene Therapies, Center for Biologics Evaluation and Research (CBER), FDA. On February...

  1. 78 FR 15726 - Cellular, Tissue and Gene Therapies Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-03-12

    ... HUMAN SERVICES Food and Drug Administration Cellular, Tissue and Gene Therapies Advisory Committee... portion of the meeting will be closed to the public. Name of Committee: Cellular, Tissue and Gene Therapies Advisory Committee. General Function of the Committee: To provide advice and recommendations...

  2. 76 FR 18768 - Cellular, Tissue, and Gene Therapies Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-04-05

    ... HUMAN SERVICES Food and Drug Administration Cellular, Tissue, and Gene Therapies Advisory Committee... portion of the meeting will be closed to the public. Name of Committee: Cellular, Tissue, and Gene Therapies Advisory Committee. General Function of the Committee: To provide advice and recommendations...

  3. 76 FR 81513 - Cellular, Tissue, and Gene Therapies Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-12-28

    ... HUMAN SERVICES Food and Drug Administration Cellular, Tissue, and Gene Therapies Advisory Committee..., Tissue, and Gene Therapies Advisory Committee. General Function of the Committee: To provide advice and... Gene Therapies, Center for Biologics Evaluation and Research, FDA. FDA intends to make...

  4. 76 FR 64951 - Cellular, Tissue and Gene Therapies Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-10-19

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Cellular, Tissue and Gene Therapies Advisory Committee... be open to the public. Name of Committee: Cellular, Tissue and Gene Therapies Advisory...

  5. 76 FR 22405 - Cellular, Tissue and Gene Therapies Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-04-21

    ... HUMAN SERVICES Food and Drug Administration Cellular, Tissue and Gene Therapies Advisory Committee... be open to the public. Name of Committee: Cellular, Tissue and Gene Therapies Advisory Committee... gene therapy products for the treatment of retinal disorders. Topics to be considered include...

  6. 78 FR 48438 - Pediatric Ethics Subcommittee of the Pediatric Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-08-08

    ... HUMAN SERVICES Food and Drug Administration Pediatric Ethics Subcommittee of the Pediatric Advisory... Administration (FDA). The meeting will be open to the public. Name of Subcommittee: Pediatric Ethics Subcommittee... recommendations to the Pediatric Advisory Committee on pediatric ethical issues. Date and Time: The meeting...

  7. 78 FR 77688 - Ophthalmic Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-12-24

    ... HUMAN SERVICES Food and Drug Administration Ophthalmic Devices Panel of the Medical Devices Advisory...). The meeting will be open to the public. Name of Committee: Ophthalmic Devices Panel of the Medical Devices Advisory Committee. General Function of the Committee: To provide advice and recommendations...

  8. 76 FR 6625 - Neurological Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-02-07

    ... HUMAN SERVICES Food and Drug Administration Neurological Devices Panel of the Medical Devices Advisory... Devices Advisory Committee. General Function of the Committee: To provide advice and recommendations to... Embolization Device (PED), sponsored by Chestnut Medical. The PED is indicated for the endovascular...

  9. 78 FR 13350 - Ophthalmic Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-02-27

    ... HUMAN SERVICES Food and Drug Administration Ophthalmic Devices Panel of the Medical Devices Advisory...). The meeting will be open to the public. Name of Committee: Ophthalmic Devices Panel of the Medical Devices Advisory Committee. General Function of the Committee: To provide advice and recommendations...

  10. 75 FR 44273 - Radiological Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-07-28

    ... HUMAN SERVICES Food and Drug Administration Radiological Devices Panel of the Medical Devices Advisory...). The meeting will be open to the public. Name of Committee: Radiological Devices Panel of the Medical Devices Advisory Committee. General Function of the Committee: To provide advice and recommendations...

  11. 77 FR 73034 - Neurological Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-12-07

    ... HUMAN SERVICES Food and Drug Administration Neurological Devices Panel of the Medical Devices Advisory...). The meeting will be open to the public. Name of Committee: Neurological Devices Panel of the Medical Devices Advisory Committee. General Function of the Committee: To provide advice and recommendations...

  12. 75 FR 35495 - Ophthalmic Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-06-22

    ... HUMAN SERVICES Food and Drug Administration Ophthalmic Devices Panel of the Medical Devices Advisory...). The meeting will be open to the public. Name of Committee: Ophthalmic Devices Panel of the Medical Devices Advisory Committee. General Function of the Committee: To provide advice and recommendations...

  13. 76 FR 3639 - Vaccines and Related Biological Products Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-01-20

    ... HUMAN SERVICES Food and Drug Administration Vaccines and Related Biological Products Advisory Committee... be open to the public. Name of Committee: Vaccines and Related Biological Products Advisory Committee... selection of strains to be included in the influenza virus vaccine for the 2011-2012 influenza season....

  14. 75 FR 2876 - Vaccines and Related Biological Products Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-01-19

    ... HUMAN SERVICES Food and Drug Administration Vaccines and Related Biological Products Advisory Committee... be open to the public. Name of Committee: Vaccines and Related Biological Products Advisory Committee... selection of strains to be included in the influenza virus vaccine for the 2010 - 2011 influenza season....

  15. 78 FR 5465 - Vaccines and Related Biological Products Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-01-25

    ... HUMAN SERVICES Food and Drug Administration Vaccines and Related Biological Products Advisory Committee... be open to the public. Name of Committee: Vaccines and Related Biological Products Advisory Committee... strains to be included in the influenza virus vaccine for the 2013- 2014 influenza season. FDA intends...

  16. 76 FR 52334 - Arthritis Advisory Committee; Notice of Postponement of Meeting

    Science.gov (United States)

    2011-08-22

    ... Administration (FDA) is postponing the Arthritis Advisory Committee meeting scheduled for September 13, 2011. This meeting was announced in the Federal Register of July 19, 2011 (76 FR 42715). The postponement is... HUMAN SERVICES Food and Drug Administration Arthritis Advisory Committee; Notice of Postponement...

  17. 77 FR 14769 - Meeting of the Uniform Formulary Beneficiary Advisory Panel

    Science.gov (United States)

    2012-03-13

    ... Department of Defense (DoD) announces the following Federal Advisory Committee meeting of the Uniform... Formulary Beneficiary Advisory Panel, 4130 Stanley Road, Suite 208, Building 1000, San Antonio, TX 78234...: Dipeptidyl Peptidase--4(DPP-4) Inhibitors. d. Designated Newly Approved Drugs in Already-Reviewed Classes....

  18. 76 FR 14980 - National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; Notice of...

    Science.gov (United States)

    2011-03-18

    ... HUMAN SERVICES National Institutes of Health National Institute on Alcohol Abuse and Alcoholism... Council on Alcohol Abuse and Alcoholism and the National Advisory Council on Drug Abuse. The meeting will...: National Advisory Council on Alcohol Abuse and Alcoholism and National Advisory Council on Drug Abuse....

  19. Antimicrobial Activity of Lippia Species from the Brazilian Semiarid Region Traditionally Used as Antiseptic and Anti-Infective Agents

    Directory of Open Access Journals (Sweden)

    Cristiana da Purificação Pinto

    2013-01-01

    Full Text Available Lippia origanoides Kunth, Lippia alnifolia Schauer, and Lippia thymoides Martius and Schauer are shrubs used in the traditional Brazilian medicine as antiseptics, as well as in the treatment of infectious diseases. This study was designed to investigate the antibacterial and antifungal activities of the methanolic extracts of these species, as new potential sources of antimicrobial drugs. The antimicrobial activity of methanolic extracts was investigated against resistant yeasts and bacteria by agar disk diffusion. Then, the MIC determination of the most active species and its fractions in hexane, dichloromethane, ethyl acetate, and water was performed. By the agar diffusion assay, all species were active against at least two microorganisms, giving evidence to support their use in the popular medicine. L. origanoides leaves exhibited the widest antimicrobial action, inhibiting the growth of two Gram-positive bacteria and two yeasts; this activity was also confirmed by the MIC evaluation. The fractionation of L. origanoides crude extracts improved the activity in spectrum and intensity. The results obtained in this study indicate that L. origanoides may be a promising alternative in the treatment of bacterial and fungal infections and in the seeking of new antimicrobial drugs.

  20. 76 FR 38668 - Advisory Committee for Pharmaceutical Science and Clinical Pharmacology; Notice of Meeting

    Science.gov (United States)

    2011-07-01

    ... Pharmacology; Notice of Meeting AGENCY: Food and Drug Administration, HHS. ACTION: Notice. This notice... Science and Clinical Pharmacology. General Function of the Committee: To provide advice and... April 13, 2010, Advisory Committee for Pharmaceutical Science and Clinical Pharmacology...

  1. 78 FR 104 - Advisory Committees; Tentative Schedule of Meetings for 2013

    Science.gov (United States)

    2013-01-02

    ... dates to be determined. Cardiovascular and Renal Drugs Advisory April 17 and other date(s) to Committee.... Ophthalmic Devices Panel June 14, August 23. Orthopaedic and Rehabilitation Devices April 5, September...

  2. 75 FR 30002 - Federal Advisory Committee; Threat Reduction Advisory Committee

    Science.gov (United States)

    2010-05-28

    ... Office of the Secretary Federal Advisory Committee; Threat Reduction Advisory Committee AGENCY... the charter for the Threat Reduction Advisory Committee (hereafter referred to as the Committee). FOR... Acquisition, Technology and Logistics and the Director of the Defense Threat Reduction Agency on the...

  3. 75 FR 60430 - Federal Advisory Committee; Threat Reduction Advisory Committee

    Science.gov (United States)

    2010-09-30

    ... of the Secretary Federal Advisory Committee; Threat Reduction Advisory Committee AGENCY: Office of... announces a meeting of the Threat Reduction Advisory Committee (hereafter referred to as ``the Committee..., October 21, 2010, from 9 a.m. to 5 p.m. ADDRESSES: The meeting will be held at the Heritage...

  4. Pharmaceutical Care for Elderly Patient with Chronic Obstructive Pulmonary Disease in Anti-infection and Immunoregulation Therapy by Clinical Pharmacists%临床药师参与慢性阻塞性肺疾病老年患者抗感染及免疫调节治疗的药学监护

    Institute of Scientific and Technical Information of China (English)

    张志清; 屠文莲; 曹玮

    2016-01-01

    OBJECTIVE:To provide reference for the anti-infection and immunoregulation therapy participated by the clinical pharmacists in respiration medicine .METHODS: By introducing the adjustments of anti-infection and immunoregulation therapy scheme for one elderly patient with chronic obstructive pulmonary disease with acute attack participated by the clinical pharmacists , the clinical characteristics of antibiotics were fully considered , the clinicians were suggested to select the related treatment drugs and increase the immunomodulator .RESULTS:Combined with the characteristics of the elderly patient , the clinical pharmacists cooperated with the clinicians from the aspect of anti-infection and immunoregulation therapy on chronic obstructive pulmonary disease with acute attack , so as to provide rational medication scheme for the patient .After treatment , the patient showed good infection control , and the acute attacking symptoms of chronic obstructive pulmonary disease were improved .CONCLUSIONS: The participation of clinical pharmacists in the clinical practice of anti-infection can took advantage in the perspective of pharmacy , optimize the treatment scheme , reduce the incidence of chronic obstructive pulmonary disease with acute attack and improve the life quality of patients .%目的:为临床药师在呼吸内科参与抗感染及免疫调节治疗提供参考。方法:介绍临床药师参与1例老年慢性阻塞性肺疾病急性发作患者抗感染及免疫调节治疗方案的调整,充分考虑抗菌药物的临床特点,建议医师选用相关治疗药物,增加免疫调节剂的过程。结果:临床药师结合老年患者的特点,从慢性阻塞性肺疾病急性发作抗感染及免疫调节方面积极配合医师,为患者提供了合理的用药方案。经治疗后,患者的感染控制良好,慢性阻塞性肺疾病急性发作症状得以缓解。结论:临床药师参与抗感染临床实践,可从药学的角

  5. 76 FR 53901 - The President's Management Advisory Board (PMAB); Notification of Upcoming Public Advisory Meeting

    Science.gov (United States)

    2011-08-30

    ... management, SES leadership development, and SES performance appraisal systems. The meeting minutes will be... ADMINISTRATION The President's Management Advisory Board (PMAB); Notification of Upcoming Public Advisory Meeting.... SUMMARY: The President's Management Advisory Board (PMAB), a Federal Advisory Committee established...

  6. Quercetin-loaded PLGA nanoparticles: a highly effective antibacterial agent in vitro and anti-infection application in vivo

    Energy Technology Data Exchange (ETDEWEB)

    Sun, Dongdong; Li, Nuan; Zhang, Weiwei; Yang, Endong; Mou, Zhipeng; Zhao, Zhiwei; Liu, Haiping; Wang, Weiyun, E-mail: weiywswzy@163.com [Anhui Agricultural University, School of Life Sciences (China)

    2016-01-15

    Nanotechnology-based approaches have tremendous potential for enhancing efficacy against infectious diseases. PLGA-based nanoparticles as drug delivery carrier have shown promising potential, owing to their sizes and related unique properties. This article aims to develop nanosized poly (d, l-lactide-co-glycolide) PLGA nanoparticle formulation loaded with quercetin (QT). QT is an antioxidant and antibacterial compound isolated from Chinese traditional medicine with low skin permeability and extreme water insolubility. The quercetin-loaded PLGA nanoparticles (PQTs) were synthesized by emulsion–solvent evaporation method and stabilized by coating with poly (vinyl alcohol). The characteristics of PQTs were analyzed by Fourier transform infrared spectroscopy, Ultraviolet–Visible spectroscopy, scanning electron microscope, transmission electron microscopy, and atomic force microscopy, respectively. The PQTs showed a spherical shape with an average size of 100–150 nm. We compared the antibacterial effects of PQTs against Escherichia coli (E. coli) and Micrococcus tetragenus (M. tetragenus).The PQTs produced stronger antibacterial activity to E. coli than that to M. tetragenus through disrupting bacterial cell wall integrity. The antibacterial ratio was increased with the increasing dosages and incubation time. Next, we tested the in vivo antibacterial activity in mice. No noticeable organ damage was captured from H&E-staining organ slices, suggesting the promise of using PQTs for in vivo applications. The results of this study demonstrated the interaction between bacteria and PLGA-based nanoparticles, providing encouragement for conducting further investigations on properties and antimicrobial activity of the PQTs in clinical application.

  7. 78 FR 20328 - Orthopaedic and Rehabilitation Devices Panel of the Medical Devices Advisory Committee: Notice of...

    Science.gov (United States)

    2013-04-04

    ... HUMAN SERVICES Food and Drug Administration Orthopaedic and Rehabilitation Devices Panel of the Medical Devices Advisory Committee: Notice of Postponement of Meeting AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration (FDA) is postponing the meeting of...

  8. 75 FR 42100 - National Institute on Drug Abuse; Notice of Meeting

    Science.gov (United States)

    2010-07-20

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Meeting... hereby given of a meeting of the National Advisory Council on Drug Abuse. The meeting will be open to the... unwarranted invasion of personal privacy. Name of Committee: National Advisory Council on Drug Abuse....

  9. 76 FR 2697 - National Institute on Drug Abuse; Notice of Meeting

    Science.gov (United States)

    2011-01-14

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Meeting... ] hereby given of a meeting of the National Advisory Council on Drug Abuse. The meeting will be open to the... unwarranted invasion of personal privacy. Name of Committee: National Advisory Council on Drug Abuse....

  10. 76 FR 81952 - National Institute on Drug Abuse; Notice of Meeting

    Science.gov (United States)

    2011-12-29

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Meeting... hereby given of a meeting of the National Advisory Council on Drug Abuse. The meeting will be open to the... unwarranted invasion of personal privacy. Name of Committee: National Advisory Council on Drug Abuse....

  11. 77 FR 52752 - National Institute on Drug Abuse; Notice of Meeting

    Science.gov (United States)

    2012-08-30

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Meeting... hereby given of a meeting of the National Advisory Council on Drug Abuse. The meeting will be open to the... unwarranted invasion of personal privacy. Name of Committee: National Advisory Council on Drug Abuse....

  12. 77 FR 22581 - National Institute on Drug Abuse; Notice of Meeting

    Science.gov (United States)

    2012-04-16

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Meeting... hereby given of a meeting of the National Advisory Council on Drug Abuse. The meeting will be open to the... unwarranted invasion of personal privacy. Name of Committee: National Advisory Council on Drug Abuse....

  13. 76 FR 51381 - National Institute on Drug Abuse; Notice of Meeting

    Science.gov (United States)

    2011-08-18

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Meeting... hereby given of a meeting of the National Advisory Council on Drug Abuse. The meeting will be open to the... unwarranted invasion of personal privacy. Name of Committee: National Advisory Council on Drug Abuse....

  14. 75 FR 14176 - National Institute on Drug Abuse; Notice of Meeting

    Science.gov (United States)

    2010-03-24

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Meeting... hereby given of a meeting of the National Advisory Council on Drug Abuse. The meeting will be open to the... unwarranted invasion of personal privacy. Name of Committee: National Advisory Council on Drug Abuse....

  15. 78 FR 45252 - National Institute on Drug Abuse; Notice of Meeting

    Science.gov (United States)

    2013-07-26

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Meeting... hereby given of a meeting of the National Advisory Council on Drug Abuse. The meeting will be open to the... unwarranted invasion of personal privacy. Name of Committee: National Advisory Council on Drug Abuse....

  16. 77 FR 72365 - National Institute on Drug Abuse; Notice of Meeting

    Science.gov (United States)

    2012-12-05

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Meeting... hereby given of a meeting of the National Advisory Council on Drug Abuse. The meeting will be open to the... unwarranted invasion of personal privacy. Name of Committee: National Advisory Council on Drug Abuse....

  17. Drug repurposing: a new front in the war against Staphylococcus aureus.

    Science.gov (United States)

    Das, Swetarka; Dasgupta, Arunava; Chopra, Sidharth

    2016-08-01

    Staphylococcus aureus continues its domination of worldwide bacterial infection rates, thereby remaining a pathogen of significant public health interest. A major reason for its continued success is its ability to acquire and maintain diverse drug resistance mechanisms, leading to a paucity of antimicrobials active against it, concomitantly leading to a continuous search for new antimicrobial agents. However, with the withdrawal of the major pharmaceutical firms from the anti-infective area, drug repurposing has provided a potential boost to the drug pipeline. In this review, we provide an overview of the currently approved drugs with repurposing potential against Staphylococcus aureus, thus augmenting the classical drug discovery pathway. PMID:27494302

  18. 76 FR 42713 - General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee; Amendment of...

    Science.gov (United States)

    2011-07-19

    ... HUMAN SERVICES Food and Drug Administration General and Plastic Surgery Devices Panel of the Medical... General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee. This meeting was... of the General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee would...

  19. Use of Cough and Cold Medications in Severe Bronchiolitis Before and After a Health Advisory Warning against Their Use

    Science.gov (United States)

    O’Donnell, Katherine; Mansbach, Jonathan M.; LoVecchio, Frank; Cheng, John; Piedra, Pedro A.; Clark, Sunday; Sullivan, Ashley F.; Camargo, Carlos A.

    2015-01-01

    We compared the use of cough and cold medications in two multicenter studies of young children hospitalized with bronchiolitis before and after the 2008 Food and Drug Administration cough and cold medications advisory. Although cough and cold medications use decreased after the advisory, nearly 20% of children age 12–23.9 months with severe bronchiolitis received cough and cold medications. PMID:25888349

  20. 78 FR 50040 - Technology Advisory Committee

    Science.gov (United States)

    2013-08-16

    ... COMMISSION Technology Advisory Committee AGENCY: Commodity Futures Trading Commission. ACTION: Notice of Meeting of Technology Advisory Committee. SUMMARY: The Commodity Futures Trading Commission (CFTC) announces that on September 12, 2013, the CFTC's Technology Advisory Committee (TAC) will hold a...

  1. 76 FR 776 - Technology Advisory Committee

    Science.gov (United States)

    2011-01-06

    ... COMMISSION Technology Advisory Committee AGENCY: Commodity Futures Trading Commission (``CFTC''). ACTION: Notice of meeting of Technology Advisory Committee. SUMMARY: The Technology Advisory Committee will hold...., Washington, DC 20581, attention: Office of the Secretary. Please use the title ``Technology...

  2. 75 FR 58367 - Technology Advisory Committee Meeting

    Science.gov (United States)

    2010-09-24

    ... COMMISSION Technology Advisory Committee Meeting AGENCY: Commodity Futures Trading Commission (``CFTC''). ACTION: Notice of meeting of Technology Advisory Committee. SUMMARY: The Technology Advisory Committee...., Washington, DC 20581, attention: Office of the Secretary. Please use the title ``Technology...

  3. 75 FR 28542 - Superior Resource Advisory Committee

    Science.gov (United States)

    2010-05-21

    ... orient the new Superior Resource Advisory Committee members on their roles and responsibilities. DATES... of the roles and responsibilities of the Superior Resource Advisory Committee members; Election of... Forest Service Superior Resource Advisory Committee AGENCY: Forest Service, USDA. ACTION: Notice...

  4. 77 FR 36250 - Recreation Resource Advisory Committees

    Science.gov (United States)

    2012-06-18

    ... Forest Service Recreation Resource Advisory Committees AGENCY: Forest Service, USDA. ACTION: Call for nominations for the Pacific Northwest Recreation Resource Advisory Committee. SUMMARY: The Secretary of Agriculture has established the Pacific Northwest Recreation Resource Advisory Committee (Recreation...

  5. Citizen Advisory Committees.

    Science.gov (United States)

    Miller, Leann R.

    This guide, describing community involvement through citizen advisory committees, is a summary of the literature on such committees. Its main concern is district committees created by school boards. Citations in the bibliography contain all points of view on committees and present many alternatives on most of the topics covered in the guide.…

  6. Anti-infective treatment for the HIV-infected patient during perioperative period%围手术期HIV感染者的抗感染治疗

    Institute of Scientific and Technical Information of China (English)

    刘保池; 张磊; 李垒; 司炎辉; 宋言峥; 赵中辛

    2012-01-01

      Objective:To investigate anti-infective treatments in HIV-infected surgical patients during the perioperative period. Methods 〓 A retrospective study of sepsis and surgical site infections (SSIs) was conducted in 266 HIV-infected patients from January 2009 to December 2011 in Shanghai Public Health Clinical Center. The patients were divided into 3 groups based on CD4 cells counts in the preoperative period: group A (<200 cell/μl), group B (200-349 cell/μl) and group C (≥350 cell/μl). Highly active anti-retrovirus therapy (HAART) was started in group B. Preoperative antibiotic medication SMZ and fluconazole against Pneumocystis carinii pneumonia (PCP) and other fungal infection was started in group A. No special treatment in group C. Results〓There were only 6 patients dead at 30 days after surgery, with the death rate of 2.3%. Sepsis appeared in 110 patients (41.3%). Patients in group A were more likely to get sepsis than patients in the other two groups (P <0.01). Conclusion〓Complete evalua- tion of surgical risk and suitable perioperative anti-infective treatment may lead to better outcome for HIV-infected surgical patients.%  〓〓[]〓目的〓探讨 HIV 感染者围手术期合理的抗感染治疗.方法〓回顾性分析上海市公共卫生临床中心外科2009年1月至2011年12月救治的266例 HIV 感染患者围手术期临床资料,根据患者术前 CD4 T 淋巴细胞水平分 A 组<200 cell/μl,B 组200~349 cell/μl 和 C 组≥350 cell/μl 三组,对 B 组给予抗 HIV 病毒治疗,对 A 组给予抗 HIV 病毒、磺胺甲唑(SMZ)和氟康唑预防肺孢子虫和真菌感染,对已经合并结核、真菌等机会性感染者给予相应的抗感染治疗.对 C组无特殊处理.结果〓经适当的抗感染治疗,266例患者手术后30 d 内死亡6例,病死率2.3%.110例发生脓毒症,脓毒症发生率41.3%.A 组脓毒症发病率明显高于 B 组和 C 组(P <0.01).结论〓精细的手术与合理的围手术

  7. 76 FR 62419 - General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee; Notice of...

    Science.gov (United States)

    2011-10-07

    ..., Salons A, B, C and D, 620 Perry Pkwy., Gaithersburg, MD. Contact Person: Avena Russell, Food and Drug... Spring, MD 20993-0002, 301-796-3805, Avena.Russell@fda.hhs.gov , or FDA Advisory Committee...

  8. Atmospheric release advisory capability

    International Nuclear Information System (INIS)

    The ARAC system (Atmospheric Release Advisory Capability) is described. The system is a collection of people, computers, computer models, topographic data and meteorological input data that together permits a calculation of, in a quasi-predictive sense, where effluent from an accident will migrate through the atmosphere, where it will be deposited on the ground, and what instantaneous and integrated dose an exposed individual would receive

  9. Complexities of Particulate Matter Measurement in Parenteral Formulations of Small-Molecule Amphiphilic Drugs

    OpenAIRE

    Hickey, Magali B.; Waggener, Sara; Gole, Dilip; Jimidar, Ilias; Vermeersch, Hans; Ratanabanangkoon, Poe; Tinke, Arjen P.; Almarsson, Örn

    2011-01-01

    Reconstituted parenteral solutions of three surface-active anti-infective small-molecule drugs and solutions of sodium dodecyl sulfate (SDS, a model surfactant) were studied to quantify the impact of sample preparation and handling on particle counts. Turbidimetry and light obscuration profiles were recorded as a function of agitation and shearing with and without the introduction of foam into the solutions. SDS solutions at concentrations above the critical micelle concentration (CMC) show s...

  10. 77 FR 25183 - Circulatory System Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-04-27

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Circulatory System Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting AGENCY: Food and Drug Administration, HHS. ACTION: Notice. This notice announces a forthcoming meeting of a...

  11. 77 FR 71195 - Orthopaedic and Rehabilitation Devices Panel of the Medical Devices Advisory Committee; Notice of...

    Science.gov (United States)

    2012-11-29

    ... From the Federal Register Online via the Government Publishing Office ] DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Orthopaedic and Rehabilitation Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting AGENCY: Food and Drug Administration, HHS. ACTION: Notice. This notice announces a...

  12. 76 FR 55398 - Immunology Devices Panel of the Medical Devices Advisory Committee: Notice of Postponement of...

    Science.gov (United States)

    2011-09-07

    ... in the Federal Register of August 9, 2011 (76 FR 48871). The meeting is postponed so that FDA can... HUMAN SERVICES Food and Drug Administration Immunology Devices Panel of the Medical Devices Advisory.... SUMMARY: The Food and Drug Administration (FDA) is postponing the meeting of the Immunology Devices...

  13. 76 FR 60848 - National Mammography Quality Assurance Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-09-30

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration National Mammography Quality Assurance Advisory Committee; Notice of Meeting AGENCY: Food and Drug Administration, HHS. ACTION: Notice. This notice announces a forthcoming meeting of a public...

  14. 21 CFR 20.84 - Disclosure to consultants, advisory committees, State and local government officials commissioned...

    Science.gov (United States)

    2010-04-01

    ..., State and local government officials commissioned pursuant to 21 U.S.C. 372(a), and other special government employees. 20.84 Section 20.84 Food and Drugs FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH... consultants, advisory committees, State and local government officials commissioned pursuant to 21 U.S.C....

  15. 77 FR 50701 - Radiological Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-08-22

    .... The Selenia Dimensions 3D System is currently approved for breast cancer screening and diagnosis. The... HUMAN SERVICES Food and Drug Administration Radiological Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting AGENCY: Food and Drug Administration, HHS. ] ACTION: Notice. This...

  16. 抗生素在抗感染中应用的药理分析%Pharmacological Analysis of Antibiotics in Application of Anti-infection

    Institute of Scientific and Technical Information of China (English)

    苗春红

    2016-01-01

    Objective Pharmacological analysis on antibiotics and its application to anti-infection are to be investigated. Methods Chose 172 patients with infectious disease who were given antibiotics treatment in hospital from September 2014 to November 2015 to study,and then made a pharmacological analysis on antibiotics and its application effect. Results Based on pharmacological analysis on antibiotics,it could be separated into time-dependent antibiotics and concentration-dependent antibiotics,and as for patients with a cold or diarrhea,they must be cautious to antibiotics usage. It was necessary to use antibiotics reasonably in accordance with il ness condition in order to increase treatment efficiency,otherwise,it would be ineffective and harmful to patients’immune system. Conclusion Antibiotics abuse is a serious problem in our nation,this study starts with pharmacological analysis on antibiotics and explores proper usage of it with investigation on its application method and principle in order to standard antibiotics application.%目的:探究抗生素在抗感染中的应用和药理分析。方法本次研究选取2014年9月~2015年11月收治的172例感染患者采用抗生素的治疗,对抗生素的药理进行分析,观察患者的治疗效果。结果对抗生素进行药理分析,有时间依赖性抗生素和浓度依赖性抗生素,感冒和腹泻患者慎用抗生素,要针对疾病类型,合理采用抗生素的治疗,才可提高治疗效果,否则不仅没有治疗效果,还会降低患者的免疫力。结论我国抗生素滥用的问题严重,本次研究在药理入手,对抗感染采用抗生素治疗进行合理应用,分析用药方法和用药原则,规范抗生素的合理应用。

  17. 78 FR 70317 - Invasive Species Advisory Committee

    Science.gov (United States)

    2013-11-25

    ... Office of the Secretary Invasive Species Advisory Committee AGENCY: Office of the Secretary, Interior. ACTION: Notice of Public Meeting (via Teleconference) of the Invasive Species Advisory Committee. SUMMARY... Invasive Species Advisory Committee. The purpose of the Advisory Committee is to provide advice to...

  18. 76 FR 55079 - Homeland Security Advisory Council

    Science.gov (United States)

    2011-09-06

    ... SECURITY Homeland Security Advisory Council AGENCY: The Office of Policy, DHS. ACTION: Notice of Open Teleconference Federal Advisory Committee Meeting. SUMMARY: The Homeland Security Advisory Council (HSAC) will... subject line of the message. Fax: (202) 282-9207. Mail: Homeland Security Advisory Council, Department...

  19. 77 FR 26774 - Homeland Security Advisory Council

    Science.gov (United States)

    2012-05-07

    ... SECURITY Homeland Security Advisory Council AGENCY: The Office of Policy, DHS. ACTION: Notice of partially closed federal advisory committee meeting. SUMMARY: The Homeland Security Advisory Council (HSAC) will... number in the subject line of the message. Fax: (202) 282-9207. Mail: Homeland Security Advisory...

  20. 76 FR 58813 - Homeland Security Advisory Council

    Science.gov (United States)

    2011-09-22

    ... SECURITY Homeland Security Advisory Council AGENCY: The Office of Policy, DHS. ACTION: Notice of open teleconference Federal Advisory Committee meeting. SUMMARY: The Homeland Security Advisory Council (HSAC) will... message. Fax: (202) 282-9207 Mail: Homeland Security Advisory Council, Department of Homeland...

  1. 77 FR 59627 - Homeland Security Advisory Council

    Science.gov (United States)

    2012-09-28

    ... SECURITY Homeland Security Advisory Council AGENCY: The Office of Policy, DHS. ACTION: Notice of open teleconference federal advisory committee meeting. SUMMARY: The Homeland Security Advisory Council (HSAC) will... line of the message. Fax: (202) 282-9207. Mail: Homeland Security Advisory Council, Department...

  2. 75 FR 26782 - Homeland Security Advisory Council

    Science.gov (United States)

    2010-05-12

    ... SECURITY Homeland Security Advisory Council AGENCY: The Office of Policy, DHS. ACTION: Notice of Open Teleconference Federal Advisory Committee Meeting. SUMMARY: The Homeland Security Advisory Council (HSAC) will... (Homeland Security) Review Advisory Committee. DATE: The HSAC conference call will take place from 4 p.m....

  3. 75 FR 53707 - Homeland Security Advisory Council

    Science.gov (United States)

    2010-09-01

    ... SECURITY Homeland Security Advisory Council AGENCY: The Office of Policy, DHS. ACTION: Notice of Open Teleconference Federal Advisory Committee Meeting. SUMMARY: The Homeland Security Advisory Council (HSAC) will...: Homeland Security Advisory Council, Department of Homeland Security, Mailstop 0850, 245 Murray Lane,...

  4. 75 FR 59278 - Homeland Security Advisory Council

    Science.gov (United States)

    2010-09-27

    ... SECURITY Homeland Security Advisory Council AGENCY: The Office of Policy, DHS. ACTION: Notice of Closed Federal Advisory Committee Meeting. SUMMARY: The Homeland Security Advisory Council (HSAC) will meet on... message. Fax: (202) 282-9207. Mail: Homeland Security Advisory Council, Department of Homeland...

  5. 78 FR 77443 - Electricity Advisory Committee

    Science.gov (United States)

    2013-12-23

    ... Electricity Advisory Committee AGENCY: Office of Electricity Delivery and Energy Reliability, Department of... Electricity Advisory Committee (EAC). The Federal Advisory Committee Act (Pub. L. 92-463, 86 Stat. 770.../oe/services/electricity-advisory-committee-eac . FOR FURTHER INFORMATION CONTACT: Matthew...

  6. 77 FR 2277 - Federal Advisory Committee; Defense Intelligence Agency (DIA) Advisory Board; Closed Meeting

    Science.gov (United States)

    2012-01-17

    ... of the Secretary Federal Advisory Committee; Defense Intelligence Agency (DIA) Advisory Board; Closed... discussions of classified information relating to DIA's intelligence operations including its support to... Advisory Board to discuss DIA operations and capabilities in support of current intelligence...

  7. 78 FR 295 - Federal Advisory Committee; Defense Intelligence Agency (DIA) Advisory Board; Closed Meeting

    Science.gov (United States)

    2013-01-03

    ... of the Secretary Federal Advisory Committee; Defense Intelligence Agency (DIA) Advisory Board; Closed... discussions of classified information relating to DIA's intelligence operations including its support to... the Advisory Board to discuss DIA operations and capabilities in support of current...

  8. 77 FR 62222 - Federal Advisory Committee; Defense Intelligence Agency (DIA) Advisory Board; Closed Meeting

    Science.gov (United States)

    2012-10-12

    ... of the Secretary Federal Advisory Committee; Defense Intelligence Agency (DIA) Advisory Board; Closed... discussions of classified information relating to DIA's intelligence operations including its support to... the Advisory Board to discuss DIA operations and capabilities in support of current...

  9. 76 FR 70425 - Federal Advisory Committee; Defense Intelligence Agency (DIA) Advisory Board; Closed Meeting

    Science.gov (United States)

    2011-11-14

    ... Office of the Secretary Federal Advisory Committee; Defense Intelligence Agency (DIA) Advisory Board... discussions of classified information relating to DIA's intelligence operations including its support to... Advisory Board to discuss DIA operations and capabilities in support of current intelligence...

  10. 76 FR 64122 - NASA Advisory Committee; Renewal of NASA's International Space Station Advisory Committee Charter

    Science.gov (United States)

    2011-10-17

    ... SPACE ADMINISTRATION NASA Advisory Committee; Renewal of NASA's International Space Station Advisory... and amendment of the Charter of the International Space Station Advisory Committee. SUMMARY: Pursuant... the National ] Aeronautics and Space Administration has determined that a renewal of the...

  11. 76 FR 52016 - NASA International Space Station Advisory Committee and the Aerospace Safety Advisory Panel; Meeting

    Science.gov (United States)

    2011-08-19

    ... SPACE ADMINISTRATION NASA International Space Station Advisory Committee and the Aerospace Safety... International Space Station Advisory Committee and the Aerospace Safety Advisory Panel. The purpose of this... consideration by NASA for Commercial Resupply Services for the International Space Station (ISS),...

  12. 75 FR 70004 - Federal Advisory Committee Act; Advisory Committee on Diversity for Communications in the Digital...

    Science.gov (United States)

    2010-11-16

    ... From the Federal Register Online via the Government Publishing Office FEDERAL COMMUNICATIONS COMMISSION Federal Advisory Committee Act; Advisory Committee on Diversity for Communications in the Digital... Communications Commission's (FCC) Advisory Committee on Diversity for Communications in the Digital...

  13. 78 FR 39289 - Federal Advisory Committee Act; Advisory Committee on Diversity for Communications in the Digital...

    Science.gov (United States)

    2013-07-01

    ... From the Federal Register Online via the Government Publishing Office ] FEDERAL COMMUNICATIONS COMMISSION Federal Advisory Committee Act; Advisory Committee on Diversity for Communications in the Digital... Communications Commission's (FCC) Advisory Committee on Diversity for Communications in the Digital...

  14. 78 FR 21354 - Federal Advisory Committee Act; Advisory Committee on Diversity for Communications in the Digital...

    Science.gov (United States)

    2013-04-10

    ... From the Federal Register Online via the Government Publishing Office FEDERAL COMMUNICATIONS COMMISSION Federal Advisory Committee Act; Advisory Committee on Diversity for Communications in the Digital... Communications Commission's (FCC) Advisory Committee on Diversity for Communications in the Digital...

  15. 76 FR 64348 - Federal Advisory Committee Act; Advisory Committee on Diversity for Communications in the Digital...

    Science.gov (United States)

    2011-10-18

    ... From the Federal Register Online via the Government Publishing Office FEDERAL COMMUNICATIONS COMMISSION Federal Advisory Committee Act; Advisory Committee on Diversity for Communications in the Digital... Communications Commission's (FCC) Advisory Committee on Diversity for Communications in the Digital...

  16. 75 FR 20844 - Federal Advisory Committee Act; Advisory Committee on Diversity for Communications in the Digital...

    Science.gov (United States)

    2010-04-21

    ... From the Federal Register Online via the Government Publishing Office FEDERAL COMMUNICATIONS COMMISSION Federal Advisory Committee Act; Advisory Committee on Diversity for Communications in the Digital... Communications Commission's (FCC) Advisory Committee on Diversity for Communications in the Digital...

  17. 77 FR 6113 - Federal Advisory Committee Act; Advisory Committee on Diversity for Communications in the Digital...

    Science.gov (United States)

    2012-02-07

    ... From the Federal Register Online via the Government Publishing Office FEDERAL COMMUNICATIONS COMMISSION Federal Advisory Committee Act; Advisory Committee on Diversity for Communications in the Digital... Communications Commission's (FCC's) Advisory Committee on Diversity for Communications in the Digital...

  18. 77 FR 57085 - Federal Advisory Committee Act; Advisory Committee on Diversity for Communications in the Digital...

    Science.gov (United States)

    2012-09-17

    ... From the Federal Register Online via the Government Publishing Office ] FEDERAL COMMUNICATIONS COMMISSION Federal Advisory Committee Act; Advisory Committee on Diversity for Communications in the Digital... Communications Commission's (FCC) Advisory Committee on Diversity for Communications in the Digital...

  19. 75 FR 60458 - Federal Advisory Committee Act; Advisory Committee on Diversity for Communications in the Digital...

    Science.gov (United States)

    2010-09-30

    ... From the Federal Register Online via the Government Publishing Office FEDERAL COMMUNICATIONS COMMISSION Federal Advisory Committee Act; Advisory Committee on Diversity for Communications in the Digital... Communications Commission's (FCC) Advisory Committee on Diversity for Communications in the Digital...

  20. 75 FR 53694 - Federal Advisory Committee Act; Advisory Committee on Diversity for Communications in the Digital...

    Science.gov (United States)

    2010-09-01

    ... From the Federal Register Online via the Government Publishing Office FEDERAL COMMUNICATIONS COMMISSION Federal Advisory Committee Act; Advisory Committee on Diversity for Communications in the Digital... Communications Commission's (FCC) Advisory Committee on Diversity for Communications in the Digital...

  1. 75 FR 6031 - Federal Advisory Committee Act; Advisory Committee on Diversity for Communications in the Digital...

    Science.gov (United States)

    2010-02-05

    ... From the Federal Register Online via the Government Publishing Office FEDERAL COMMUNICATIONS COMMISSION Federal Advisory Committee Act; Advisory Committee on Diversity for Communications in the Digital... Communications Commission's (FCC) Advisory Committee on Diversity for Communications in the Digital...

  2. 78 FR 28237 - President's National Security Telecommunications Advisory Committee

    Science.gov (United States)

    2013-05-14

    ... SECURITY President's National Security Telecommunications Advisory Committee AGENCY: National Protection... Advisory Committee Meeting. SUMMARY: The President's National Security Telecommunications Advisory... Telecommunications Advisory Committee, National Protection and Programs Directorate, Department of Homeland...

  3. Drugs + HIV, Learn the Link

    Medline Plus

    Full Text Available ... About NIDA Director's Page Organization Legislative Activities Advisory Boards & Groups Working at NIDA Donating to NIDA Contact Us Sharing Tools and Badges Other Resources Strategic Plan Search Share Print Home » News & Events » Public Education Projects » Learn the Link - Drugs and HIV Learn ...

  4. Joint Advisory Appeals Board

    CERN Multimedia

    2003-01-01

    The Joint Advisory Appeals Board was convened to examine the appeal lodged by Mr Poul Frandsen concerning his assimilation into the new career structure. As the appellant has not objected, the report of the Board and the final decision of the Director-General are brought to the notice of the personnel in accordance with Article R VI 1.20 of the Staff Regulations. The relevant documents will therefore be posted on the notice boards of the Administration Building (N° 60) from 13 to 24 January 2003. Human Resources Division Tel. 74128

  5. Joint Advisory Appeals Board

    CERN Multimedia

    2003-01-01

    The Joint Advisory Appeals Board was convened to examine the appeal lodged by Mr Aloïs Girardoz with regard to classification and advancement. As the appellant has not objected, the Board's report and the Director-General's decision will be brought to the notice of the personnel in accordance with Article R VI 1.20 of the Staff Regulations. The relevant documents will therefore be posted on the notice boards of the Administration Building (N° 60) from 15 to 29 August 2003. Human Resources Division Tel. 74128

  6. JOINT ADVISORY APPEALS BOARD

    CERN Multimedia

    Personnel Division

    1999-01-01

    The Joint Advisory Appeals Board was convened to examine the appeal lodged by Mr Joào Bento with regard to residential category. As the appellant has not objected, the recommendations of the Board and the final decision of the Director-General are brought to the notice of the personnel in accordance with Article RÊVIÊ1.20 of the Staff Regulations.The relevant documents will therefore be posted on the notice boards of the Administration Building (N¡ 60) from 29 October to 12 November 1999.Personnel DivisionTel. 74128

  7. Joint Advisory Appeals Board

    CERN Multimedia

    HR Department

    2008-01-01

    The Joint Advisory Appeals Board has examined the internal appeal lodged by a member of the personnel against the decision to grant him only a periodic one-step advancement for the 2006 reference year. The person concerned has not objected to the report of the Board and the final decision of the Director-General being brought to the attention of the members of the personnel. In application of Article R VI 1.18 of the Staff Regulations, these documents will therefore be posted on the notice board of the Main building (bldg. 500) from 1 September to 14 September 2008. Human Resources Department (73911)

  8. Joint Advisory Appeals Board

    CERN Multimedia

    HR Department

    2008-01-01

    The Joint Advisory Appeals Board has examined the internal appeal lodged by a member of the personnel against the decision to grant him only a periodic one-step advancement for the 2006 reference year. The person concerned has not objected to the report of the Board and the final decision of the Director-General being brought to the attention of the members of the personnel. In application of Article R VI 1.18 of the Staff Regulations, these documents will therefore be posted on the notice board of the Main Building (Bldg. 500) from 1 September to 14 September 2008. Human Resources Department (73911)

  9. Joint Advisory Appeals Board

    CERN Multimedia

    HR Department

    2007-01-01

    The Joint Advisory Appeals Board was convened to examine an internal appeal lodged by a member of the personnel with regard to the decision not to grant him an indefinite contract. The person concerned has requested that the report of the Board and the final decision of the Director-General be brought to the notice of the members of the personnel, in accordance with Article R VI 1.18 of the Staff Regulations. The relevant documents will therefore be posted on the notice board of the Main building (Bldg. 60) from 24 September to 7 October 2007. Human Resources Department

  10. Joint Advisory Appeals Board

    CERN Multimedia

    HR Department

    2008-01-01

    The Joint Advisory Appeals Board has examined the internal appeal lodged by a member of the personnel with regard to the decision not to grant him an indefinite contract. The person concerned has not objected to the report of the Board and the final decision of the Director-General being brought to the notice of the members of the personnel. In application of Article R VI 1.18 of the Staff Regulations, these documents will therefore be posted on the notice board of the Main Building (Bldg. 500) from 26 May to 6 June 2008. Human Resources Department (73911)

  11. Joint Advisory Appeals Board

    CERN Multimedia

    HR Department

    2008-01-01

    The Joint Advisory Appeals Board was convened to examine an internal appeal lodged by a member of the personnel with regard to the decision not to grant him an indefinite contract. The person concerned has not objected to the report of the Board and the final decision of the Director-General being brought to the notice of the members of the personnel, in accordance with Article R VI 1.18 of the Staff Regulations. These documents will therefore be posted on the notice board of the Main Building (Bldg. 60) from 21 January to 3 February 2008. Human Resources Department (73911)

  12. Joint Advisory Appeals Board

    CERN Multimedia

    HR Department

    2006-01-01

    The Joint Advisory Appeals Board was convened to examine an appeal lodged by a member of the personnel with regard to advancement. The person concerned has requested that the report of the Board and the final decision of the Director-General be brought to the notice of the personnel in accordance with Article R VI 1.20 of the Staff Regulations. The relevant documents will therefore be posted on the notice boards of the Administration Building (No. 60) from 24 March to 10 April 2006. Human Resources Department Tel. 74128

  13. Joint Advisory Appeals Board

    CERN Multimedia

    HR Department

    2008-01-01

    The Joint Advisory Appeals Board has examined the internal appeal lodged by a member of the personnel with regard to the decision not to award him a periodic one-step advancement for the 2006 reference year. The person concerned has not objected to the report of the Board and the final decision of the Director-General being brought to the notice of the members of the personnel. In application of Article R VI 1.18 of the Staff Regulations, these documents will therefore be posted on the notice board of the Main building (Bldg. 500) from 17 March to 30 March 2008. Human Resources Department Tel. 73911

  14. Joint Advisory Appeals Board

    CERN Multimedia

    2013-01-01

    The Joint Advisory Appeals Board has examined the internal appeal lodged by a former member of the personnel, a beneficiary of the CERN Pension Fund, against the calculation of his pension in the framework of the Progressive Retirement Programme.   The person concerned has not objected to the report of the Board and the final decision of the Director-General being brought to the attention of the members of the personnel. In application of Article R VI 1.18 of the Staff Regulations, these documents will therefore be available from 26 July to 11 August 2013 at the following link. HR Department Head Office

  15. NIOSOMES IN TARGETED DRUG DELIVERY : A REVIEW

    Directory of Open Access Journals (Sweden)

    PRAGNA GADHIYA

    2012-05-01

    Full Text Available Over the past several years, treatment of infectious diseases and immunization has undergone aparadigm shift. Stemming from the nanobiotechnology research, not only a large number of diseasespecificbiologicals have been developed, but also enormous efforts have been made to effectivelydeliver these biologicals. Non-ionic surfactant vesicles (or niosomes are now widely studied asalternates to liposomes. Different novel approaches used for delivering these drugs include liposomes,Microspheres, nanotechnology, micro emulsions, antibody-loaded drug delivery, magneticMicrocapsules, implantable pumps and niosomes. Niosomes and liposomes are equiactive In drugdelivery potential and both increase drug efficacy as compared with that of free Drug. Niosomes arepreferred over liposomes because the former exhibit high chemical Stability and economy. Niosomes areself assembled vesicles composed primarily of synthetic surfactants and cholesterol. They are analogousin structure to the more widely studied liposomes formed from biologically derived phospholipids.Niosomes represent an emerging class of novel vesicular systems. Niosome formation requires thepresence of a particular class of amphiphile and aqueous solvent. In recent years a comprehensiveresearch carried over niosome as a drug carrier. Various drugs are enlisted and tried in niosomesurfactant vesicles. Niosome appears to be a Well preferred drug delivery system over liposome asniosome being stable and economic. Also niosomes have great drug delivery potential for targeteddelivery of anti-cancer, Anti-infective agents. Drug delivery potential of niosome can enhance by usingnovel Concepts like proniosomes, discomes and aspasome. Niosomes also serve better aid in diagnosticimaging and as a vaccine adjuvant.

  16. KZBW Center Weather Advisory (CWA)

    Data.gov (United States)

    National Oceanic and Atmospheric Administration, Department of Commerce — The CWA is an aviation weather warning for conditions meeting or approaching national in-flight advisory (AIRMET, SIGMET or SIGMET for convection) criteria. CWAs...

  17. Crash course in readers' advisory

    CERN Document Server

    Orr, Cynthia

    2014-01-01

    One of the key services librarians provide is helping readers find books they'll enjoy. This ""crash course"" will furnish you with the basic, practical information you need to excel at readers' advisory (RA) for adults and teens.

  18. 78 FR 60863 - Threat Reduction Advisory Committee; Notice of Federal Advisory Committee Meeting

    Science.gov (United States)

    2013-10-02

    ... of the Secretary Threat Reduction Advisory Committee; Notice of Federal Advisory Committee Meeting... Federal advisory committee meeting of the Threat Reduction Advisory Committee (``the Committee''). DATES...: Mr. William Hostyn, DoD, Defense Threat Reduction Agency/J2/5/8R-ACP, 8725 John J. Kingman Road,...

  19. 78 FR 29334 - Threat Reduction Advisory Committee; Notice of Federal Advisory Committee Meeting

    Science.gov (United States)

    2013-05-20

    ... of the Secretary Threat Reduction Advisory Committee; Notice of Federal Advisory Committee Meeting... advisory committee meeting of the Threat Reduction Advisory Committee (``the Committee''). DATES: Wednesday... Hostyn, DoD, Defense Threat Reduction Agency/J2/5/8R-ACP, 8725 John J. Kingman Road, MS 6201,...

  20. 77 FR 15751 - Meetings of the Local Government Advisory Committee and the Small Communities Advisory Subcommittee

    Science.gov (United States)

    2012-03-16

    ... AGENCY Meetings of the Local Government Advisory Committee and the Small Communities Advisory... requests for appearances requires it. The Local Government Advisory Committee (LGAC) will meet at EPA's...: Local Government Advisory Committee (LGAC) contact Frances Eargle at (202) 564-3115 or email at...

  1. 77 FR 2539 - Meetings of the Small Communities Advisory Subcommittee and the Local Government Advisory Committee

    Science.gov (United States)

    2012-01-18

    ... AGENCY Meetings of the Small Communities Advisory Subcommittee and the Local Government Advisory... if the number of requests for appearances requires it. The Local Government Advisory Committee (LGAC... at davis.catherinem@epa.gov . For the Local Government Advisory Committee (LGAC) contact...

  2. 75 FR 22754 - Federal Advisory Committee; Chief of Engineers Environmental Advisory Board; Charter Renewal

    Science.gov (United States)

    2010-04-30

    ... of the Secretary Federal Advisory Committee; Chief of Engineers Environmental Advisory Board; Charter... that it is renewing the charter for the Chief of Engineers Environmental Advisory Board (hereafter referred to as the Board). FOR FURTHER INFORMATION CONTACT: Jim Freeman, Deputy Advisory...

  3. 75 FR 22560 - Federal Advisory Committee; U.S. Air Force Scientific Advisory Board; Charter Renewal

    Science.gov (United States)

    2010-04-29

    ... of the Secretary Federal Advisory Committee; U.S. Air Force Scientific Advisory Board; Charter... that it is renewing the charter for the U.S. Air Force Scientific Advisory Board (hereafter referred to as the Board). FOR FURTHER INFORMATION CONTACT: Jim Freeman, Deputy Advisory Committee...

  4. Atmospheric Release Advisory Capability

    International Nuclear Information System (INIS)

    The Atmospheric Release Advisory Capability (ARAC) project is a Department of Energy (DOE) sponsored real-time emergency response service available for use by both federal and state agencies in case of a potential or actual atmospheric release of nuclear material. The project, initiated in 1972, is currently evolving from the research and development phase to full operation. Plans are underway to expand the existing capability to continuous operation by 1984 and to establish a National ARAC Center (NARAC) by 1988. This report describes the ARAC system, its utilization during the past two years, and plans for its expansion during the next five to six years. An integral part of this expansion is due to a very important and crucial effort sponsored by the Defense Nuclear Agency to extend the ARAC service to approximately 45 Department of Defense (DOD) sites throughout the continental US over the next three years

  5. Payload advisory panel recommendations

    Science.gov (United States)

    Moore, Berrien, III

    1991-01-01

    The Payload Advisory Panel proposes a restructured Earth Observing System (EOS) mission to address high-priority science and environmental policy issues in Earth System Science. These issues have been identified through studies conducted by the Intergovernmental Panel on Climate Change (IPCC), the United States Environmental Protection Agency (EPA), and the Committee on Earth and Environmental Sciences (CEES). The restructured EOS defers efforts to improve the understanding of the middle and upper stratosphere and solid earth geophysics. The strategy of the mission combines high priority new measurements with continuation of critical data sets begun by missions which precede EOS. Collaborative arrangements with international partners are an essential part of the program and additional arrangements are posed. The need for continuity in Earth observations and the urgency of environmental questions require launch of some EOS elements as soon as possible. They further require maintenance of the EOS objective of obtaining consistent 15-year measurement records.

  6. 75 FR 67351 - Environmental Management Advisory Board

    Science.gov (United States)

    2010-11-02

    ... Environmental Management Advisory Board AGENCY: Department of Energy. ACTION: Notice of Open Teleconference. SUMMARY: This notice announces a teleconference of the Environmental Management Advisory Board (EMAB). The... is to provide the Assistant Secretary for Environmental Management (EM) with advice...

  7. 75 FR 51026 - Environmental Management Advisory Board

    Science.gov (United States)

    2010-08-18

    ... Environmental Management Advisory Board AGENCY: Department of Energy. ACTION: Notice of open meeting. SUMMARY: This notice announces a meeting of the Environmental Management Advisory Board (EMAB). The Federal... Assistant Secretary for Environmental Management (EM) with advice and recommendations on corporate...

  8. 75 FR 9416 - Advisory Committee Information Hotline

    Science.gov (United States)

    2010-03-02

    ... OF THE COMMISSIONER Pediatric Advisory Committee 8732310001 Risk Communication Advisory Committee... 3014512396 Orthopaedic and Rehabilitation Devices Panel 3014512521 Radiological Devices Panel 3014512526...: February 24, 2010. Joanne Less, Acting Associate Commissioner for Special Medical Programs. BILLING...

  9. 77 FR 58356 - Science Advisory Board

    Science.gov (United States)

    2012-09-20

    ... the meeting date. SUPPLEMENTARY INFORMATION: The Science Advisory Board (SAB) was established by a... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF COMMERCE National Oceanic and Atmospheric Administration Science Advisory Board AGENCY: Office of Oceanic...

  10. 75 FR 19608 - Recreation Resource Advisory Committees

    Science.gov (United States)

    2010-04-15

    ...; ] DEPARTMENT OF AGRICULTURE Forest Service Recreation Resource Advisory Committees AGENCY: Forest Service, USDA. ACTION: Call for nominations for the Pacific Northwest Recreation Resource Advisory Committees. SUMMARY: The Secretary of Agriculture has established the Pacific Northwest Recreation Resource...

  11. 77 FR 4238 - Advisory Committee Management

    Science.gov (United States)

    2012-01-27

    ... Part 8 RIN 1400-AC64 Advisory Committee Management AGENCY: Department of State. ACTION: Final rule... establish uniform administrative guidelines and management controls for advisory committees established by... of Subjects in 22 CFR Part 8 Advisory Committee Management. Accordingly, under the authority of 22...

  12. 77 FR 15091 - Environmental Management Advisory Board

    Science.gov (United States)

    2012-03-14

    ... Environmental Management Advisory Board AGENCY: Department of Energy. ACTION: Notice of Solicitation of Nominations for Appointment as a member of the Environmental Management Advisory Board. SUMMARY: In accordance... soliciting nominations for candidates to fill vacancies on the Environmental Management Advisory Board...

  13. 76 FR 21877 - Environmental Management Advisory Board

    Science.gov (United States)

    2011-04-19

    ... Environmental Management Advisory Board AGENCY: Department of Energy. ACTION: Notice of call for nominations for appointment to the Environmental Management Advisory Board. SUMMARY: This notice constitutes an open call to the public to submit nominations for membership on the Environmental Management Advisory Board....

  14. 77 FR 40032 - Methane Hydrate Advisory Committee

    Science.gov (United States)

    2012-07-06

    ... Methane Hydrate Advisory Committee AGENCY: Office of Fossil Energy, Department of Energy. ACTION: Notice of open meeting. SUMMARY: This notice announces a meeting of the Methane Hydrate Advisory Committee.... SUPPLEMENTARY INFORMATION: Purpose of the Committee: The purpose of the Methane Hydrate Advisory Committee is...

  15. 76 FR 30955 - Invasive Species Advisory Committee

    Science.gov (United States)

    2011-05-27

    ... Office of the Secretary Invasive Species Advisory Committee AGENCY: Office of the Secretary, Interior. ACTION: Notice of public meetings of the Invasive Species Advisory Committee. SUMMARY: Pursuant to the provisions of the Federal Advisory Committee Act, notice is hereby given of meetings of the Invasive...

  16. 75 FR 69698 - Invasive Species Advisory Committee

    Science.gov (United States)

    2010-11-15

    ... Office of the Secretary Invasive Species Advisory Committee AGENCY: Office of the Secretary, Interior. ACTION: Notice of public meetings of the Invasive Species Advisory Committee. SUMMARY: Pursuant to the provisions of the Federal Advisory Committee Act, notice is hereby given of meetings of the Invasive...

  17. 76 FR 68776 - Invasive Species Advisory Committee

    Science.gov (United States)

    2011-11-07

    ...Pursuant to the provisions of the Federal Advisory Committee Act, notice is hereby given of meetings of the Invasive Species Advisory Committee (ISAC). Comprised of 29 nonfederal invasive species experts and stakeholders from across the nation, the purpose of the Advisory Committee is to provide advice to the National Invasive Species Council, as authorized by Executive Order 13112, on a broad......

  18. 77 FR 23740 - Invasive Species Advisory Committee

    Science.gov (United States)

    2012-04-20

    ...Pursuant to the provisions of the Federal Advisory Committee Act, notice is hereby given of meetings of the Invasive Species Advisory Committee (ISAC). Comprised of 30 nonfederal invasive species experts and stakeholders from across the nation, the purpose of the Advisory Committee is to provide advice to the National Invasive Species Council, as authorized by Executive Order 13112, on a broad......

  19. 75 FR 38086 - Technology Advisory Committee Meeting

    Science.gov (United States)

    2010-07-01

    ... COMMISSION Technology Advisory Committee Meeting The Commodity Futures Trading Commission's (``Commission'') Technology Advisory Committee will conduct a meeting on Wednesday, July 14, 2010, beginning at 1 p.m. The...://www.cftc.gov . This will be the first meeting of the reestablished Technology Advisory...

  20. 77 FR 15737 - Technology Advisory Committee

    Science.gov (United States)

    2012-03-16

    ... COMMISSION Technology Advisory Committee AGENCY: Commodity Futures Trading Commission (``CFTC''). ACTION: Notice of meeting of Technology Advisory Committee. SUMMARY: The CFTC announces that on March 29, 2012, the CFTC's Technology Advisory Committee (``TAC'') will hold a public meeting at the CFTC's...

  1. 75 FR 20371 - Homeland Security Advisory Council

    Science.gov (United States)

    2010-04-19

    ... SECURITY Homeland Security Advisory Council AGENCY: The Office of Policy, DHS. ACTION: Notice of Open Teleconference Federal Advisory Committee Meeting. SUMMARY: The Homeland Security Advisory Council (HSAC) will... . Include docket number in the subject line of the message. Fax: (202) 282-9207 Mail: Homeland...

  2. 77 FR 476 - Science Advisory Board

    Science.gov (United States)

    2012-01-05

    ... National Oceanic and Atmospheric Administration (NOAA) Science Advisory Board AGENCY: Office of Oceanic and... agenda of a forthcoming meeting of the NOAA Science Advisory Board. The members will discuss and provide... be reviewed prior to the meeting date. SUPPLEMENTARY INFORMATION: The Science Advisory Board...

  3. 76 FR 10577 - Electricity Advisory Committee Meeting

    Science.gov (United States)

    2011-02-25

    ... Electricity Advisory Committee Meeting AGENCY: Office of Electricity Delivery and Energy Reliability... reestablished Electricity Advisory Committee (EAC). The Federal Advisory Committee Act (Pub. L. 92-463, 86 Stat... of Electricity Delivery and Energy Reliability, U.S. Department of Energy, Forrestal Building,...

  4. 75 FR 61454 - Electricity Advisory Committee

    Science.gov (United States)

    2010-10-05

    ... Electricity Advisory Committee AGENCY: Department of Energy, Office of Electricity Delivery and Energy...-established DOE Electricity Advisory Committee. The Federal Advisory Committee Act (Pub. L. 92-463, 86 Stat...: David Meyer, Designated Federal Officer, Office of Electricity Delivery and Energy Reliability,...

  5. 78 FR 15928 - Forestry Research Advisory Council

    Science.gov (United States)

    2013-03-13

    ...; ] DEPARTMENT OF AGRICULTURE Office of the Secretary Forestry Research Advisory Council AGENCY: Forest Service...: The Department of Agriculture intends to re-establish the Forestry Research Advisory Council (Council... intends to re-establish the Forestry Research Advisory Council (FRAC). The Council, a statutory...

  6. 78 FR 30847 - Forestry Research Advisory Council

    Science.gov (United States)

    2013-05-23

    ... Forest Service Forestry Research Advisory Council AGENCY: Forest Service, USDA. ACTION: Notice of meeting. SUMMARY: The Forestry Research Advisory Council will meet in Washington, DC, June 13 and 14, 2013. The... Apple, Designated Federal Officer, Forestry Research Advisory Council, USDA Forest Service Research...

  7. 78 FR 2950 - Forestry Research Advisory Council

    Science.gov (United States)

    2013-01-15

    ... Forest Service Forestry Research Advisory Council AGENCY: Forest Service, USDA. ACTION: Notice of meeting. SUMMARY: The Forestry Research Advisory Council will meet in Washington, DC February 7-8, 2013. The... Apple, Designated Federal Officer, Forestry Research Advisory Council, USDA Forest Service Research...

  8. Drug-Induced Nephrotoxicity and Dose Adjustment Recommendations: Agreement Among Four Drug Information Sources

    Directory of Open Access Journals (Sweden)

    Millena Drumond Bicalho

    2015-09-01

    Full Text Available : Hospitalized patients require the use of a variety of drugs, many of which individually or in combination have the potential to cause kidney damage. The use of potentially nephrotoxic drugs is often unavoidable, and the need for dose adjustment should be evaluated. This study is aimed at assessing concordance in information on drug-induced nephrotoxicity and dose adjustment recommendations by comparing four drug information sources (DRUGDEX®, UpToDate®, Medscape® and the Brazilian Therapeutic Formulary using the formulary of a Brazilian public hospital. A total of 218 drugs were investigated. The global Fleiss’ kappa coefficient was 0.265 for nephrotoxicity (p < 0.001; CI 95%, 0.211–0.319 and 0.346 for recommendations (p < 0.001; CI 95%, 0.292–0.401, indicating fair concordance among the sources. Anti-infectives and anti-hypertensives were the main drugs cited as nephrotoxic by the different sources. There were no clear definitions for qualitative data or quantitative values for dose adjustments among the four information sources. There was no advice for dosing for a large number of the drugs in the international databases. The National Therapeutic Formulary offered imprecise dose adjustment recommendations for many nephrotoxic drugs. Discrepancies among information sources may have a clinical impact on patient care and contribute to drug-related morbidity and mortality.

  9. Drug-Induced Nephrotoxicity and Dose Adjustment Recommendations: Agreement Among Four Drug Information Sources.

    Science.gov (United States)

    Bicalho, Millena Drumond; Soares, Danielly Botelho; Botoni, Fernando Antonio; Reis, Adriano Max Moreira; Martins, Maria Auxiliadora Parreiras

    2015-09-09

    : Hospitalized patients require the use of a variety of drugs, many of which individually or in combination have the potential to cause kidney damage. The use of potentially nephrotoxic drugs is often unavoidable, and the need for dose adjustment should be evaluated. This study is aimed at assessing concordance in information on drug-induced nephrotoxicity and dose adjustment recommendations by comparing four drug information sources (DRUGDEX(®), UpToDate(®), Medscape(®) and the Brazilian Therapeutic Formulary) using the formulary of a Brazilian public hospital. A total of 218 drugs were investigated. The global Fleiss' kappa coefficient was 0.265 for nephrotoxicity (p < 0.001; CI 95%, 0.211-0.319) and 0.346 for recommendations (p < 0.001; CI 95%, 0.292-0.401), indicating fair concordance among the sources. Anti-infectives and anti-hypertensives were the main drugs cited as nephrotoxic by the different sources. There were no clear definitions for qualitative data or quantitative values for dose adjustments among the four information sources. There was no advice for dosing for a large number of the drugs in the international databases. The National Therapeutic Formulary offered imprecise dose adjustment recommendations for many nephrotoxic drugs. Discrepancies among information sources may have a clinical impact on patient care and contribute to drug-related morbidity and mortality.

  10. 78 FR 9060 - Request for Nominations for Voting Members on Public Advisory Panels or Committees

    Science.gov (United States)

    2013-02-07

    ... Radiological Health, Food and Drug Assurance Advisory Committee. Administration, 10903 New Hampshire Dental... Anesthesiology and Respiratory Spring, MD 20993, 301-796-6639, email: Therapy Devices Panel. Shanika.Craig@fda... Approximate date needed needed vacancies Anesthesiology and 3 December 1, 2013. Respiratory Therapy...

  11. 78 FR 20663 - Vaccines and Related Biological Products Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-04-05

    ... DNA Viruses, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics... HUMAN SERVICES Food and Drug Administration Vaccines and Related Biological Products Advisory Committee... portion of the meeting will be closed to the public. Name of Committee: Vaccines and Related...

  12. 78 FR 11208 - Circulatory System Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-02-15

    ... HUMAN SERVICES Food and Drug Administration Circulatory System Devices Panel of the Medical Devices... the Medical Devices Advisory Committee. General Function of the Committee: To provide advice and... three major components: The delivery catheter, the steerable sleeve, and the MitraClip device. The...

  13. 75 FR 7282 - Circulatory System Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-02-18

    ... HUMAN SERVICES Food and Drug Administration Circulatory System Devices Panel of the Medical Devices... the Medical Devices Advisory Committee. General Function of the Committee: To provide advice and... Warner, Acting Associate Commissioner for Special Medical Programs. BILLING CODE 4160-01-S...

  14. 75 FR 81282 - Circulatory System Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-12-27

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Circulatory System Devices Panel of the Medical Devices... the Medical Devices Advisory Committee. General Function of the Committee: To provide advice...

  15. 76 FR 56200 - Circulatory System Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-09-12

    ... HUMAN SERVICES Food and Drug Administration Circulatory System Devices Panel of the Medical Devices... the Medical Devices Advisory Committee. General Function of the Committee: To provide advice and... and are pre-loaded onto 6 or 7 Fr \\1\\ (diameter of 2 or 2.3 mm) delivery systems. Upon deployment,...

  16. 77 FR 3780 - Vaccines and Related Biological Products Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-01-25

    ... HUMAN SERVICES Food and Drug Administration Vaccines and Related Biological Products Advisory Committee... portion of the meeting will be closed to the public. Name of Committee: Vaccines and Related Biological..., Parasitic and Allergenic Products, Office of Vaccines Research and Review, Center for Biologics...

  17. 78 FR 67365 - Circulatory System Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-11-12

    ... HUMAN SERVICES Food and Drug Administration Circulatory System Devices Panel of the Medical Devices... the Medical Devices Advisory Committee. General Function of the Committee: To provide advice and... percutaneously delivered permanent cardiac implant placed in the left atrial appendage. This device is...

  18. 76 FR 36548 - Circulatory System Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-06-22

    ... HUMAN SERVICES Food and Drug Administration Circulatory System Devices Panel of the Medical Devices... the Medical Devices Advisory Committee. General Function of the Committee: To provide advice and... vote on information related to the humanitarian device exemption for the Berlin Heart EXCOR...

  19. 76 FR 58019 - Circulatory System Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-09-19

    ... HUMAN SERVICES Food and Drug Administration Circulatory System Devices Panel of the Medical Devices... the Medical Devices Advisory Committee. General Function of the Committee: To provide advice and... Medtronic Ablation Frontiers Cardiac Ablation System is a catheter-based device developed for the...

  20. 76 FR 48871 - Immunology Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-08-09

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Immunology Devices Panel of the Medical Devices Advisory...). The meeting will be open to the public. Name of Committee: Immunology Devices Panel of the...

  1. 75 FR 22147 - Tobacco Product Constituents Subcommittee of the Tobacco Products Scientific Advisory Committee...

    Science.gov (United States)

    2010-04-27

    ... HUMAN SERVICES Food and Drug Administration Tobacco Product Constituents Subcommittee of the Tobacco... Administration (FDA). The meeting will be open to the public. Name of Committee: Tobacco Product Constituents Subcommittee of the Tobacco Products Scientific Advisory Committee. General Function of the Committee:...

  2. 75 FR 33814 - Tobacco Product Constituents Subcommittee of the Tobacco Products Scientific Advisory Committee...

    Science.gov (United States)

    2010-06-15

    ... HUMAN SERVICES Food and Drug Administration Tobacco Product Constituents Subcommittee of the Tobacco... Administration (FDA). The meeting will be open to the public. Name of Committee: Tobacco Product Constituents Subcommittee of the Tobacco Products Scientific Advisory Committee. General Function of the Committee:...

  3. 78 FR 26786 - Microbiology Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-05-08

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Microbiology Devices Panel of the Medical Devices Advisory...). The meeting will be open to the public. Name of Committee: Microbiology Devices Panel of the...

  4. 76 FR 50485 - Obstetrics and Gynecology Devices Panel of the Medical Devices Advisory Committee; Amendment of...

    Science.gov (United States)

    2011-08-15

    ... Obstetrics and Gynecology Devices Panel of the Medical Devices Advisory Committee. This meeting was announced in the Federal Register of July 14, 2011 (76 FR 41507). The amendment is being made to reflect a... HUMAN SERVICES Food and Drug Administration Obstetrics and Gynecology Devices Panel of the...

  5. 78 FR 13347 - Clinical Chemistry and Clinical Toxicology Devices Panel of the Medical Devices Advisory...

    Science.gov (United States)

    2013-02-27

    ... From the Federal Register Online via the Government Publishing Office ] DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Clinical Chemistry and Clinical Toxicology Devices Panel of... Chemistry and Clinical Toxicology Devices Panel of the Medical Devices Advisory Committee. General...

  6. 78 FR 46977 - Ophthalmic Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-08-02

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Ophthalmic Devices Panel of the Medical Devices Advisory...). The meeting will be open to the public. Name of Committee: Ophthalmic Devices Panel of the...

  7. Alerts and Advisories

    Science.gov (United States)

    ... Undeclared Sibutramine ( FDA ; 06/07/16 ) FTC Charges Marketers Used Massive Spam Campaign To Pitch Bogus Weight- ... contains hidden drug ingredient ( FDA ; 06/01/16 ) Marketers of Dietary Supplement Amberen Settle FTC Charges Regarding ...

  8. 神经外科手术患者应用氟喹诺酮类药抗感染疗效的影响因素%Analysis of influencing factors for anti-infection efficacy of fluoroquinolones in neurosurgical patients

    Institute of Scientific and Technical Information of China (English)

    唐宗椿; 王晓峰; 杨兴奎; 张荣军

    2012-01-01

    Objective To analyze the influencing factors of therapeutic efficacy of antibacterial fluoroquinolones in neurosurgical patients, and to provide reference for rational use of fluoroquinolones in clinic. Methods The scale of influencing factors for 133 neurosurgical patients who treated with fluoroquinolones , including age, gender, liver and renal function index, and other factors, were designed and filled according to the data of clinical case. The data were analyzed through Logistic regression analysis to determine the main factors that influenced therapeutic effects. Results In 133 cases,pathogens were cultured by microbial test in 16 cases (12. 03% ). Among influencing factors of therapeutic efficacy of fluoroquinolones, the age, gender, creatinine, alanine aminotransferase and aspartate aminotransferase were major factors. Logistic regression analysis showed that the OR values were from 0. 029 to 5. 317 and P values from 0. 003 to 0.026. Conclusion The results suggest that elderly and poor liver and kidney function patients using fluoroquinolones as anti-infective therapy are ineffective. Fluoroquinolone drugs for the elderly and liver and kidney dysfunction patients with anti-infective therapy, individual therapy should be based on susceptibility testing and changes in condition.%目的 对影响神经外科手术中氟喹诺酮类药抗感染疗效的影响因素进行分析,为该类药临床合理应用提供参考.方法 对133例使用氟喹诺酮类药治疗的神经外科手术患者制定抗感染疗效影响因素调查量表,并根据患者临床病例提供的数据填写,对包括年龄、性别、肝肾功能等在内的11个因素进行多因素Logistic回归分析,确定影响抗感染疗效的主要因素.结果 在133例患者中,有16例(12.03%)微生物试验培养出致病菌.影响氟喹诺酮类药物疗效的主要因素包括年龄、性别、血清肌酐、丙氨酸氨基转移酶、天门冬氨酸氨基转移酶

  9. 76 FR 37312 - Fruit and Vegetable Industry Advisory Committee

    Science.gov (United States)

    2011-06-27

    ...; ] DEPARTMENT OF AGRICULTURE Agricultural Marketing Service Fruit and Vegetable Industry Advisory Committee... Agriculture (USDA) Fruit and Vegetable Industry Advisory Committee and a Request for Nominations. SUMMARY: The USDA intends to reestablish the Fruit and Vegetable Industry Advisory Committee (Committee)....

  10. 78 FR 9724 - Invasive Species Advisory Committee; Meetings

    Science.gov (United States)

    2013-02-11

    ... Office of the Secretary Invasive Species Advisory Committee; Meetings AGENCY: Office of the Secretary, Interior. ACTION: Notice of public meetings of the Invasive Species Advisory Committee. SUMMARY: Pursuant... Invasive Species Advisory Committee (ISAC). Comprised of 31 nonfederal invasive species experts...

  11. 78 FR 45255 - President's National Security Telecommunications Advisory Committee

    Science.gov (United States)

    2013-07-26

    ... SECURITY President's National Security Telecommunications Advisory Committee AGENCY: National Protection... Committee Teleconference. SUMMARY: The President's National Security Telecommunications Advisory Committee... INFORMATION: Notice of this meeting is given under the Federal Advisory Committee Act (FACA), 5 U.S.C....

  12. 77 FR 23494 - Invasive Species Advisory Committee; Request for Nominations

    Science.gov (United States)

    2012-04-19

    ... Invasive Species Advisory Committee; Request for Nominations AGENCY: Office of the Secretary, National Invasive Species Council. ACTION: Request for Nominations for the Invasive Species Advisory Committee....gov . SUPPLEMENTARY INFORMATION: Advisory Committee Scope and Objectives The purpose and role of...

  13. 76 FR 16434 - Merchant Marine Personnel Advisory Committee

    Science.gov (United States)

    2011-03-23

    ... SECURITY Coast Guard Merchant Marine Personnel Advisory Committee AGENCY: Coast Guard, DHS. ACTION... determined that the establishment of the Merchant Marine Personnel Advisory Committee (MERPAC) is necessary... of Committee: Merchant Marine Personnel Advisory Committee. ADDRESSES: If you desire to...

  14. 12 CFR 7.2004 - Honorary directors or advisory boards.

    Science.gov (United States)

    2010-01-01

    ... appoint honorary or advisory members of a board of directors to act in advisory capacities without voting... or advisory directors must distinguish between them and the bank's board of directors or...

  15. 76 FR 24505 - Great Lakes Pilotage Advisory Committee

    Science.gov (United States)

    2011-05-02

    ... SECURITY Coast Guard Great Lakes Pilotage Advisory Committee AGENCY: Coast Guard, DHS. ACTION: Committee Management; Notice of Federal Advisory Committee Meeting. SUMMARY: The Great Lakes Pilotage Advisory... Great Lakes pilot registration, operating requirements, training policies, and pilotage rates and...

  16. 78 FR 53497 - Commercial Space Transportation Advisory Committee; Closed Session

    Science.gov (United States)

    2013-08-29

    ... Federal Aviation Administration Commercial Space Transportation Advisory Committee; Closed Session AGENCY: Federal Aviation Administration (FAA), DOT. ACTION: Notice of Commercial Space Transportation Advisory... closed session of the Commercial Space Transportation Advisory Committee (COMSTAC). The special...

  17. 75 FR 3913 - President's National Security Telecommunications Advisory Committee

    Science.gov (United States)

    2010-01-25

    ... SECURITY National Communications System President's National Security Telecommunications Advisory Committee...: The President's National Security Telecommunications Advisory Committee (NSTAC) will be meeting by... telecommunications policy. Notice of this meeting is given under the Federal Advisory Committee Act (FACA),...

  18. 75 FR 29781 - President's National Security Telecommunications Advisory Committee

    Science.gov (United States)

    2010-05-27

    ... SECURITY National Communications System President's National Security Telecommunications Advisory Committee... meeting. SUMMARY: The President's National Security Telecommunications Advisory Committee (NSTAC) will be... preparedness telecommunications policy. Notice of this meeting is given under the Federal Advisory...

  19. 76 FR 43988 - National Technical Information Service Advisory Board

    Science.gov (United States)

    2011-07-22

    ... National Technical Information Service National Technical Information Service Advisory Board AGENCY: National Technical Information Service, Commerce. ACTION: Notice of open meeting. SUMMARY: This notice announces the next meeting of the National Technical Information Service Advisory Board (the Advisory...

  20. 78 FR 61337 - National Technical Information Service Advisory Board

    Science.gov (United States)

    2013-10-03

    ... National Technical Information Service National Technical Information Service Advisory Board AGENCY: National Technical Information Service, Commerce. ACTION: Notice of open meeting SUMMARY: This notice announces the next meeting of the National Technical Information Service Advisory Board (the Advisory...

  1. 78 FR 16255 - National Technical Information Service Advisory Board

    Science.gov (United States)

    2013-03-14

    ... National Technical Information Service National Technical Information Service Advisory Board AGENCY: National Technical Information Service, Commerce. ACTION: Notice of Open Meeting. SUMMARY: This notice announces the next meeting of the National Technical Information Service Advisory Board (the Advisory...

  2. 77 FR 779 - National Technical Information Service Advisory Board

    Science.gov (United States)

    2012-01-06

    ... National Technical Information Service National Technical Information Service Advisory Board AGENCY: National Technical Information Service, Commerce. ACTION: Notice of open meeting. SUMMARY: This notice announces the next meeting of the National Technical Information Service Advisory Board (the Advisory...

  3. 76 FR 2348 - National Technical Information Service Advisory Board

    Science.gov (United States)

    2011-01-13

    ... National Technical Information Service National Technical Information Service Advisory Board AGENCY: National Technical Information Service, Commerce. ACTION: Notice of open meeting. SUMMARY: This notice announces the next meeting of the National Technical Information Service Advisory Board (the Advisory...

  4. 77 FR 57559 - National Technical Information Service Advisory Board

    Science.gov (United States)

    2012-09-18

    ... National Technical Information Service National Technical Information Service Advisory Board AGENCY: National Technical Information Service, Commerce. ACTION: Notice of open meeting. SUMMARY: This notice announces the next meeting of the National Technical Information Service Advisory Board (the Advisory...

  5. Serving Boys through Readers' Advisory

    Science.gov (United States)

    Sullivan, Michael

    2010-01-01

    Based on more than twenty years' experience working to get boys interested in reading, the author now offers his first readers' advisory volume. With an emphasis on nonfiction and the boy-friendly categories of genre fiction, the work offers a wealth of material including: (1) Suggestions for how to booktalk one-on-one as well as in large groups;…

  6. ITER management advisory committee meeting

    International Nuclear Information System (INIS)

    The ITER Management Advisory Committee (MAC) Meeting was held in Vienna on 16 July 2001. It was the last MAC Meeting and the main topics were consideration of the report by the Director on the ITER EDA status, review of the Work Programme, review of the Joint Fund and arrangements for termination and wind-up of the EDA

  7. 78 FR 11142 - The National Advisory Council on Innovation and Entrepreneurship Meeting of the National Advisory...

    Science.gov (United States)

    2013-02-15

    ... Economic Development Administration The National Advisory Council on Innovation and Entrepreneurship Meeting of the National Advisory Council on Innovation and Entrepreneurship AGENCY: U.S. Department of... Innovation and Entrepreneurship (NACIE) has cancelled its open meeting, originally planned for...

  8. 76 FR 5160 - Federal Advisory Committee Act; Advisory Committee on Diversity for Communications in the Digital...

    Science.gov (United States)

    2011-01-28

    ... From the Federal Register Online via the Government Publishing Office FEDERAL COMMUNICATIONS COMMISSION Federal Advisory Committee Act; Advisory Committee on Diversity for Communications in the Digital Age AGENCY: Federal Communications Commission. ACTION: Notice of intent to renew charter. SUMMARY:...

  9. Carbonic anhydrase inhibitors drug design.

    Science.gov (United States)

    McKenna, Robert; Supuran, Claudiu T

    2014-01-01

    Inhibition of the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1) has pharmacologic applications in the field of antiglaucoma, anticonvulsant, antiobesity, and anticancer agents but is also emerging for designing anti-infectives (antifungal and antibacterial agents) with a novel mechanism of action. As a consequence, the drug design of CA inhibitors (CAIs) is a very dynamic field. Sulfonamides and their isosteres (sulfamates/sulfamides) constitute the main class of CAIs which bind to the metal ion in the enzyme active site. Recently the dithiocarbamates, possessing a similar mechanism of action, were reported as a new class of inhibitors. Other families of CAIs possess a distinct mechanism of action: phenols, polyamines, some carboxylates, and sulfocoumarins anchor to the zinc-coordinated water molecule. Coumarins and five/six-membered lactones are prodrug inhibitors, binding in hydrolyzed form at the entrance of the active site cavity. Novel drug design strategies have been reported principally based on the tail approach for obtaining all these types of CAIs, which exploit more external binding regions within the enzyme active site (in addition to coordination to the metal ion), leading thus to isoform-selective compounds. Sugar-based tails as well as click chemistry were the most fruitful developments of the tail approach. Promising compounds that inhibit CAs from bacterial and fungal pathogens, of the dithiocarbamate, phenol and carboxylate types have also been reported. PMID:24146385

  10. 78 FR 64941 - Government-Wide Travel Advisory Committee (GTAC); Public Advisory Committee Meetings

    Science.gov (United States)

    2013-10-30

    ... GTAC November 7, 2013 meeting originally published in the Federal Register at 78 FR 56231 on September... ADMINISTRATION Government-Wide Travel Advisory Committee (GTAC); Public Advisory Committee Meetings AGENCY..., Designated Federal Officer (DFO), Government-wide Travel ] Advisory Committee (GTAC), Office of...

  11. 76 FR 52319 - Federal Advisory Committee Meeting Notice; Threat Reduction Advisory Committee

    Science.gov (United States)

    2011-08-22

    ... Federal Advisory Committee Meeting Notice; Threat Reduction Advisory Committee AGENCY: Office of the Under... Department of Defense announces the following Federal advisory committee meeting of the Threat Reduction..., Lorton, VA 22079. ] FOR FURTHER INFORMATION CONTACT: Mr. William Hostyn, Defense Threat Reduction...

  12. 77 FR 2710 - Threat Reduction Advisory Committee; Notice of Federal Advisory Committee Meeting

    Science.gov (United States)

    2012-01-19

    ... of the Secretary Threat Reduction Advisory Committee; Notice of Federal Advisory Committee Meeting... of the Threat Reduction Advisory Committee (hereafter referred to as ``the Committee''). DATES..., DoD, Defense Threat Reduction Agency/SP-ACP, 8725 John J. Kingman Road, MS 6201, Fort Belvoir,...

  13. 77 FR 19006 - Threat Reduction Advisory Committee; Notice of Federal Advisory Committee Meeting

    Science.gov (United States)

    2012-03-29

    ... of the Secretary Threat Reduction Advisory Committee; Notice of Federal Advisory Committee Meeting... the Threat Reduction Advisory Committee (hereafter referred to as ``the Committee''). DATES: Tuesday... Threat Reduction Agency/SP-ACP, 8725 John J. Kingman Road, MS 6201, Fort Belvoir, VA 22060-6201....

  14. 77 FR 50088 - Threat Reduction Advisory Committee; Notice of Federal Advisory Committee Meeting

    Science.gov (United States)

    2012-08-20

    ... of the Secretary Threat Reduction Advisory Committee; Notice of Federal Advisory Committee Meeting... committee meeting of the Threat Reduction Advisory Committee (hereafter referred to as ``the Committee.... William Hostyn, GS-15, DoD, Defense Threat Reduction Agency/J2/5/8R, 8725 John J. Kingman Road, MS...

  15. 77 FR 69807 - Threat Reduction Advisory Committee; Notice of Federal Advisory Committee Meeting

    Science.gov (United States)

    2012-11-21

    ... of the Secretary Threat Reduction Advisory Committee; Notice of Federal Advisory Committee Meeting... committee meeting of the Threat Reduction Advisory Committee (hereafter referred to as ``the Committee... Hostyn, DoD, Defense Threat Reduction Agency/J2/5/8R-ACP, 8725 John J. Kingman Road, MS 6201,...

  16. 77 FR 18797 - Federal Advisory Committee; Defense Intelligence Agency (DIA) Advisory Board; Closed Meeting

    Science.gov (United States)

    2012-03-28

    ... of the Secretary Federal Advisory Committee; Defense Intelligence Agency (DIA) Advisory Board; Closed... discussions of classified information relating to DIA's intelligence operations including its support to... intelligence operations. Agenda May 2, 2012 S 8:30 a.m Convene Advisory Board Meeting Mr. William...

  17. 75 FR 43493 - Office of the Secretary; Federal Advisory Committee; Defense Intelligence Agency Advisory Board...

    Science.gov (United States)

    2010-07-26

    ... of the Secretary; Federal Advisory Committee; Defense Intelligence Agency Advisory Board; Closed Meeting AGENCY: Defense Intelligence Agency, DOD. ACTION: Meeting notice. SUMMARY: Under the provisions of... that Defense Intelligence Agency Advisory Board will meet on September 1 and 2, 2010. The meeting...

  18. 75 FR 81245 - Federal Advisory Committee; Defense Intelligence Agency Advisory Board; Closed Meeting

    Science.gov (United States)

    2010-12-27

    ... of the Secretary Federal Advisory Committee; Defense Intelligence Agency Advisory Board; Closed Meeting AGENCY: Defense Intelligence Agency, DoD. ACTION: Notice. SUMMARY: Under the provisions of the... Defense Intelligence Agency Advisory Board and two of its subcommittees will meet on January 26 and...

  19. 76 FR 41220 - Federal Advisory Committee; Defense Intelligence Agency Advisory Board; Closed Meeting

    Science.gov (United States)

    2011-07-13

    ... of the Secretary Federal Advisory Committee; Defense Intelligence Agency Advisory Board; Closed Meeting AGENCY: Defense Intelligence Agency, DoD. ACTION: Meeting notice. SUMMARY: Under the provisions of... that Defense Intelligence Agency Advisory Board and two of its subcommittees will meet on August 4...

  20. 75 FR 24926 - Federal Advisory Committee; Defense Intelligence Agency Advisory Board; Closed Meeting

    Science.gov (United States)

    2010-05-06

    ... of the Secretary Federal Advisory Committee; Defense Intelligence Agency Advisory Board; Closed Meeting AGENCY: Defense Intelligence Agency, DoD. ACTION: Meeting notice. SUMMARY: Under the provisions of... that Defense Intelligence Agency Advisory Board, and its subcommittees, will meet on June 15 and...

  1. 76 FR 53671 - Federal Advisory Committee; Defense Intelligence Agency Advisory Board; Closed Meeting

    Science.gov (United States)

    2011-08-29

    ... of the Secretary Federal Advisory Committee; Defense Intelligence Agency Advisory Board; Closed Meeting AGENCY: Defense Intelligence Agency (DIA), Department of Defense (DoD). ACTION: Meeting notice... Department of Defense announces that Defense Intelligence Agency Advisory Board and two of its...

  2. 77 FR 41403 - Meetings of the Local Government Advisory Committee and the Small Communities Advisory...

    Science.gov (United States)

    2012-07-13

    ... AGENCY Meetings of the Local Government Advisory Committee and the Small Communities Advisory.../or Title VI, and other environmental issues of importance to local governments. ADDRESSES: EPA's Local Government Advisory Committee meetings will be held via teleconference. Meeting summaries will...

  3. 76 FR 22395 - Federal Advisory Committee Act; Open Internet Advisory Committee

    Science.gov (United States)

    2011-04-21

    ... Internet rules (available at http://www.fcc.gov/Daily_Releases/Daily_Business/2010/db1223/FCC-10-201A1.pdf... COMMISSION Federal Advisory Committee Act; Open Internet Advisory Committee AGENCY: Federal Communications... ``Open Internet Advisory Committee'' (hereinafter ``the Committee''), is being established. FOR...

  4. 78 FR 17993 - Request for Nominations for the General Advisory Committee and the Scientific Advisory...

    Science.gov (United States)

    2013-03-25

    ...-American Tropical Tuna Commission (IATTC) as well as to a Scientific Advisory Subcommittee of the General... for Nominations for the General Advisory Committee and the Scientific Advisory Subcommittee to the United States Section to the Inter-American Tropical Tuna Commission SUMMARY: The Department of State...

  5. 77 FR 62621 - Advisory Committee Charter Renewals

    Science.gov (United States)

    2012-10-15

    ... missions of the Departments of Defense and Homeland Security). Geriatrics and Gerontology Advisory... geriatrics and gerontology by assessing the capability of VA health care facilities to meet the...

  6. Adverse drug reactions in children reported by European consumers from 2007 to 2011

    DEFF Research Database (Denmark)

    Aagaard, Lise; Hansen, Ebba Holme

    2014-01-01

    Background Information about medicines safety in children is very limited. Consumer adverse drug reaction (ADR) reports can provide information about serious and unknown ADRs from medicine use in children. Objective To characterize ADRs in children reported by consumers in Europe from 2007 to 2011...... of the general type (20 %) and nervous system disorders (15 %). The largest share of serious ADRs was of the type nervous system disorders (17 % of all serious). Three cases of death were reported. Vaccines and anti-infectives for systemic use contributed to 30 % of ADRs, antineoplastic and immunomodulating...

  7. Afghanistan; Joint Staff Advisory Note

    OpenAIRE

    International Monetary Fund

    2010-01-01

    This Joint Staff Advisory Note discusses Afghanistan’s Poverty Reduction Strategy Paper's annual progress report. Afghanistan has experienced a number of extraordinary challenges that delayed its implementation. The security situation deteriorated markedly and has been dominated by the cross-border Taliban insurgency. Growth started to recover from a devastating drought. In May 2008, food and fuel prices peaked, leading to high inflation and pressure on the budget for additional fuel and fo...

  8. Drug Facts

    Medline Plus

    Full Text Available ... People Drug Abuse Hurts Families Drug Abuse Hurts Kids Drug Abuse Hurts Unborn Children Drug Abuse Hurts ... Children and Teens Stay Drug-Free Talking to Kids About Drugs: What To Say if You Were ...

  9. Anti-infective activities of Pelargonium sidoides (EPS® 7630): effects of induced NO production on Leishmania major in infected macrophages and antiviral effects as assessed in a fibroblast-virus protection assay.

    Science.gov (United States)

    Thäle, Carsten; Kiderlen, Albrecht Ferdinand; Kolodziej, Herbert

    2011-05-01

    EPs® 7630 is an aqueous-ethanolic extract of the roots of Pelargonium sidoides, employed in the treatment of upper respiratory tract infections. Its anti-infective activity is supposed to be associated with the activation of the nonspecific immune system. Using Leishmania major GFP-infected murine BMMΦ, the NO production of EPs® 7630-activated macrophages was correlated with the reduction of the GFP signal measured at single cell levels using flow cytometry. The anti-infectious effect of EPs® 7630 (3-10 µg/mL) on its own (NO production: 4-13 µM; signal reduction: 25-73 %) was less prominent than that in combination with IFN- γ (100 U/mL) (NO production: 20-27 µM; signal reduction: 35-78 %). Furthermore, supernatants of EPs® 7630-stimulated BMMΦ (10 µg/mL) significantly reduced the cytopathic effect of EMCV on L929 fibroblasts (antiviral activity 80 U/mL) when compared with an IFN- γ standard (100 U/mL). Direct addition of EPs® 7630 to L929 did not mediate cytoprotective effects. The antiviral components induced in BMMΦ by EPs® 7630 remain to be identified. Detection of any IFNs by ELISA was unsuccessful, which may be due to their very low concentrations in cell supernatants. The current data provide convincing support for the induction of anti-infectious responses by EPs® 7630.

  10. Research status of defensins and cathelicidins/LL-37 in pulmonary anti-infection immune defense%防御素和cathelicidins/LL-37在肺部抗感染防御中的研究现状

    Institute of Scientific and Technical Information of China (English)

    郭书真; 李昌崇; 林立

    2014-01-01

    抗菌肽是宿主防御系统的重要组成部分.在人气道上皮中主要表达2种阳离子小分子抗菌肽,即防御素和cathelicidins/LL-37,它们通过直接杀菌、调节天然或适应性免疫、损伤修复等生物学活性对抗肺部常见病原体的侵袭.本文就防御素和cathelicidins/LL-37的来源及结构特征、表达调节、在肺部抗感染免疫防御中的作用进行综述.%Antimicrobial protein/peptides (AMPs) are an important part of the defense system.Defensins and cathelicidins/LL-37 are the two main small cationic AMPs which are present in airway epithelial cells.AMPs play a critical role in resisting pathongens of invading lung through direct antimicrobial activity,modulating innate or adaptive immunity,and wound repair.The orign and architectural feature,expression regulation and research progress in pulmonary anti-infection immune defense of defensins and cathelicidins/LL-37 are reviewed here.

  11. Working with Advisory Committees . . . Promising Practices. Operations Notebook 16.

    Science.gov (United States)

    Olivero, James L.

    This publication is intended to aid school-level educational administrators in working with citizen advisory committees. After a brief discussion of the rationale for advisory committees, it focuses in turn on 1) functions of advisory committees, 2) ways to determine philosophical positions of agreement and disagreement among advisory committee…

  12. 76 FR 65750 - Aerospace Safety Advisory Panel; Charter Renewal

    Science.gov (United States)

    2011-10-24

    ... SPACE ADMINISTRATION Aerospace Safety Advisory Panel; Charter Renewal AGENCY: National Aeronautics and... Aerospace Safety Advisory Panel. SUMMARY: Pursuant to sections 14(b)(1) and 9(c) of the Federal Advisory... of the NASA Aerospace Safety Advisory Panel is in the public interest in connection with...

  13. IMPACT: Virginia Potato Disease Advisory Impact

    OpenAIRE

    Herbert, D. Ames (David Ames), 1949-; Long, Theresa; Deitch, Ursula T.; Laub, Curtis A., 1955-; Rideout, Steven Lewis; Moore, David; Tucker, Lindy; Archibald, Tom

    2014-01-01

    To help potato growers more efficiently manage disease problems, Virginia Cooperative Extension initiated the Virginia Potato Disease Advisory to provide growers with weather-based disease forecast information. Advisories not only alert growers to periods of risk, they also assist growers in making management decisions, such as when protective fungicide applications are needed.

  14. 78 FR 54680 - NASA Federal Advisory Committees

    Science.gov (United States)

    2013-09-05

    ...- ] nominations for consideration as potential members of NASA's Federal advisory committees. NASA's Federal..., experience, and current/past contributions to the relevant subject area. DATES: The deadline for NASA receipt... specific NASA Federal advisory committee of interest for NASA consideration. Nominations and...

  15. 77 FR 4556 - Environmental Management Advisory Board

    Science.gov (United States)

    2012-01-30

    ... Environmental Management Advisory Board AGENCY: Office of Environmental Management, Department of Energy. ACTION... hereby given that the Environmental Management Advisory Board will be renewed for a two-year period... Environmental Management (EM) on a broad range of corporate issues affecting the EM program. These...

  16. 78 FR 37536 - Methane Hydrate Advisory Committee

    Science.gov (United States)

    2013-06-21

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF ENERGY Methane... meeting. SUMMARY: This notice announces a meeting of the Methane Hydrate Advisory Committee. The Federal... of the Methane Hydrate Advisory Committee is to provide advice on potential applications of...

  17. 76 FR 59667 - Methane Hydrate Advisory Committee

    Science.gov (United States)

    2011-09-27

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF ENERGY Methane... Meeting. SUMMARY: This notice announces a meeting of the Methane Hydrate Advisory Committee. Federal... of the Committee: The purpose of the Methane Hydrate Advisory Committee is to provide advice...

  18. 78 FR 26337 - Methane Hydrate Advisory Committee

    Science.gov (United States)

    2013-05-06

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF ENERGY Methane... Meeting. SUMMARY: This notice announces a meeting of the Methane Hydrate Advisory Committee. The Federal... of the Methane Hydrate Advisory Committee is to provide advice on potential applications of...

  19. 75 FR 9886 - Methane Hydrate Advisory Committee

    Science.gov (United States)

    2010-03-04

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF ENERGY Methane... meeting. SUMMARY: This notice announces a meeting of the Methane Hydrate Advisory Committee. Federal... Methane Hydrate Advisory Committee is to provide advice on potential applications of methane hydrate...

  20. A Look at Citizen Advisory Committees.

    Science.gov (United States)

    Baker, Ronald E.; Ostertag, Bruce A.

    This overview of citizens advisory committees examines their history in public schools and school systems, different types of committees, their roles and functions, and the problems that accompany them. The history of advisory committees is covered from the 1940s on, with an emphasis on their expansion in the 1960s under the impetus of the civil…

  1. Impact of Technology and Innovation Advisory Services

    OpenAIRE

    Shapira P., & Youtie J.

    2014-01-01

    This report identifies and reviews literature that evaluates the impacts of technology and innovation advisory services. These services provide information, technical assistance, consulting, mentoring, and other services to support enterprises in adopting and deploying new technologies and in commercialising innovations. Examples include the: Manufacturing Advisory Service (UK), the Manufacturing Extension Partnership (USA), and the Industrial Research Assistance Program (Canada). Technology ...

  2. 77 FR 50460 - Cherokee Resource Advisory Committee

    Science.gov (United States)

    2012-08-21

    ... Forest Service Cherokee Resource Advisory Committee AGENCY: Forest Service, USDA. ACTION: Notice of meeting. SUMMARY: The Cherokee Resource Advisory Committee will meet in Knoxville, Tennessee. The... Coordinator, Cherokee National Forest, 423-476-9729, twmcdonald@fs.fed.us . Individuals who...

  3. 78 FR 70987 - Proxy Advisory Firm Roundtable

    Science.gov (United States)

    2013-11-27

    ...The Securities and Exchange Commission will host a roundtable about proxy advisory firms. The panel will be asked to discuss topics including the current state of proxy advisory firm use by investment advisers and institutional investors and potential changes that have been suggested by market participants. Panelists will also be invited to discuss any new ideas. The roundtable discussion will......

  4. 78 FR 61348 - Electricity Advisory Committee

    Science.gov (United States)

    2013-10-03

    ... Electricity Advisory Committee AGENCY: Department of Energy. ACTION: Notice of Cancellation of Open Meeting. SUMMARY: On September 11, 2013, in FR Doc. 2013-22119, on pages 55692- 55693, the Department of Energy... Advisory Committee (78 FR 55692). This notice announces the cancellation of this meeting. FOR...

  5. 77 FR 49441 - Electricity Advisory Committee

    Science.gov (United States)

    2012-08-16

    ... Electricity Advisory Committee AGENCY: Office of Electricity Delivery and Energy Reliability, Department of... that the Electricity Advisory ] Committee's (EAC) charter has been renewed for a two-year period... Secretary for Electricity Delivery and Energy Reliability on programs to modernize the Nation's...

  6. 76 FR 3677 - Arts Advisory Panel

    Science.gov (United States)

    2011-01-20

    ... ARTS AND THE HUMANITIES National Endowment for the Arts Arts Advisory Panel Pursuant to Section 10(a)(2... meeting of the Arts Advisory Panel to the National Council on the Arts will be held at the Nancy Hanks..., discussion, evaluation, and recommendations on financial assistance under the National Foundation on the...

  7. 78 FR 59978 - Arts Advisory Panel Meeting

    Science.gov (United States)

    2013-09-30

    ... ARTS AND THE HUMANITIES Arts Advisory Panel Meeting AGENCY: National Endowment for the Arts, National Foundation on the Arts and Humanities. ACTION: Notice of meeting. SUMMARY: Pursuant to Section 10(a)(2) of... meeting of the Arts Advisory Panel to the National Council on the Arts will be held at the Nancy...

  8. 76 FR 23845 - Arts Advisory Panel

    Science.gov (United States)

    2011-04-28

    ... ARTS AND THE HUMANITIES National Endowment for the Arts Arts Advisory Panel Pursuant to Section 10(a)(2... meeting of the Arts Advisory Panel to the National Council on the Arts will be held at the Nancy Hanks..., evaluation, and recommendations on financial assistance under the National Foundation on the Arts and...

  9. 77 FR 13154 - Arts Advisory Panel Meeting

    Science.gov (United States)

    2012-03-05

    ... ARTS AND THE HUMANITIES Arts Advisory Panel Meeting AGENCY: National Endowment for the Arts, National Foundation on the Arts and Humanities. ACTION: Notice--meeting. Pursuant to Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), as amended, notice is hereby given that a meeting of the...

  10. 77 FR 61643 - Arts Advisory Panel Meeting

    Science.gov (United States)

    2012-10-10

    ... ARTS AND THE HUMANITIES Arts Advisory Panel Meeting AGENCY: National Endowment for the Arts, National Foundation on the Arts and Humanities. ACTION: Notice of meeting. SUMMARY: Pursuant to Section 10(a)(2) of... meetings of the Arts Advisory Panel to the National Council on the Arts will be held at the Nancy...

  11. 78 FR 21978 - Arts Advisory Panel Meeting

    Science.gov (United States)

    2013-04-12

    ... ARTS AND THE HUMANITIES Arts Advisory Panel Meeting AGENCY: National Endowment for the Arts, National Foundation on the Arts and Humanities. ACTION: Notice of meeting. SUMMARY: Pursuant to Section 10(a)(2) of... meeting of the Arts Advisory Panel to the National Council on the Arts will be held at the Nancy...

  12. 78 FR 42982 - Arts Advisory Panel Meeting

    Science.gov (United States)

    2013-07-18

    ... ARTS AND THE HUMANITIES Arts Advisory Panel Meeting AGENCY: National Endowment for the Arts, National Foundation on the Arts and Humanities. ACTION: Notice of Meetings SUMMARY: Pursuant to Section 10(a)(2) of... the Arts Advisory Panel to the National Council on the Arts will be held at the Nancy Hanks...

  13. 75 FR 56146 - Arts Advisory Panel; Meetings

    Science.gov (United States)

    2010-09-15

    ... ARTS AND THE HUMANITIES National Endowment for the Arts Arts Advisory Panel; Meetings Pursuant to... given that four meetings of the Arts Advisory Panel to the National Council on the Arts will be held at... are approximate): Arts Education (application review): October 4-5, 2010 in Room 716. A portion...

  14. 76 FR 50499 - Arts Advisory Panel

    Science.gov (United States)

    2011-08-15

    ... ARTS AND THE HUMANITIES National Endowment for the Arts Arts Advisory Panel Pursuant to Section 10(a)(2... meeting of the Arts Advisory Panel to the National Council on the Arts will be held at the Nancy Hanks... financial assistance under the National Foundation on the Arts and the Humanities Act of 1965, as...

  15. 78 FR 26399 - Arts Advisory Panel Meeting

    Science.gov (United States)

    2013-05-06

    ... ARTS AND THE HUMANITIES Arts Advisory Panel Meeting AGENCY: National Endowment for the Arts, National Foundation on the Arts and Humanities. ACTION: Notice of Meeting. SUMMARY: Pursuant to Section 10(a)(2) of... meeting of the Arts Advisory Panel to the National Council on the Arts will be held by teleconference...

  16. 77 FR 49026 - Arts Advisory Panel Meeting

    Science.gov (United States)

    2012-08-15

    ... ARTS AND THE HUMANITIES Arts Advisory Panel Meeting AGENCY: National Endowment for the Arts, National Foundation on the Arts and Humanities. ACTION: Notice of meeting. SUMMARY: Pursuant to Section 10(a)(2) of... meeting of the Arts Advisory Panel to the National Council on the Arts will be held at the Nancy...

  17. 75 FR 27825 - Arts Advisory Panel

    Science.gov (United States)

    2010-05-18

    ... ARTS AND THE HUMANITIES National Endowment for the Arts Arts Advisory Panel Pursuant to Section 10(a)(2... meeting of the Arts Advisory Panel to the National Council on the Arts will be held at the Nancy Hanks... financial assistance under the National Foundation on the Arts and the Humanities Act of 1965, as...

  18. 78 FR 50451 - Arts Advisory Panel Meeting

    Science.gov (United States)

    2013-08-19

    ... ARTS AND THE HUMANITIES Arts Advisory Panel Meeting AGENCY: National Endowment for the Arts, National Foundation on the Arts and Humanities. ACTION: Notice of Meetings. SUMMARY: Pursuant to Section 10(a)(2) of... meeting of the Arts Advisory Panel to the National Council on the Arts will be held at the Nancy...

  19. 77 FR 13367 - Arts Advisory Panel Meeting

    Science.gov (United States)

    2012-03-06

    ... ARTS AND THE HUMANITIES Arts Advisory Panel Meeting AGENCY: National Endowment for the Arts, National Foundation on the Arts and Humanities. ACTION: Notice of meeting. SUMMARY: Pursuant to Section 10(a)(2) of... of the Arts Advisory Panel to the National Council on the Arts will be held by teleconference at...

  20. 78 FR 17942 - Arts Advisory Panel Meeting

    Science.gov (United States)

    2013-03-25

    ... ARTS AND THE HUMANITIES Arts Advisory Panel Meeting AGENCY: National Endowment for the Arts, National Foundation on the Arts and Humanities. ACTION: Notice of meetings. SUMMARY: Pursuant to Section 10(a)(2) of... meetings of the Arts Advisory Panel to the National Council on the Arts will be held at the Nancy...

  1. 78 FR 5213 - Arts Advisory Panel Meeting

    Science.gov (United States)

    2013-01-24

    ... ARTS AND THE HUMANITIES Arts Advisory Panel Meeting AGENCY: National Endowment for the Arts, National Foundation on the Arts and Humanities. ACTION: Notice of meeting. SUMMARY: Pursuant to Section 10(a)(2) of... meeting of the Arts Advisory Panel to the National Council on the Arts will be held at the Nancy...

  2. 77 FR 56875 - Arts Advisory Panel Meeting

    Science.gov (United States)

    2012-09-14

    ... ARTS AND THE HUMANITIES Arts Advisory Panel Meeting AGENCY: National Endowment for the Arts, National Foundation on the Arts and Humanities. ACTION: Notice of meeting. SUMMARY: Pursuant to Section 10(a)(2) of... meetings of the Arts Advisory Panel to the National Council on the Arts will be held by teleconference...

  3. 77 FR 74661 - Open Internet Advisory Committee

    Science.gov (United States)

    2012-12-17

    ... Internet at http://www.fcc.gov/events/open-internet-advisory-committee . Federal Communications Commission... COMMISSION Open Internet Advisory Committee AGENCY: Federal Communications Commission. ACTION: Notice. SUMMARY: The Commission announces the next meeting date, time, and agenda of the Open Internet...

  4. 75 FR 7255 - Army Educational Advisory Committee

    Science.gov (United States)

    2010-02-18

    ... Department of the Army Army Educational Advisory Committee AGENCY: Department of the Army, DoD. ACTION... CFR 102-3.150, the following meeting notice is announced: Name of Committee: U.S. Army War College Subcommittee of the Army Education Advisory Committee. Date of Meeting: March 11, 2010. Place of Meeting:...

  5. 75 FR 60145 - PNT Advisory Board; Meeting

    Science.gov (United States)

    2010-09-29

    ... SPACE ADMINISTRATION PNT Advisory Board; Meeting AGENCY: National Aeronautics and Space Administration. ACTION: Notice of Meeting. SUMMARY: In accordance with the Federal Advisory Committee Act, Public Law 92-463, as amended, the National Aeronautics and Space Administration announces a meeting of the...

  6. 76 FR 2672 - Science Advisory Board Meeting

    Science.gov (United States)

    2011-01-14

    ... National Oceanic and Atmospheric Administration Science Advisory Board Meeting AGENCY: Office of Oceanic... Commerce (DOC). ACTION: Notice of public meeting. SUMMARY: This notice sets forth the schedule and proposed agenda of a forthcoming meeting of the NOAA Science Advisory Board. The members will discuss and...

  7. 76 FR 35410 - Science Advisory Board; Meeting

    Science.gov (United States)

    2011-06-17

    ... National Oceanic and Atmospheric Administration Science Advisory Board; Meeting AGENCY: Office of Oceanic... Commerce (DOC). ACTION: Notice of open meeting. SUMMARY: The Science Advisory Board (SAB) was established... meeting will be held Wednesday, July 20, 2011, from 9:30 a.m. to 5:30 p.m. and Thursday, July 21,...

  8. 75 FR 61774 - Advisory Board Meeting

    Science.gov (United States)

    2010-10-06

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF JUSTICE National Institute of Corrections Advisory Board Meeting Time and Date: 8 a.m. to 4:30 p.m. on Monday... Considered: Welcome New Advisory Board Members; NIC Orientation; Briefing on NIC Reports; Agency...

  9. 77 FR 13634 - Advisory Board Meeting

    Science.gov (United States)

    2012-03-07

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF JUSTICE National Institute of Corrections Advisory Board Meeting Time and Date: 8 a.m.-4:30 p.m. on Monday, April... outcomes of November 2-3, 2011 Advisory Board Hearing (Shifting the Focus to Reshape Our Thinking...

  10. 78 FR 60851 - Science Advisory Board Meeting

    Science.gov (United States)

    2013-10-02

    ... National Oceanic and Atmospheric Administration Science Advisory Board Meeting AGENCY: Office of Oceanic... Commerce (DOC). ACTION: Notice of open meeting. SUMMARY: The NOAA Science Advisory Board (SAB) was... meeting will be held Tuesday, November 19, 2013 from 10:00 a.m. to 5:30 p.m. and Wednesday, November...

  11. 77 FR 14425 - Advisory Board Meeting

    Science.gov (United States)

    2012-03-09

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF JUSTICE National Institute of Corrections Advisory Board Meeting Time and Date: 8 AM-4:30 PM on Monday, April 02... November 2-3, 2011 Advisory Board Hearing (Shifting the Focus to Reshape Our Thinking Toward...

  12. 77 FR 69503 - Advisory Board Meeting

    Science.gov (United States)

    2012-11-19

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF JUSTICE National Institute of Corrections Advisory Board Meeting TIME AND DATE: 8:00 a.m.-4:30 p.m. on Monday...; review of outcomes of August 22-23, 2012 Advisory Board Hearing (Balancing Fiscal Challenges,...

  13. 77 FR 38273 - Science Advisory Board; Meeting

    Science.gov (United States)

    2012-06-27

    ... National Oceanic and Atmospheric Administration Science Advisory Board; Meeting AGENCY: Office of Oceanic... Commerce (DOC). ACTION: Notice of open meeting. SUMMARY: The Science Advisory Board (SAB) was established... meeting will be held Monday, July 16, 2012 from 9 a.m. to 5:30 p.m. and Tuesday, July 17, 2012 from 8:30...

  14. 75 FR 13269 - Nuclear Energy Advisory Committee

    Science.gov (United States)

    2010-03-19

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF ENERGY Nuclear Energy Advisory Committee AGENCY: Department of Energy, Office of Nuclear Energy. ACTION: Notice of open meeting. SUMMARY: This notice announces a meeting of the Nuclear Energy Advisory Committee (NEAC)....

  15. 75 FR 67351 - Nuclear Energy Advisory Committee

    Science.gov (United States)

    2010-11-02

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF ENERGY Nuclear Energy Advisory Committee AGENCY: Office of Nuclear Energy, Department of Energy. ACTION: Notice of open meeting. SUMMARY: This notice announces a meeting of the Nuclear Energy Advisory Committee (NEAC)....

  16. 76 FR 67717 - Nuclear Energy Advisory Committee

    Science.gov (United States)

    2011-11-02

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF ENERGY Nuclear Energy Advisory Committee AGENCY: Department of Energy, Office of Nuclear Energy. ACTION: Notice of open meeting. SUMMARY: This notice announces a meeting of the Nuclear Energy Advisory Committee (NEAC)....

  17. 77 FR 67809 - Nuclear Energy Advisory Committee

    Science.gov (United States)

    2012-11-14

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF ENERGY Nuclear Energy Advisory Committee AGENCY: Department of Energy, Office of Nuclear Energy. ACTION: Notice of Open Meeting. SUMMARY: This notice announces a meeting of the Nuclear Energy Advisory Committee (NEAC)....

  18. 77 FR 26274 - Nuclear Energy Advisory Committee

    Science.gov (United States)

    2012-05-03

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF ENERGY Nuclear Energy Advisory Committee AGENCY: Department of Energy, Office of Nuclear Energy. ACTION: Notice of open meeting. SUMMARY: This notice announces a meeting of the Nuclear Energy Advisory Committee (NEAC)....

  19. 78 FR 70932 - Nuclear Energy Advisory Committee

    Science.gov (United States)

    2013-11-27

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF ENERGY Nuclear Energy Advisory Committee AGENCY: Office of Nuclear Energy, Department of Energy. ACTION: Notice of open meeting. SUMMARY: This notice announces a meeting of the Nuclear Energy Advisory Committee (NEAC)....

  20. 78 FR 76599 - Nuclear Energy Advisory Committee

    Science.gov (United States)

    2013-12-18

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF ENERGY Nuclear Energy Advisory Committee AGENCY: Office of Nuclear Energy, Department of Energy. ACTION: Notice of... that the Nuclear Energy Advisory Committee (NEAC) will be renewed for a two-year period beginning...

  1. 76 FR 43651 - Forestry Research Advisory Council

    Science.gov (United States)

    2011-07-21

    ... Forest Service Forestry Research Advisory Council AGENCY: Forest Service, USDA. ACTION: Notice of meeting. SUMMARY: The Forestry Research Advisory Council will meet in Washington DC August 16-17, 2011. The purpose of the meeting is to discuss emerging issues in forestry research. DATES: The meeting will be...

  2. 77 FR 26734 - Forestry Research Advisory Council

    Science.gov (United States)

    2012-05-07

    ... Forest Service Forestry Research Advisory Council AGENCY: Forest Service, USDA. ACTION: Notice of meeting. SUMMARY: The Forestry Research Advisory Council will meet in Washington, DC, on June 6-7, 2012. The purpose of the meeting is to discuss emerging issues in forestry research. DATES: The meeting will be...

  3. 75 FR 46903 - Forestry Research Advisory Council

    Science.gov (United States)

    2010-08-04

    ... Forest Service Forestry Research Advisory Council AGENCY: Forest Service, USDA. ACTION: Notice of meeting. SUMMARY: The Forestry Research Advisory Council will meet in Washington, DC September 8-9, 2010. The purpose of the meeting is to discuss emerging issues in forestry research. DATES: The meeting will be...

  4. 75 FR 6358 - Federal Advisory Committee; Defense Advisory Board for Employer Support of the Guard and Reserve...

    Science.gov (United States)

    2010-02-09

    ... of the Secretary Federal Advisory Committee; Defense Advisory Board for Employer Support of the Guard and Reserve; Defense Advisory Board for Employer Partnership; Charter Revision AGENCY: Department of... intends to revise the charter for the Defense Advisory Board for Employer Support of the Guard and...

  5. 78 FR 23540 - General Advisory Committee and Scientific Advisory Subcommittee to the U.S. Section to the Inter...

    Science.gov (United States)

    2013-04-19

    ... National Oceanic and Atmospheric Administration RIN 0648-XC613 General Advisory Committee and Scientific Advisory Subcommittee to the U.S. Section to the Inter-American Tropical Tuna Commission; Meeting... Scientific Advisory Subcommittee (SAS) and the General Advisory Committee (GAC) to the U.S. Section to...

  6. 75 FR 61507 - General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee; Amendment of...

    Science.gov (United States)

    2010-10-05

    ... HUMAN SERVICES Food and Drug Administration General and Plastic Surgery Devices Panel of the Medical... General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee. This meeting was announced in the Federal Register of August 16, 2010 (75 FR 49940). The amendment is being made to reflect...

  7. 75 FR 1395 - General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee; Amendment of...

    Science.gov (United States)

    2010-01-11

    ... HUMAN SERVICES Food and Drug Administration General and Plastic Surgery Devices Panel of the Medical... the General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee. This meeting was announced in the Federal Register of November 17, 2009 (74 FR 59194). The amendment is being...

  8. 76 FR 65200 - General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee: Notice of...

    Science.gov (United States)

    2011-10-20

    ... HUMAN SERVICES Food and Drug Administration General and Plastic Surgery Devices Panel of the Medical... and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee scheduled for December 1, 2011. The meeting was announced in the Federal Register of Friday, October 7, 2011 (76 FR 62419)....

  9. 76 FR 72708 - Medicare Program; Renaming and Other Changes to the Advisory Panel on Hospital Outpatient Payment...

    Science.gov (United States)

    2011-11-25

    ...' Information Lines: You may also refer to the CMS Federal Advisory Committee Hotlines at 1-(877) 449-5659 (toll...; APC grouping; Current Procedural Terminology codes and Healthcare Common Procedure Coding System coding experts; the use of, and payment for, drugs and medical devices, and other services in...

  10. Prospective risk analysis of the anti-infective medication administration process Análisis prospectivo de riesgo del proceso de administración de medicamentos anti-infecciosos Análise prospectiva de risco do processo de administração de medicamentos anti-infecciosos

    OpenAIRE

    Ana Elisa Bauer de Camargo Silva; Silvia Helena De Bortoli Cassiani

    2013-01-01

    OBJECTIVE: The objective of this study was to analyze the potential risks involved in the administration process of intravenous anti-infective medication at a medical clinic, using the Failure Mode and Effect Analysis. METHOD: This exploratory study was conducted at the medical clinic of a hospital in the State of Goiás. For data collection we convened a team comprised of six professionals involved in medication treatment: a doctor, nurse, nursing technician, pharmacist, a nursing and a risk ...

  11. 76 FR 52016 - NASA Federal Advisory Committees; Nominations and Self-Nominations

    Science.gov (United States)

    2011-08-19

    ... SPACE ADMINISTRATION NASA Federal Advisory Committees; Nominations and Self- Nominations AGENCY...-nominations for consideration as potential members of NASA's Federal advisory committees. NASA's Federal... NASA Federal Advisory Committees. SUMMARY: In accordance with the Federal Advisory Committee...

  12. 78 FR 71631 - Committee Name: Homeland Security Information Network Advisory Committee (HSINAC)

    Science.gov (United States)

    2013-11-29

    ... SECURITY Committee Name: Homeland Security Information Network Advisory Committee (HSINAC) AGENCY... Management; Notice of Federal Advisory Committee Meeting. SUMMARY: The Homeland Security Information Network... Homeland Security Information Network Advisory Committee (HSINAC) is an advisory body to the...

  13. Drug Facts

    Medline Plus

    Full Text Available ... Addiction? Addiction Risk Factors Does Addiction Run in Families? Why Is It So Hard to Quit Drugs? ... Drug Abuse Hurts Other People Drug Abuse Hurts Families Drug Abuse Hurts Kids Drug Abuse Hurts Unborn ...

  14. Drug Facts

    Medline Plus

    Full Text Available ... Abuse Hurts Unborn Children Drug Abuse Hurts Your Health Drug Abuse Hurts Bodies Drug Abuse Hurts Brains Drug Abuse and Mental Health Problems Often Happen Together The Link Between Drug ...

  15. Sepsis Caused by Extended-Spectrum Beta-Lactamase (ESBL)-Positive K. pneumoniae and E. coli: Comparison of Severity of Sepsis, Delay of Anti-Infective Therapy and ESBL Genotype

    Science.gov (United States)

    Steinmetz, Ivo; Kohler, Christian; Pfeifer, Yvonne; Gastmeier, Petra; Schwab, Frank; Kola, Axel; Deja, Maria; Leistner, Rasmus

    2016-01-01

    Infections with extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) are associated with increased mortality. Outcome differences due to various species of ESBL-E or ESBL genotypes are not well investigated. We conducted a cohort study to assess risk factors for mortality in cases of ESBL-E bacteremia (K. pneumoniae or E. coli) and the risk factors for sepsis with organ failure. All consecutive patients of our institution from 2008 to 2011 with bacteremia due to ESBL-E were included. Basic epidemiological data, underlying comorbidities, origin of bacteremia, severity of sepsis and delay of appropriate anti-infective treatment were collected. Isolates were PCR-screened for the presence of ESBL genes and plasmid-mediated AmpC β-lactamases. Cox proportional hazard regression on mortality and multivariable logistic regression on risk factors for sepsis with organ failure was conducted. 219 cases were included in the analysis: 73.1% due to E. coli, 26.9% due to K. pneumoniae. There was no significant difference in hospital mortality (ESBL-E. coli, 23.8% vs. ESBL-K. pneumoniae 27.1%, p = 0.724). However, the risk of sepsis with organ failure was associated in cases of K. pneumoniae bacteremia (OR 4.5, p<0.001) and patients with liver disease (OR 3.4, p = 0.004) or renal disease (OR 6.8, p<0.001). We found significant differences in clinical presentation of ESBL-E bacteremia due to K. pneumoniae compared to E. coli. As K. pneumoniae cases showed a more serious clinical presentation as E. coli cases and were associated with different risk factors, treatment and prevention strategies should be adjusted accordingly. PMID:27442425

  16. Re-Inventing Infectious Disease: Antibiotic Resistance and Drug Development at the Bayer Company 1945-80.

    Science.gov (United States)

    Gradmann, Christoph

    2016-04-01

    This paper analyses how research on antibiotic resistance has been a driving force in the development of new antibiotics. Drug resistance, while being a problem for physicians and patients, offers attractive perspectives for those who research and develop new medicines. It imposes limits on the usability of older medicines and simultaneously modifies pathologies in a way that opens markets for new treatments. Studying resistance can thus be an important part of developing and marketing antibiotics. The chosen example is that of the German pharmaceutical company Bayer. Before World War Two, Bayer had pioneered the development of anti-infective chemotherapy, sulpha drugs in particular, but had missed the boat when it came to fungal antibiotics. Exacerbated by the effects of war, Bayer's world market presence, which had been considerable prior to the war, had plummeted. In this critical situation, the company opted for a development strategy that tried to capitalise on the problems created by the use of first-generation antibiotics. Part and parcel of this strategy was monitoring what can be called the structural change of infectious disease. In practice, this meant to focus on pathologies resulting from resistance and hospital infections. In addition, Bayer also focused on lifestyle pathologies such as athlete's foot. This paper will follow drug development and marketing at Bayer from 1945 to about 1980. In this period, Bayer managed to regain some of its previous standing in markets but could not escape from the overall crisis of anti-infective drug development from the 1970s on.

  17. Re-Inventing Infectious Disease: Antibiotic Resistance and Drug Development at the Bayer Company 1945-80.

    Science.gov (United States)

    Gradmann, Christoph

    2016-04-01

    This paper analyses how research on antibiotic resistance has been a driving force in the development of new antibiotics. Drug resistance, while being a problem for physicians and patients, offers attractive perspectives for those who research and develop new medicines. It imposes limits on the usability of older medicines and simultaneously modifies pathologies in a way that opens markets for new treatments. Studying resistance can thus be an important part of developing and marketing antibiotics. The chosen example is that of the German pharmaceutical company Bayer. Before World War Two, Bayer had pioneered the development of anti-infective chemotherapy, sulpha drugs in particular, but had missed the boat when it came to fungal antibiotics. Exacerbated by the effects of war, Bayer's world market presence, which had been considerable prior to the war, had plummeted. In this critical situation, the company opted for a development strategy that tried to capitalise on the problems created by the use of first-generation antibiotics. Part and parcel of this strategy was monitoring what can be called the structural change of infectious disease. In practice, this meant to focus on pathologies resulting from resistance and hospital infections. In addition, Bayer also focused on lifestyle pathologies such as athlete's foot. This paper will follow drug development and marketing at Bayer from 1945 to about 1980. In this period, Bayer managed to regain some of its previous standing in markets but could not escape from the overall crisis of anti-infective drug development from the 1970s on. PMID:26971595

  18. NEW ASPECTS OF ANTI-INFECTION IMMUNITY

    Directory of Open Access Journals (Sweden)

    E. P. Kisseleva

    2011-01-01

    Full Text Available Abstract. Four types of adaptive immune response which are regulated by different T-cell populations, namely Th1, Th2, Th17 and T regs have been described. At the first time classification is based on the difference in transcription factors but not due to diversity of cytokines produced. Each population of T-lymphocytes possesses a set of unique transcription factors and directions of cell signaling. Each type of immune responses plays a key role in the protection against certain types of pathogens. The Th1-response is important against intracellular bacteria and fungi, the Th17 — against extracellular, the Th2 — against yeasts and protozoa. T-regulatory cells control all types of immune responses. Diversity of immune response mechanisms occurs due to involvement of different effector cells. The Th1-type of response is connected with macrophage activation, Th2-cells cooperate with B-lymphocytes as well as attract eosinophils and mast cells. Th17 lymphocytes stimulate neutrophils and epithelial cells. T-cell differentiation is directed by the cytokines produced by innate immune cells. Phagocytes recognize molecular patterns at the surface of pathogens via pattern-recognition receptors (PRR, become activated and synthesize cytokines. Pathogen plays important role in this process while instructing dendritic cells. Pathogen dials a special code from a number of phagocyte surface receptors, which is named as «combinatory» recognition. Phagocytes possess several different types of activation and synthesize different cytokines that direct T-lymphocytes to a certain type of differentiation.

  19. Drug Facts

    Medline Plus

    Full Text Available ... Health Drug Abuse Hurts Bodies Drug Abuse Hurts Brains Drug Abuse and Mental Health Problems Often Happen Together The Link Between Drug Abuse and HIV/AIDS Recovery & Treatment Drug Treatment Facts Does Drug Treatment Work? Types of Drug Treatment What Is a Relapse? ...

  20. Drug allergies

    Science.gov (United States)

    Allergic reaction - drug (medication); Drug hypersensitivity; Medication hypersensitivity ... A drug allergy involves an immune response in the body that produces an allergic reaction to a medicine. The ...

  1. Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs.

    Science.gov (United States)

    Mao, Fei; Ni, Wei; Xu, Xiang; Wang, Hui; Wang, Jing; Ji, Min; Li, Jian

    2016-01-12

    The chemical structure of a drug determines its physicochemical properties, further determines its ADME/Tox properties, and ultimately affects its pharmacological activity. Medicinal chemists can regulate the pharmacological activity of drug molecules by modifying their structure. Ring systems and functional groups are important components of a drug. The proportion of non-hydrocarbon atoms among non-hydrogen atoms reflects the heavy atoms proportion of a drug. The three factors have considerable potential for the assessment of the drug-like properties of organic molecules. However, to the best of our knowledge, there have been no studies to systematically analyze the simultaneous effects of the number of aromatic and non-aromatic rings, the number of some special functional groups and the proportion of heavy atoms on the drug-like properties of an organic molecule. To this end, the numbers of aromatic and non-aromatic rings, the numbers of some special functional groups and the heavy atoms proportion of 6891 global approved small drugs have been comprehensively analyzed. We first uncovered three important structure-related criteria closely related to drug-likeness, namely: (1) the best numbers of aromatic and non-aromatic rings are 2 and 1, respectively; (2) the best functional groups of candidate drugs are usually -OH, -COOR and -COOH in turn, but not -CONHOH, -SH, -CHO and -SO3H. In addition, the -F functional group is beneficial to CNS drugs, and -NH2 functional group is beneficial to anti-infective drugs and anti-cancer drugs; (3) the best R value intervals of candidate drugs are in the range of 0.05-0.50 (preferably 0.10-0.35), and R value of the candidate CNS drugs should be as small as possible in this interval. We envision that the three chemical structure-related criteria may be applicable in a prospective manner for the identification of novel candidate drugs and will provide a theoretical foundation for designing new chemical entities with good drug

  2. 77 FR 35063 - Whistleblower Protection Advisory Committee

    Science.gov (United States)

    2012-06-12

    ... Occupational Safety and Health Administration Whistleblower Protection Advisory Committee AGENCY: Occupational..., Director, Office of the Whistleblower Protection Program, Occupational Safety and Health Administration, U... INFORMATION: The Assistant Secretary of Labor for Occupational Safety and Health (Assistant......

  3. Right Whale Sightings Advisory System (RWSAS)

    Data.gov (United States)

    National Oceanic and Atmospheric Administration, Department of Commerce — The Right Whale Sighting Advisory System (RWSAS) is a NOAA Fisheries program which was designed to reduce collisions between ships and the critically endangered...

  4. 78 FR 38297 - Science Advisory Board (SAB)

    Science.gov (United States)

    2013-06-26

    ...) NOAA Social Science Needs Assessment; (3) Terms of Reference and Membership Approach for Gulf Coast... National Oceanic and Atmospheric Administration Science Advisory Board (SAB) AGENCY: Office of Oceanic and Atmospheric Research (OAR), National Oceanic and Atmospheric Administration (NOAA), Department of...

  5. 77 FR 16894 - Financial Research Advisory Committee

    Science.gov (United States)

    2012-03-22

    ... recognized experts in the fields of economics, financial institutions and markets, statistical analysis, financial markets analysis, econometrics, applied sciences, risk management, data, information standards... Financial Research Advisory Committee AGENCY: Office of Financial Research, Treasury. ACTION: Notice...

  6. 78 FR 28594 - Advisory Committee Meeting

    Science.gov (United States)

    2013-05-15

    ... discussions on the following topics: Ex-Im Bank business review, Ex-Im Bank 2012 draft competitiveness report and Advisory Committee letter statement on the findings of the draft competitiveness report, and...

  7. 76 FR 78252 - Nuclear Energy Advisory Committee

    Science.gov (United States)

    2011-12-16

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF ENERGY Nuclear Energy Advisory Committee AGENCY: Department of Energy, Office of Nuclear Energy. ACTION: Notice of... Management Secretariat, General Services Administration, notice is hereby given that the Nuclear...

  8. 77 FR 38630 - Open Internet Advisory Committee

    Science.gov (United States)

    2012-06-28

    ... meeting. By notice of intent to establish the Open Internet Advisory Committee, published at 76 FR 22395... Vigil Security, LLC) Neil Hunt, Chief Product Officer, Netflix Charles Kalmanek, Vice President...

  9. Female gender as a susceptibility factor for drug-induced liver injury.

    Science.gov (United States)

    Amacher, David E

    2014-09-01

    Adverse drug reactions (ADRs) can involve all tissues and organs, but liver injuries are considered among the most serious. A number of prospective, multicenter studies have confirmed a higher risk of ADRs in general among female subjects compared to a male cohort. Although drug-induced liver injury (DILI) is infrequently encountered, the preponderance of evidence suggests that women appear to be more susceptible than men to fulminate hepatic/acute liver failure especially in response to some anti-infective drugs and to autoimmune-like hepatitis following exposure to certain other therapeutic drugs. A number of hypotheses have been proposed to explain this sex difference in susceptibility to DILI. Collectively, these hypotheses suggest three basic sex-dependent mechanisms that include differences in various aspects of drug pharmacokinetics (PK) or pharmacodynamics following the administration of certain drugs; specific hormonal effects or interactions with immunomodulating agents or signaling molecules; and differences in the adverse response of the immune system to some drugs, reactive drug metabolites, or drug-protein adducts. At the preclinical drug safety stage, there is a need for more research on hormonal effects on drug PK and for additional research on gender differences in aberrant immune responses that may lead to idiosyncratic DILI in some female patients. Because the detection of rare but serious hepatic ADRs requires the exposure of very large patient populations, pharmacovigilance networks will continue to play a key role in the postmarketing surveillance for their detection and reporting. PMID:24299907

  10. 76 FR 44595 - Oncologic Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-07-26

    ...) for this product is for the treatment of patients with transfusional iron overload (excess iron in the... prostate-specific antigen (PSA) despite being on androgen deprivation therapy (ADT). There are no...

  11. 75 FR 65362 - Oncologic Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-10-22

    ... associated risk factors such as age, race, and family history. There is no proposed expansion of the... AVODART (dutasteride) is for reduction in the risk of prostate cancer in men at increased risk of developing the disease. The population at increased risk of prostate cancer includes men with an...

  12. 78 FR 57166 - Antiviral Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-09-17

    ... the treatment of chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and... disease (including cirrhosis) who are treatment- na ve or who have failed previous interferon...

  13. 76 FR 1181 - Oncologic Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-01-07

    ... pediatric patients 1 to 21 years old with acute lymphoblastic leukemia (ALL) whose disease has not responded... treatment of patients with types of leukemia or lymphoma known as T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment...

  14. 77 FR 5813 - Oncologic Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-02-06

    ... treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in second or greater relapse or whose disease has progressed following two or more treatment lines of...

  15. 75 FR 9419 - Oncologic Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-03-02

    ... meeting originally announced in the Federal Register of December 17, 2009 (74 FR 66986) to take place on... provide advice and recommendations to the agency on FDA's regulatory issues. Date and Time: The meeting... product is for the treatment of adults with chronic myeloid leukemia bearing a genetic alteration known...

  16. 78 FR 48690 - Oncologic Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-08-09

    ... receptor 2 (HER2)-positive, locally advanced, inflammatory, or early stage breast cancer (tumor greater than 2 cm in diameter) as part of a complete early breast cancer regimen containing either...

  17. 75 FR 75176 - Gastrointestinal Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-12-02

    ... specialized proteins called enzymes. Exocrine pancreatic insufficiency is a decreased ability to digest food due to deficient enzyme production by the pancreas. FDA intends to make background material available... exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy...

  18. 77 FR 32125 - Oncologic Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-05-31

    ... will be held on July 24, 2012, from 8 a.m. to 5 p.m. Location: FDA White Oak Campus, 10903 New...,'' click on ``Public Meetings at the FDA White Oak Campus.'' Please note that visitors to the White Oak... submitted by SmithKline Beecham (Cork) Ltd, Ireland d/b/a GlaxoSmithKline. The proposed indication (use)...

  19. 75 FR 59732 - Gastrointestinal Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-09-28

    ... proton pump inhibitors in gastroespohageal reflux disease (GERD) in patients less than 1 year of age... LP). The pathophysiology (disease process) of GERD, its diagnosis and management, and issues...

  20. Drug resistance of bacteria——present situation and treatment

    Directory of Open Access Journals (Sweden)

    Min ZHAO

    2011-02-01

    Full Text Available Antimicrobial resistance of bacteria is a serious problem worldwide.It has become the difficulty of anti-infection that multidrug-resistance(MDR and drug wide-resistance(DWR gram-negative bacteria are increasing year and year.Alarm has been knolled again on the emerging of Gram-negative pathogens producing the NDM-1 worldwide in 2010.NDM-1 is a new metallo-carbapenemase which is highly resistant to all antibiotics,and has been mostly found among Escherichia coli and Klebsiella pneumoniae.Infections of MDR and DWR Enterobacteriaceae can be effectively treated with tigecycline,polymyxin and fosfomycin on clinic trail.Prevention is very important for reducing the occurring and spreading of MDR and DWR bacteria.

  1. Advisory Tools for Use in Organic Farming

    OpenAIRE

    Peers, David; van Diepen, Pauline

    2008-01-01

    Advisory tools are an invaluable aid for advisers in providing farmers with the necessary information for analysis and planning of all aspects of the farm. The review of Advisory Tools provides access to and a comprehensive list of all the templates, calculators and analytical tools available to organic advisers, covering the nutrient managment, business, soils and animal husbandry. The review identifies relevant research and development, the tools developed and draws on farm and adviso...

  2. Club Drugs

    Science.gov (United States)

    ... uses. Other uses of these drugs are abuse. Club drugs are also sometimes used as "date rape" drugs, to make someone unable to say no to or fight back against sexual assault. Abusing these drugs can ...

  3. Generic Drugs

    Science.gov (United States)

    ... name drug. A brand- name drug has a patent. When the patent runs out— usually after 10 to 14 years— ... if you do not have drug coverage. Condition Diabetes Heart failure High cholesterol Migraine Brand-name drug ...

  4. Drug Facts

    Science.gov (United States)

    ... text to you. This web site talks about drug abuse, addiction and treatment. Watch Videos Information About Drugs Alcohol ... of the drug. "Max" was addicted to prescription drugs. The addiction slowly took over his life. I need different ...

  5. 75 FR 9184 - Federal Advisory Committee; Advisory Council on Dependents' Education; Open Meeting

    Science.gov (United States)

    2010-03-01

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF DEFENSE Office of the Secretary Federal Advisory Committee; Advisory Council on Dependents' Education; Open Meeting AGENCY: Department of Defense Education Activity (DoDEA). ACTION: Open meeting notice. SUMMARY: Under...

  6. 75 FR 64711 - Federal Advisory Committee; Threat Reduction Advisory Committee; Correction

    Science.gov (United States)

    2010-10-20

    ... of the Secretary Federal Advisory Committee; Threat Reduction Advisory Committee; Correction AGENCY... closed meeting; correction. SUMMARY: On September 30, 2010 (75 FR 60430) the Department of Defense published a notice in the Federal Register announcing an October 21, 2010, meeting of the Threat...

  7. 75 FR 25212 - Federal Advisory Committee; Defense Audit Advisory Committee (DAAC)

    Science.gov (United States)

    2010-05-07

    ... Balance sheet property valuation 4:35 Internal Audit Role 4:55 Closing Remarks Accessibility to the... include financial reporting processes, systems of internal controls, audit processes, and processes for... of the Secretary Federal Advisory Committee; Defense Audit Advisory Committee (DAAC) AGENCY:...

  8. 77 FR 72322 - The National Advisory Council on Innovation and Entrepreneurship Meeting of the National Advisory...

    Science.gov (United States)

    2012-12-05

    ... Economic Development Administration The National Advisory Council on Innovation and Entrepreneurship Meeting of the National Advisory Council on Innovation and Entrepreneurship AGENCY: U.S. Department of... Entrepreneurship will hold a meeting on Tuesday, December 11, 2012. The open meeting will be held from 10:00...

  9. 78 FR 5772 - The National Advisory Council on Innovation and Entrepreneurship Meeting of the National Advisory...

    Science.gov (United States)

    2013-01-28

    ... Economic Development Administration The National Advisory Council on Innovation and Entrepreneurship Meeting of the National Advisory Council on Innovation and Entrepreneurship AGENCY: U.S. Department of... Entrepreneurship will hold a meeting on Tuesday, February 19, 2013. The open meeting will be held from 10:00...

  10. 78 FR 801 - National Emergency Medical Services Advisory Council (NEMSAC); Notice of Federal Advisory...

    Science.gov (United States)

    2013-01-04

    ... Office of EMS and FICEMS Agencies (3) Discussion of the EMS Culture of Safety Strategy Draft Document (4.... Advisory on Leadership Developmental Planning in EMS b. Advisory on NEMSIS: Achieving its Full Potential... 2:30 p.m. EST) (6) Discussion of NEMSAC Priorities, Strategies and Values (7) Business of...

  11. 77 FR 56192 - Federal Advisory Committee; Defense Intelligence Agency (DIA) Advisory Board; Closed Meeting

    Science.gov (United States)

    2012-09-12

    ... of the Secretary Federal Advisory Committee; Defense Intelligence Agency (DIA) Advisory Board; Closed... discussions of classified information relating to DIA's intelligence operations including its support to... intelligence operations. Agenda September 26, 2012: ] 8:30 a.m Call to Order........ Ms. Ellen M....

  12. 77 FR 38041 - Federal Advisory Committee; Defense Intelligence Agency (DIA) Advisory Board; Closed Meeting

    Science.gov (United States)

    2012-06-26

    ... of the Secretary Federal Advisory Committee; Defense Intelligence Agency (DIA) Advisory Board; Closed... discussions of classified information relating to DIA's intelligence operations including its support to... intelligence operations. Agenda July 23, 2012 1 p.m.--Call to Order Mr. William Caniano, Designated...

  13. 76 FR 35891 - Meeting of the Local Government Advisory Committee and Small Community Advisory Subcommittee

    Science.gov (United States)

    2011-06-20

    ... AGENCY Meeting of the Local Government Advisory Committee and Small Community Advisory Subcommittee AGENCY: Environmental Protection Agency (EPA). ACTION: Notice. SUMMARY: The U.S. EPA's Local Government...., Chicago, Illinois. FOR FURTHER INFORMATION CONTACT: Paula Zampieri, DFO for the Local Government...

  14. 78 FR 66929 - Meetings of the Local Government Advisory Committee and the Small Communities Advisory...

    Science.gov (United States)

    2013-11-07

    ... AGENCY Meetings of the Local Government Advisory Committee and the Small Communities Advisory... comments may be extended if the number of requests for appearances requires it. The Local Government... local governments. This is an open meeting and all interested persons are invited to participate....

  15. Comparative study on anti-infection ability of pericardial and polyester patch against staphylococcus aureus%心包片和涤纶片抗金黄色葡萄球菌感染能力比较研究

    Institute of Scientific and Technical Information of China (English)

    许赓; 马震

    2016-01-01

    目的:通过对心包片和涤纶片两种生物膜抵抗金黄色葡萄球菌感染能力进行比较分析,从而判断两种材料的可用性。方法通过观察金黄色葡萄球菌于6h、12h、18h、24h四个时间点在心包片和涤纶片表面形成生物膜的数量和厚度,比较二者对金黄色葡萄球菌感染的抵抗能力。结果心包片表面金黄色葡萄球菌生物膜数量和厚度均小于涤纶片,且金黄色葡萄球菌在心包片的生长速度也低于其在涤纶片的生长速度。结论与涤纶片相比,心包片具有更好的抗感染能力。%Objective Comparative antibacterial properties of the two kinds of biological membranes of the pericardial and polyester film for Staphylococcus aureus, so as to judge the availability of the two material.Methods To compare the infection ability of staphylococcus aureus on pericardium and polyester film through observe the density and thickness of the staphylococcus aureu biofilm on the surface of the pericardium and polyester film in 6h ,12h, 18h, 24h.Results The density and thickness of Staphylococcus aureus biofilms on the pericardium surface was less than the polyester film surface, and the growth rate of Staphylococcus aureus in the pericardial patch was also lower than that in the polyester chip.Conclusion The pericardium had better anti-infection ability than the polyester film.

  16. Autecology Essential Oil Composition, Antibacterial, Anti Candidacies and Ethnopharmacological Survey of Ferula Gummosa L. As Anti Infection to Treat Of Vaginal Infections in Traditional Medicine of Razavi Khorasan Province (North East of Iran

    Directory of Open Access Journals (Sweden)

    Mazandarani Masoumeh

    2015-04-01

    used as natural anti-infection to treat of many infection diseases, especially in vaginal infection.

  17. Research Advances of Aminoacyl-tRNA Synthetase Inhibitors as Novel Anti-infective Agents%氨酰tRNA合成酶抑制剂作为新型抗感染药物的研究进展

    Institute of Scientific and Technical Information of China (English)

    王庆; 孟青青; 周虎臣

    2012-01-01

    Increasing rates of bacterial resistance to known classes of antibiotics present a severe global challenge. As a consequence, the search for new chemical entities that address novel bacterial targets remains ongoing. Aminoacyl-tRNA synthetases (aaRS) catalyze the ligation of amino acids to their cognate tRNAs and they are essential for protein synthesis. Inhibition of aaRS leads to protein synthesis inhibition, which cause cell growth arrest. Consequently, aminoacyl-tRNA synthetase is a class of potential anti-infective target. AaRS inhibitors identified from natural products and their derivatives, substrate and reaction intermediate mimics, synthetic compounds and hits of virtual screening as novel antibacterial and antifungal agents are summarized in this article. The target characteristic, classification and catalytic mechanism of aminoacyl-tRNA synthetases are also introduced.%细菌耐药性的不断上升对现有阶段的抗生素类药物提出了一个严峻的挑战,同时也掀起了针对于新靶标的抗菌药物的研究.氨酰tRNA合成酶(aaRS)催化特定氨基酸连接到相应的tRNA分子上,在蛋白质的合成过程中起着必不可少的作用.氨酰tRNA合成酶的抑制会导致蛋白质合成的停止,扰乱细菌和真菌的生长,因此氨酰tRNA合成酶是一类潜在的抗感染靶标.本文分别综述了天然产物及其衍生的aaRS抑制剂,底物和反应中间体模拟物,通过合成和通过虚拟筛选得到的aaRS抑制剂作为新型抗细菌和抗真菌药物的研究进展,并对aaRS的靶标特点、分类和催化机制作一简要介绍.

  18. Drug Facts

    Medline Plus

    Full Text Available ... Drug Abuse Hurts Other People Drug Abuse Hurts Families Drug Abuse Hurts Kids Drug Abuse Hurts Unborn Children ... a Relapse? Find Treatment/Rehab Resources Friends and Family Can Help Prevent Drug Abuse Help Children and Teens Stay Drug-Free ...

  19. 77 FR 24760 - Safety Advisory 2012-02; Restricted Speed

    Science.gov (United States)

    2012-04-25

    ... Federal Railroad Administration Safety Advisory 2012-02; Restricted Speed AGENCY: Federal Railroad... speed. This safety advisory contains a preliminary discussion of recent train accidents involving a failure to operate at restricted speed and makes recommendations to railroads to ensure...

  20. Federal Advisory Committee Act (FACA) Database-Complete-Raw

    Data.gov (United States)

    General Services Administration — The Federal Advisory Committee Act (FACA) database is used by Federal agencies to continuously manage an average of 1,000 advisory committees government-wide. This...

  1. 77 FR 51753 - Daniel Boone National Forest Resource Advisory Committee

    Science.gov (United States)

    2012-08-27

    ... Forest Service Daniel Boone National Forest Resource Advisory Committee AGENCY: Forest Service, USDA. ACTION: Notice of meeting. SUMMARY: The Daniel Boone National Forest Resource Advisory Committee (RAC... public may inspect comments received at Daniel Boone National Forest, 1700 Bypass Road,...

  2. 78 FR 10213 - NASA Advisory Council; Commercial Space Committee; Meeting

    Science.gov (United States)

    2013-02-13

    ... SPACE ADMINISTRATION NASA Advisory Council; Commercial Space Committee; Meeting AGENCY: National... (NASA) announces a meeting of the Commercial Space Committee of the NASA Advisory Council (NAC). This.... Rathjen, Human Exploration and Operations Mission Directorate, NASA Headquarters, Washington, DC...

  3. CDC Ends Zika Travel Advisory for Miami Neighborhood

    Science.gov (United States)

    ... medlineplus.gov/news/fullstory_161032.html CDC Ends Zika Travel Advisory for Miami Neighborhood Pregnant women still ... News) -- U.S. health officials on Monday lifted the Zika virus travel advisory that urged pregnant women to ...

  4. 77 FR 41203 - NASA International Space Station Advisory Committee; Meeting

    Science.gov (United States)

    2012-07-12

    ... SPACE ADMINISTRATION NASA International Space Station Advisory Committee; Meeting AGENCY: National... Administration announces an open meeting of the NASA International Space Station (ISS) Advisory Committee. The... aboard the International Space Station, including transportation, and crew rotation; and, to assess...

  5. 78 FR 77502 - NASA International Space Station Advisory Committee; Meeting

    Science.gov (United States)

    2013-12-23

    ... SPACE ADMINISTRATION NASA International Space Station Advisory Committee; Meeting AGENCY: National Aeronautics and Space Administration (NASA). ACTION: Notice of Meeting. SUMMARY: In accordance with the... Administration announces a meeting of the NASA International Space Station (ISS) Advisory Committee. The...

  6. 78 FR 49296 - NASA International Space Station Advisory Committee; Meeting

    Science.gov (United States)

    2013-08-13

    ... SPACE ADMINISTRATION NASA International Space Station Advisory Committee; Meeting AGENCY: National Aeronautics and Space Administration (NASA). ACTION: Notice of meeting. SUMMARY: In accordance with the... Administration announces a meeting of the NASA International Space Station (ISS) Advisory Committee. The...

  7. 77 FR 2765 - NASA International Space Station Advisory Committee; Meeting

    Science.gov (United States)

    2012-01-19

    ... SPACE ADMINISTRATION NASA International Space Station Advisory Committee; Meeting AGENCY: National... Administration announces an open meeting of the NASA International Space Station (ISS) Advisory Committee. The... aboard the International Space Station, including transportation, and crew rotation; and, to assess...

  8. 77 FR 66082 - NASA International Space Station Advisory Committee; Meeting

    Science.gov (United States)

    2012-11-01

    ... SPACE ADMINISTRATION NASA International Space Station Advisory Committee; Meeting AGENCY: National... Administration announces an open meeting of the NASA International Space Station (ISS) Advisory Committee. The... aboard the International Space Station, including transportation, and crew rotation; and, to assess...

  9. 75 FR 51852 - NASA International Space Station Advisory Committee; Meeting

    Science.gov (United States)

    2010-08-23

    ... SPACE ADMINISTRATION NASA International Space Station Advisory Committee; Meeting AGENCY: National... Administration announces an open meeting of the NASA International Space Station Advisory Committee. The purpose... the International Space Station, including transportation, crew rotation, training, and...

  10. 75 FR 22553 - Technology Innovation Program Advisory Board

    Science.gov (United States)

    2010-04-29

    ... National Institute of Standards and Technology Technology Innovation Program Advisory Board AGENCY: National Institute of Standards and Technology, Department of Commerce. ACTION: Notice of public meeting. SUMMARY: The Technology Innovation Program Advisory Board, National Institute of Standards and...

  11. 76 FR 18166 - Technology Innovation Program Advisory Board

    Science.gov (United States)

    2011-04-01

    ... National Institute of Standards and Technology Technology Innovation Program Advisory Board AGENCY: National Institute of Standards and Technology, Department of Commerce. ACTION: Notice of public meeting. SUMMARY: The Technology Innovation Program Advisory Board, National Institute of Standards and...

  12. 75 FR 62369 - Technology Innovation Program Advisory Board

    Science.gov (United States)

    2010-10-08

    ... National Institute of Standards and Technology Technology Innovation Program Advisory Board AGENCY: National Institute of Standards and Technology, Department of Commerce. ACTION: Notice of public meeting. SUMMARY: The Technology Innovation Program Advisory Board, National Institute of Standards and...

  13. 75 FR 69916 - Southern New Mexico Resource Advisory Committee

    Science.gov (United States)

    2010-11-16

    ... Forest Service Southern New Mexico Resource Advisory Committee AGENCY: Forest Service, USDA. ACTION: Notice of meeting. SUMMARY: The Southern New Mexico Resource Advisory Committee (RAC) will meet in... CODE 3410-11-P...

  14. 76 FR 16603 - Southern New Mexico Resource Advisory Committee

    Science.gov (United States)

    2011-03-24

    ... Forest Service Southern New Mexico Resource Advisory Committee AGENCY: Forest Service, USDA. ACTION: Notice of meeting. SUMMARY: The Southern New Mexico Resource Advisory Committee (RAC) will meet in..., Designated Federal Official. BILLING CODE 3410-11-P...

  15. 77 FR 5494 - Commerce Spectrum Management Advisory Committee Meeting

    Science.gov (United States)

    2012-02-03

    ... (Search for 500 MHz, Spectrum Sharing, Spectrum Management Improvements, and Unlicensed), and identify... National Telecommunications and Information Administration Commerce Spectrum Management Advisory Committee... Management Advisory Committee (Committee). The Committee provides advice to the Assistant Secretary...

  16. 78 FR 2407 - Medicare Payment Advisory Commission Nomination Letters

    Science.gov (United States)

    2013-01-11

    ... From the Federal Register Online via the Government Publishing Office GOVERNMENT ACCOUNTABILITY OFFICE Medicare Payment Advisory Commission Nomination Letters AGENCY: Government Accountability Office... the Medicare Payment Advisory Commission (MedPAC) and gave the Comptroller General responsibility...

  17. 76 FR 5591 - Medicare Payment Advisory Commission Nomination Letters

    Science.gov (United States)

    2011-02-01

    ... From the Federal Register Online via the Government Publishing Office GOVERNMENT ACCOUNTABILITY OFFICE Medicare Payment Advisory Commission Nomination Letters AGENCY: Government Accountability Office... the Medicare Payment Advisory Commission (MedPAC) and gave the Comptroller General responsibility...

  18. Beach Advisory and Closing Online Notification (BEACON) system

    Data.gov (United States)

    U.S. Environmental Protection Agency — Beach Advisory and Closing Online Notification system (BEACON) is a colletion of state and local data reported to EPA about beach closings and advisories. BEACON is...

  19. 75 FR 28275 - Homeland Security Science and Technology Advisory Committee

    Science.gov (United States)

    2010-05-20

    ... SECURITY Homeland Security Science and Technology Advisory Committee AGENCY: Science and Technology...: On April 12, 2010, the Homeland Security Science and Technology Advisory Committee announced in the... supplements that original meeting notice. DATES: The Homeland Security Science and Technology...

  20. 77 FR 65570 - Merchant Marine Personnel Advisory Committee: Intercessional Meeting

    Science.gov (United States)

    2012-10-29

    ... SECURITY Coast Guard Merchant Marine Personnel Advisory Committee: Intercessional Meeting AGENCY: Coast... of the Merchant Marine Personnel Advisory Committee (MERPAC) will meet to discuss Task Statement 80....S. merchant marine, including but not limited to training, qualifications,...